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1. ABSTRACT 
Cisplatin-based chemotherapy improves survival in cervical and ovarian cancer; 
however, treatment is associated with tumor resistance and significant toxicity.  
Lipoplatin (Regulon Inc., Mountain View, California) is a liposomal encapsulated 
form of cisplatin, developed in an effort to reduce cisplatin‟s systemic toxicity, 
while simultaneously improving the targeting of drugs to primary tumor and 
metastasis. Lipoplatin has been successfully administered in several randomized 
Phase II and III clinical trials, but not in cervical and ovarian cancer.  
The aim of this project was to analyze the antitumoral activity of lipoplatin in 
cisplatin-sensitive and cisplatin-resistant cervical and ovarian cancer cells. 
I evaluated the antiproliferative activity of lipoplatin, with cisplatin as reference 
drug, in the ME-180 cervical cancer cell line and its cisplatin-resistant clone R-
ME-180, and in a panel of ovarian cancer cell lines: A2780, its cisplatin-resistant 
clone A2780cis, MDAH, OVACR3, OVCAR5, SKOV3, and TOV21G. Results 
demonstrated that lipoplatin exhibited a potent antitumoral activity in all the 
tested cell lines, including cisplatin-resistant cells, indicating that there is no 
cross-resistance between the two drugs. 
Lipoplatin induced apoptosis, as evaluated by Annexin-V staining and DNA 
fragmentation. In particular, it induced the mitochondrial apoptotic pathway 
causing mitochondrial membrane permeabilization, cytochrome-c release, Bcl-2 
down-regulation, but Bax up-regulation, and caspases 9 and 3 activation. At the 
same experimental conditions cisplatin induced apoptosis only in cisplatin-
sensitive cells. Moreover, lipoplatin, but not cisplatin, increased reactive oxygen 
species (ROS) accumulation and inhibited the enzymatic activity of thioredoxin 
reductase (TrxR), an enzyme involved in ROS detoxification and over-expressed 
in many tumor cells contributing to drug resistance. Furthermore, lipoplatin 
reduced EGFR expression and inhibited both migration and invasion.  
Multiple drug treatment is widely used in chemotherapy to obtain an additive or a 
synergistic effect (more than additive). I combined lipoplatin with the 
chemotherapeutic agents mostly used in ovarian cancer treatment. The results 
showed that the combination of lipoplatin with doxorubicin or abraxane 
demonstrated a synergistic effect, whereas the combination of lipoplatin with 
docetaxel or paclitaxel was less effective or at best additive. 
In the ascites of ovarian cancer patients there are multicellular aggregates or 
spheroids that are involved in tumor progression. Thus, spheroid-based assays are 
more predictive of in vivo therapeutic efficacy because they more closely 
resemble tumor microenvironment. Furthermore, cancer stem cells (CSC), rare 
tumor cells involved in initiating cancer growth, drug resistance, and disease 
recurrence, are also present in spheroids. The treatment with lipoplatin reduced 
stem cell markers in a dose-dependent manner and inhibited spheroid formation in 
both cervical and ovarian cancer models. Furthermore, it decreased ovarian cancer 
spheroid growth, vitality, and migration. 
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Finally, lipoplatin treatment of nude mice with cervical and ovarian tumors 
significantly inhibited tumor growth in vivo, with low toxicities. Moreover, even 
after treatment interruption the tumors did not show any regrowth. 
 
In conclusion, in this project lipoplatin demonstrated an antitumoral activity in 
monolayer cultures, three-dimensional spheroids, and in vivo studies using  
cisplatin-resistant cervical and ovarian cancer cells. These promising results 
suggest lipoplatin as a novel chemotherapeutic agent for the treatment of cervical 
and ovarian cancer.  
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2. SOMMARIO 
Il cisplatino è uno dei farmaci più utilizzati per il trattamento del carcinoma della 
cervice e dell‟ovaio. Purtroppo il suo utilizzo in chemioterapia presenta importanti 
limitazioni, quali l‟elevata tossicità e l‟insorgenza di resistenza intrinseca o 
acquisita.  
Il lipoplatino è una formulazione liposomiale del cisplatino (Regulon, Inc., Mt. 
View, U.S.A), sintetizzata allo scopo di ridurre la tossicità sistemica del cisplatino 
e contemporaneamente di incrementarne l‟accumulo nel tumore primario e nelle 
metastasi. Studi clinici di Fase II e III sono stati effettuati in diversi tumori ma 
non nel carcinoma della cervice uterina e dell‟ovaio. 
In questo lavoro è stata analizzata l‟attività antitumorale del lipoplatino in modelli 
preclinici di carcinoma della cervice uterina e carcinoma ovarico sensibili e 
resistenti al cisplatino. 
L‟attività antiproliferativa del lipoplatino è stata studiata nella linea cellulare 
derivata da carcinoma della cervice uterina ME-180 e nel suo clone resistente al 
cisplatino R-ME-180, come pure in un pannello di linee cellulari derivanti da 
carcinoma ovarico: A2780, il suo clone cisplatino-resistente A2780cis, MDAH, 
OVACR3, OVCAR5, SKOV3, e TOV21G. Il cisplatino è stato introdotto nello 
studio come farmaco di riferimento. I risultati hanno dimostrato che il lipoplatino 
esibisce una potente attività antitumorale in tutte le linee cellulari analizzate, 
incluse le cisplatino-resistenti, dimostrando assenza di cross-resistenza con il 
farmaco cisplatino.  
Il lipoplatino induce apoptosi, valutata tramite l‟esternalizzazione della 
fosfatidilserina (marcatore precoce di apoptosi) e la frammentazione del DNA. In 
particolare, il lipoplatino attiva la via mitocondriale dell'apoptosi, come 
dimostrato dalla depolarizzazione della membrana mitocondriale, il rilascio del 
citocromo-c , la diminuzione dell‟espressione della proteina anti-apoptotica    Bcl-
2, l‟incremento dell‟espressione della molecola pro-apoptotica Bax e l‟attivazione 
delle caspasi 9 e 3. Nelle stesse condizioni sperimentali il cisplatino attiva 
l‟apoptosi soltanto in cellule sensibili al cisplatino.  
L‟enzima tioredoxina reduttasi (TrxR) svolge una funzione ossidoriduttiva 
proteggendo la cellula da stress ossidativo. Un elevato livello dell‟enzima si 
osserva in diversi tipi di tumore e sembra essere associato alla resistenza al 
cisplatino. I miei studi hanno dimostrato che il lipoplatino, ma non il cisplatino, 
inibisce l‟attività enzimatica della TrxR incrementando la produzione di radicali 
liberi dell‟ossigeno (ROS). Inoltre il lipoplatino riduce l‟espressione del recettore 
del fattore di crescita dell‟epidermide (EGFR), un recettore di membrana over-
espresso nei tumori, coinvolto nella proliferazione e nella migrazione delle cellule 
tumorali. Anche la migrazione e l‟invasione cellulare vengono ridotte dal 
trattamento con lipoplatino. 
Molto spesso in chemioterapia si somministra una combinazione di più farmaci 
(polichemioterapia) per ottenere un effetto additivo e/o sinergico. Si è quindi 
combinato il lipoplatino con i chemioterapici più utilizzati nel trattamento del 
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carcinoma ovarico. La combinazione del lipoplatino con i farmaci doxorubicina e 
abraxane dimostra effetti sinergici, mentre la combinazione con docetaxel e 
paclitaxel è meno efficace con effetti quasi additivi. 
Nell‟ascite di pazienti affette da carcinoma ovarico si possono ritrovare aggregati 
multicellulari, o sferoidi, che sembrano essere coinvolti nella progressione 
tumorale. Gli sferoidi rappresentano un valido modello sperimentale con 
caratteristiche biologiche e molecolari simili ai tumori solidi, tra queste la 
presenza di cellule staminali cancerose, ossia cellule con grandi capacità 
rigenerative e di resistenza alle terapie in grado di alimentare la crescita del 
tumore. Il trattamento con lipoplatino diminuisce in maniera dose-dipendente i 
marcatori di staminalità e inibisce la formazione di sferoidi in entrambi i modelli 
sperimentali. Inoltre riduce la dimensione, la vitalità e la disseminazione di 
sferoidi di carcinoma ovarico.  
Infine il lipoplatino diminuisce la crescita di tumori xenografi derivanti da cellule 
di carcinoma della cervice uterina e dell‟ovaio con ridotta tossicità. Anche in 
seguito all‟interruzione del trattamento i tumori non riprendono la crescita. 
 
Concludendo il lipoplatino dimostra un‟attività antitumorale in colture cellulari 
tradizionali, in colture tridimensionali o sferoidi ed in vivo, sia di cellule derivanti 
da carcinoma della cervice uterina cisplatino-resistenti che da carcinoma ovarico. 
Questi risultati molto promettenti suggeriscono un potenziale utilizzo di questa 
formulazione liposomiale di cisplatino per il trattamento di pazienti affette dalle 
suddette patologie. 
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3. INTRODUCTION 
3.1 Chemotherapeutic agents 
Cancer is a term used for diseases in which abnormal cells divide without control 
and are able to invade other tissues. According to the world health organization 
(WHO) more than 14.0 million people are diagnosed with cancer every year. It is 
the leading cause of death worldwide and accounted for 8.2 million deaths (13% 
of all deaths) in 2012.  
One of the most common treatments for cancer is chemotherapy, that is the use of 
anticancer drugs to treat cancerous cells. Chemotherapy may be used alone for 
some types of cancer or in combination with other treatments such as radiation or 
surgery. Often, a combination of chemotherapy drugs is used to fight a specific 
cancer (Gleeson et al., 2008).  
The majority of current anticancer drugs exert their effects by targeting and 
reducing enhanced cellular proliferation and division of cancer cells. The rationale 
being that cancer cells are more likely to be replicating than normal cells. 
Unfortunately as their action is not specific, they are associated with significant 
toxicity. Therefore effective use of cancer chemotherapy requires an 
understanding of the principles of tumor biology, cellular kinetics, pharmacology, 
and drug resistance (Gleeson et al., 2008).  
Classifying cytotoxic drugs according to their mechanism of action is the 
preferred system in use between clinicians (Figure 3.1). 
 
 
 
Figure 3.1 Mechanisms of traditional chemotherapy.  
 
ALKYLATING AGENTS 
These highly reactive compounds produce their effects by covalently linking an 
alkyl group (R-CH2) to a chemical species in nucleic acids or proteins. The site at 
which the cross-links are formed and the number of cross-links formed is drug 
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specific. Most alkylating agents are bipolar, i.e. they contain two groups capable 
of reacting with DNA. They can thus form bridges between a single strand or two 
separate strands of DNA, interfering with the action of the enzymes involved in 
DNA replication. The cell then either dies or is physically unable to divide or 
triggers apoptosis. The damage is most serious during the S-phase, as the cell has 
less time to remove the damaged fragments. Examples include: nitrogen mustards 
(e.g. melphalan and chlorambucil); oxazaphosphorenes (e.g. cyclophosphamide, 
ifosfamide); alkyl alkane sulphonates (busulphan); nitrosureas (e.g. carmustine 
(BCNU), lomustine (CCNU)); tetrazines (e.g. dacarbazine, mitozolomide and 
temozolomide); aziridines (thiopeta, mitomycin C); procarbazine (WARWICK, 
1963). 
ANTIMETABOLITES 
Antimetabolites are compounds that bear a structural similarity to naturally 
occurring substances such as vitamins, nucleosides or amino acids. They compete 
with the natural substrate for the active site on an essential enzyme or receptor. 
Some are incorporated directly into DNA or RNA. Most are phase-specific, acting 
during the S-phase of the cell cycle. There are three main classes: folic acid 
antagonists (e.g. methotrexate); pyrimidine analogues (e.g. 5-fluorouracil, 
cytarabibe); purine analogues (6-Mercaptopurine (6MP) and thioguanine are 
derivatives of adenine and guanine, respectively) (Pizzorno et al., 2000). 
ANTIMICROTUBLE AGENTS 
Vinca alkaloids 
The two prominent agents in this group are vincristine and vinblastine that are 
extracted from the periwinkle plant. Upon entering the cell, they bind rapidly to 
the tubulin. The binding occurs in the S phase. Polymerization of microtubules is 
blocked, resulting in impaired mitotic spindle formation in the M phase. Other 
newer examples include vindesine and vinorelbine (Malhotra and Perry, 2003). 
Taxanes 
Paclitaxel and docetaxel (Taxotere) are semisynthetic derivatives of extracted 
precursors from the needles of yew plants. These drugs have a novel 14-member 
ring, the taxane. Unlike the vinca alkaloids, which cause microtubular 
disassembly, the taxanes promote microtubular assembly and stability, therefore 
blocking the cell cycle in mitosis (Malhotra and Perry, 2003).  
CYTOTOXIC ANTIBIOTICS 
Most antitumor antibiotics have been produced from bacterial and fungal cultures 
(often Streptomyces species). They affect the function and synthesis of nucleic 
acids in different ways. Anthracyclines (e.g. doxorubicin, daunorubicin, 
epirubicin) intercalate with DNA and affect the topoiosmerase II enzyme. 
Actinomycin D intercalates between guanine and cytosine base pairs. This 
interferes with the transcription of DNA at high doses. At low doses DNA-
directed RNA synthesis is blocked. Bleomycin consists of a mixture of 
glycopeptides that cause DNA fragmentation. Mitomycin C inhibits DNA 
synthesis by cross-linking DNA, acting like an alkylating agent. 
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PLATINUM AGENTS 
Platinum-based are coordination complexes of platinum and are the most widely 
used classes of cancer therapeutics. Today, there are three platinum 
chemotherapeutics approved by the U.S. Food and Drug Administration, cisplatin, 
carboplatin, and oxaliplatin (Kelland, 2007). 
Platinum-based antineoplastic agents cause crosslinking of DNA as monoadduct, 
interstrand crosslinks, intrastrand crosslinks or DNA protein crosslinks. The 
resultant crosslinking inhibit DNA repair and/or DNA synthesis in cancer cells. 
Platinum-based antineoplastic agents are sometimes described as "alkylating-like" 
due to similar effects as alkylating antineoplastic agents, although they do not 
have an alkyl group (Kostova, 2006). 
TOPOISOMERASE INHIBITORS 
Topoisomerases are responsible for altering the 3D structure of DNA by a 
cleaving/unwinding/rejoining reaction. They are involved in DNA replication, 
chromatid segregation and transcription. The efficacy of topoisomerase inhibitors 
in the treatment of cancer is based solely on their ability to inhibit DNA 
replication (Guichard and Danks, 1999). The drugs are phase-specific and prevent 
cells from entering mitosis from G2. There are two broad classes:  
Topoisomerase I inhibitors  
Camptothecin, derived from Camptotheca acuminate (a Chinese tree), binds to the 
enzyme-DNA complex, stabilizing it and preventing DNA replication. Irinotecan 
and topetecan have been derived from this prototype. 
Topoisomerase II inhibitors 
Epipodophyllotoxin derivatives (e.g. etoposide, vespid) are semisynthetic 
derivatives of Podophyllum peltatum, the American mandrake. They stabilize the 
complex between topoisomerase II and DNA that causes strand breaks and 
ultimately inhibits DNA replication (Pommier, 2006). 
OTHERS 
Includes drugs that do not fall into any of these categories (Monoclonal 
antibodies, signaling inhibitors) (Boulikas, 2007). 
 
 
3.2 Cisplatin 
3.2.1 Discovery 
Cisplatin is characterized by a square planar configuration with a central atom of 
platinum linked to two chloride and two NH3 groups. Although the synthesis and 
characterization of cisplatin was first reported by Michel Peyrone in 1844 
(Peyrone, 1844), its anticancer properties remained unnoticed for about 125 years, 
until the mid-1960s, when Rosenberg and co-workers serendipitously studied the 
effects of electric fields on Escherichia coli growth (Rosenberg et al., 1965). The 
platinum electrodes released by redox reactions some platinum complexes which 
provoked complete stop of cell division in the bacterial rods. Amongst the 
platinum complexes formed, the cis form of the platinum(II) complex, 
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[PtCl2(NH3)2] or cis-diamminedichloroplatinum(II) (CDDP), was identified as the 
main antiproliferative agent; the trans complex was found to be ineffective 
(Rosenberg et al., 1967, 1969) (Figure 3.2).  
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Figure 3.2 Schematic representation of the two stereoisomers cisplatin (left) and transplatin 
(right). 
 
Given these results, it was reasoned that the complex may be interesting to be 
assessed for its anticancer activity. To this end cisplatin was tested against 
Sarcoma 180 tumors in Swiss white mice. The complex demonstrated “potent” 
activity, shrinking large solid tumors, and the mice survived and were healthy. In 
fact, after 6 months the cured mice did not show any signs of cancer (Rosenberg 
and VanCamp, 1970). Based on these results cisplatin entered clinical trials. In 
December 1978 cis-[PtCl2(NH3)2] received U.S. Food and Drug Authority 
approval as an anti-cancer drug for testicular and ovarian cancers. The formulated 
drug containing sodium chloride and mannitol is marketed under the name of 
Platinol
TM
. The bulk cis-[PtCl2(NH3)2] is referred to as cisplatin. In the U.K. the 
drug is known as Neoplatin
TM
, and this received approval in March 1979 
(Wiltshaw, 1979). 
In the next years cisplatin developed into one of the most successful and widely 
used drugs in cancer chemotherapy and it still continues to be a cornerstone in 
modern chemotherapy, playing an important role among cytotoxic agents in the 
treatment of epithelial malignancies (Rosenberg, 1977). 
 
 
3.2.2 Pharmacology and mechanism of action 
Cisplatin is administered to cancer patients by intravenous injection as sterile 
saline solution, that is, containing salt, specifically sodium chloride. Following 
administration in the bloodstream of a patient, cisplatin encounters a relatively 
high chloride concentration in the blood plasma (approximately 100 mM) that 
limits replacement of its chloride ligands by water molecules (process of 
aquation). However, cisplatin is vulnerable to attack by proteins found in blood 
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plasma, particularly those that contain thiol groups, such as human serum albumin 
(66-kDa protein) and the amino acid cysteine. In fact, studies have shown that one 
day after cisplatin administration, 65–98% of the platinum in blood plasma is 
protein bound (DeConti et al., 1973; Ivanov et al., 1998). Although many of its 
severe side effects have been attributed to protein binding, the exact role of Pt-
protein complexes in the mechanism of action of the metallodrug is still not well 
understood. It is possible that major serum proteins, albumin and transferrin, 
might take over a transport and delivery function for cisplatin, and other antitumor 
metal complexes, and thereby influence their overall distribution and efficacy. 
Albumin, for instance, is taken up by tumor cells at increased levels in 
comparison to normal cells and has been exploited as a carrier protein for organic 
anticancer drugs (Will et al., 2008). 
The biochemical mechanism by which cisplatin crosses the cell membrane still 
remains unclear. Early studies reported that cisplatin uptake was not inhibited by 
its structural analogues and this entry into the cell did not seem to be dependent 
on an optimum pH (Mann et al., 1991). In addition, cisplatin accumulation in the 
cell proceeded linearly with time over 60 minutes and did not reach a plateau up 
to a drug concentration of 1 mM. So, it was suggested that passive diffusion was 
the main mechanism by which cisplatin enters the cell. However, it was found 
later that a certain degree of cisplatin uptake seemed to be energy dependent and 
could be modulated by pharmacological agents such as the Na+/K+-ATPase 
inhibitor ouabain and the membrane-interactive agents amphotericin B and 
digitonin (Gately and Howell, 1993). Recently, carrier import proteins, like the 
organic cation transporter OCT/SLC22A, or the high-affinity copper transporter 1 
(CTR1), were identified as cellular uptake mechanisms for cisplatin (Ciarimboli et 
al., 2010). Indeed, observations point towards a direct connection between the 
cellular concentrations of copper and platinum, which leads to propose an active 
transport for cisplatin in addition to passive diffusion.  
The intracellular chloride concentration is relatively low (approximately 4-20 
mM) and hence one, or both, of the chloro ligands of the intact cisplatin are 
replaced by water, forming a reactive, positively charged species that cannot 
readily leave the cell. These mono and diaquo species of cisplatin are very 
reactive towards nucleophile centres of biomolecules because H2O is a much 
better leaving group than Cl
-
 (Figure 3.3). 
In the cytoplasm there are many cellular components that have soft nucleophilic 
sites such as membrane phospholipids, cytoskeletal microfilaments, thiol-
containing peptides and proteins, RNA, that may react with cisplatin (Jordan and 
Carmo-Fonseca, 2000). Hence, of interest is the observation that only 5-10% of 
covalently bound cell-associated cisplatin is found in the genomic DNA fraction, 
whereas 75-85% of the drug binds to proteins and other cellular constituents 
(Akaboshi et al., 1992). The most important non-DNA target of cisplatin is 
probably the tripeptide glutathione (GSH), which is present in cells at high 
concentrations (0.5-10 mM) (Figure 3.3). 
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Figure 3.3 The cellular uptake of cisplatin and its targets.  
 
GSH and other thiol-containing biomolecules such as metalothioneins (MT) bind 
quickly to platinum (Fuertes et al., 2003). Cisplatin binding to GSH and MT has 
primarily been associated with negative pharmacological properties, including the 
development of resistance and toxicity. On the other hand, cisplatin may alter the 
activity of enzymes, receptors, and other proteins through coordination to sulfur 
atoms of cysteine and/or methionine residues and to nitrogen atoms of histidine 
residues. In fact, binding of cisplatin to methionine 1 (met1) and/or histidine 68 
(his68) of ubiquitin may inhibit the ubiquitin-proteasome pathway of selective 
degradation of cellular proteins, which ends up in cytotoxic events (Peleg-
Shulman and Gibson, 2001). In addition, it has been found that cisplatin, besides 
inhibiting in vitro the activity of heat shock protein 90 (Hsp90), and ATP-binding 
chaperone, efficiently and specifically blocks its C-terminal ATP binding site. The 
C-terminal of Hsp90 via its ATP hydrolytic function is involved in the correct 
folding of proteins which play a role in signal transduction and cell cycle 
regulation (Söti et al., 2002). 
The effects of cisplatin on RNA and DNA have been studied extensively. 
Although cisplatin can coordinate to RNA, this interaction is not believed to play 
an important role in cisplatin‟s physiological mechanism of action because a 
single damaged RNA molecule can be replaced by newly synthesized material, 
and studies have revealed that cisplatin does not affect RNA synthesis. Moreover, 
when cisplatin was administrated in vitro at its lethal dose to a strain of cancer 
cells, only a small fraction (1 to 10%) of RNA molecules were damaged. On the 
contrary, there is strong evidence that cellular DNA is the main target of the drug 
(Rabik and Dolan, 2007).  
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The nitrogen atoms position 7 (N7) on the purine ring of guanine, and in less 
extend adenine, located in the major groove of the double helix are the most 
accessible and reactive nucleophilic sites for platinum coordination to DNA. 
These N7 atoms are free to coordinate to cisplatin because they do not form 
hydrogen bonds with any other DNA bases. Binding of cisplatin to DNA is 
irreversible and structurally different adducts are formed (Figure 3.4). Three 
different types of lesions can form on purine bases of DNA: monoadducts, 
intrastrand crosslinks, and interstrand crosslinks. Monoadducts are first formed as 
one molecule of water is lost from aquated platinating agents; however, greater 
than 90% of monoadducts then react to form crosslinks. Cisplatin forms about 
65% 1,2-d(GpG) intrastrand crosslinks, 25% 1,2-d(ApG) intrastrand crosslinks, 
13% interstrand or intrastrand crosslinks on d(GpXpG) sequences, and less than 
1% remains monofunctional adduct (Egger et al., 2008). Protein-DNA crosslinks 
are also formed by cisplatin (Figure 3.4).  
 
 
 
Figure 3.4 Main adducts formed in the interaction of cisplatin with DNA (left). Cisplatin 
coordination to the N7 atoms of the purine (guanine and adenine) bases (right). 
 
Also trans-platin or transplatin binds to DNA almost exclusively by coordination 
to the N7 atom of purine bases. Therefore, from a biochemical point of view the 
lack of pharmacological activity of transplatin must be related to the different type 
of DNA adducts formed by this trans isomer relative to cisplatin. Due to steric 
reasons, transplatin mainly forms 1,3-intrastrand and interstrand cross-links. 
Therefore, it is generally assumed that the 1,2-intrastrand DNA adduct is 
responsible for cisplatin cytotoxicity, although this is not a proven fact (Cepeda et 
al., 2007).  
When cisplatin binds to DNA forming adducts, it promotes superhelical 
unwinding and shortens the double helix. Cisplatin intrastrand crosslinks bend the 
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double helix by 32-35° toward the major groove. Both 1,2-d(GpG) and 1,2-
d(ApG) intrastrand crosslinks unwind DNA by 13°, while the 1,3-d(GpXpG) 
intrastrand lesion unwinds DNA by 34°. Interstrand lesions induce even more 
steric changes in DNA (Rabik and Dolan, 2007). 
When DNA is damaged, the cell cycle is arrested to provide time for repair. Cell-
cycle checkpoints monitor the proper order of events in the cell because failures in 
replication lead to the acquisition and accumulation of genetic alterations, which 
can ultimately cause tumorigenesis. The G1/S checkpoint ensures that damaged 
DNA is not replicated. Cisplatin does not cause G1 arrest in all cases. The G2/M 
checkpoint allows for the repair of DNA that was damaged late in the S or G2 
phase of the cell cycle before mitosis, to prevent damaged DNA from being 
segregated into daughter cells. It has been proposed that such G2 arrest is essential 
to the process of engaging cell death following cisplatin treatment. When DNA 
damage occurs, ataxia telangiectasia mutated (ATM) and its related ataxia-
telangiectasia and Rad3-related (ATR) kinase activate checkpoint kinases CHK1 
and CHK2 through phosphorylation, which in turn phosphorylate cell division 
cycle 25C (CDC25C). The phosphorylated CDC25C promotes its binding to 14-3-
3 adaptor proteins and is thereby separated from CDC2 by translocation of 
CDC25C to the cytoplasm. As a result, CDC2 phosphorylation is elevated and 
causes cells to arrest in G2 (Liu et al., 2000; Matsuoka et al., 2000). 
Cisplatin damaged DNA can be repaired by nucleotide excision repair proteins 
(NER), mismatch repair (MMR) proteins, and DNA-dependent protein kinase 
protein (DNA-PK) (Ahmad, 2010). 
Nucleotide excision repair proteins are ATP-dependent multiprotein complexes 
that recognize the bending induced on DNA by 1,2-intrastrand cross-links, and 
subsequently excise the part of the DNA that includes the kink as 27- to 29-base-
pair oligonucleotides. The gap that remains is then filled by DNA polymerase. 
There are 9 major proteins involved in NER in mammalian cells. Deficiencies in 
certain proteins leads to disease; protein names are associated with the disease. 
XPA, XPB, XPC, XPD, XPE, XPF, and XPG all derive from xeroderma 
pigmentosum and CSA and CSB represent proteins linked to Cockayne syndrome. 
Additionally, the proteins ERCC1, RPA, RAD23A, RAD23B, and others also 
participate in nucleotide excision repair. NER can be divided into two 
subpathways: global genomic NER (GG-NER) and transcription coupled NER 
(TC-NER). The two subpathways differ in how they recognize DNA damage but 
they share the same process for lesion incision, repair, and ligation (Zhang et al., 
2009). It has been reported that at least 16 genes are essential for the DNA 
damage recognition and excision function of the intrastrand adducts formed by 
cisplatin between two adjacent guanines (Bruhn et al., 1992). NER appears also to 
be a major mechanism of cisplatin resistance. 
Mismatch repair is a post-replication repair system that corrects unpaired or 
mispared nucleotides in DNA caused by DNA-platinum adducts. The mismatch 
repair system involves at least five proteins (MLH1, MSH2, MSH3, MSH6 and 
PMS2) and functions as a repair mechanism that needs ATP. MMR is a 
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comparative small contributor to the cisplatin resistance phenotype in comparison 
with NER. In fact in ovarian and colon cancers an intact MMR system appears to 
be essential for the linkage of DNA damage/repair with the initiation of apoptosis 
(Reed, 1999). 
The DNA-PK protein mainly repairs DNA double-strand breaks (DSB) induced 
by cell exposure to ionizing radiation. However, it has been described that the 
DNA-PK protein can also interact with cisplatin-DNA lesions (Turchi and 
Henkels, 1996). DNA binding of the Ku subunits of DNA-PK in vitro is essential 
to activate the kinase activity of DNA-PK to phosphorylate itself or transcription 
factors. Interestingly, it has been reported that in ovarian cancer cells the presence 
of cisplatin-DNA adducts serves to inhibit the ability of the Ku subunits of DNA-
PK to translocate on a duplex DNA substrate resulting in inhibition of the kinase 
activity (Henkels and Turchi, 1997). 
DNA damage recognition proteins include over 20 individual candidate (Vaisman 
et al., 1998). Special attention is focused on recognition of cisplatin modified 
DNA by high-mobility group (HMG) proteins. The HMG domain proteins are the 
largest extensively characterized group of non-histone chromosomal proteins. 
They can bind to specific structures in DNA or in chromatin with little or no 
specificity for target DNA sequence. Two families of HMG have been reported. 
The first consists of proteins containing two or more HMG domains; it includes 
HMG1 and HMG2 proteins, the nucleosomal RNA polymerase I transcription 
factor upstream binding factor (UBF) and the mitochondrial transcription factor 
(mtTF). In the second family there are proteins containing a single HMG domain, 
such as tissue-specific transcription factors (Cepeda et al., 2007).  
Several HMG domain proteins recognize and bind to cisplatin-modified DNA. 
The greatest attention has been concentrated on the studies of recognition of 
platinated DNA by HMGB1 and HMGB2. In particular, HGMB1 recognizes the 
major 1,2- d(GpG) intrastrand cisplatin-DNA adduct and may avoid that NER can 
repair this DNA lesion. In addition, HMGB1 has been linked to other DNA-
dependent pathways. Hence, HMGB1 (i) may activate cleavage of recombination 
activation genes 1 and 2 (RAG1 and RAG2), (ii) may stimulate the binding of 
sequence-specific transcription factors, (iii) may interact with the MMR protein 
MutSa then having a possible role in mismatch repair, (iv) binds to the tumor 
suppressor protein p53 in vitro therefore increasing p53 DNA-binding activity, 
and (v) HMGB1 affinity for platinated DNA is significantly improved in the 
presence of p53 (Wang and Lippard, 2005). However, it should be pointed out 
that all these biochemical functions attributed to HMGB1 in response to cisplatin 
damage to DNA are dependent on the cell type.  
 
 
3.2.3 Signals Transduction from Cisplatin-DNA Damage 
The likely role of DNA damage recognition proteins is to transduce DNA damage 
signals to downstream effectors. As a consequence of exposure to cisplatin, 
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different signaling pathways are affected. There is no general concept applicable 
to all types of tumor. It is evident that response to cisplatin is defined by cell 
specificity. Nevertheless numerous data revealed changes in activity of most 
important signaling pathways involved in cell proliferation, differentiation and 
cell death such as phosphatidylinositol 3-kinase (PI3K)/Akt, Mitogen-Activated 
Protein Kinase (MAPK), as well as signaling pathways involved in realization of 
death signals dependent or independent of death receptors (Wang and Lippard, 
2005). It is very important to note that alteration in signal transduction upon 
cisplatin treatment could be the consequence of both, DNA damage or interaction 
with proteins that are relevant for appropriate molecular response or in triggering 
programmed cell death pathways. Indeed, as mentioned before, most cisplatin 
molecules bind to proteins rather than DNA. 
The PI3K/Akt pathway is frequently activated in cancer cells. AKT molecule, as 
most important Ser/Thr protein kinase in cell survival, protects cells from damage 
induced by different stimuli, as well as cisplatin (Datta et al., 1999). Cisplatin 
downregulated XIAP protein level and promoted AKT cleavage resulting in 
apoptosis in chemosensitive but not in resistant ovarian cancer cells. Furthermore, 
PTEN is a tumor suppressor gene product believed to promote apoptosis primarily 
via inactivation of the PI3K/Akt cell survival pathway (Dan et al., 2004). 
A protein marked as the most important in the signaling of DNA damage is c-Abl 
which belongs to Src family of non receptor tyrosine kinases (Cepeda et al., 
2007). This molecule acts as transmitter of DNA damage triggered by cisplatin 
from nucleus to cytoplasm. Moreover, sensitivity to cisplatin induced apoptosis is 
directly related with c-Abl content and could be blocked by c-Abl overexpression 
(Wang and Lippard, 2005). 
Cisplatin induces oxidative stress and is an activator of stress-signaling pathways 
especially of the MAPK cascades. These enzymes are highly important in 
definition of cellular response to applied treatment because they are the major 
regulators of cell proliferation, differentiation, and cell death. Extracellular signal-
related kinase (ERK) preferentially responds to growth factor and cytokines, but 
also determines cell reaction to different stress conditions, particularly, oxidative. 
Cisplatin treatment mainly activated ERK in a dose- and time-dependent manner 
(Wang et al., 2000). Acquisition of cisplatin resistance by ovarian carcinoma cells 
was associated with the loss of ERK activation in response to cisplatin (Boulikas, 
2007). Regardless of numerous evidences about its critical role in cisplatin-
mediated cell death, ERK is not the only molecule from MAP family which 
responded to cisplatin. Several studies revealed c-Jun N-terminal kinase (JNK) 
activation upon the cisplatin addition (Mansouri et al., 2003). However, similarly 
to other molecules previously mentioned, this signal is not the unidirectional and 
could be responsible for realization but also protection from death triggered by 
cisplatin. Finally, there are numerous evidences about highly important role of a 
third member of MAP kinases, p38, in response to cisplatin. Lack of p38 MAPK 
leads to appearance of resistant phenotype in human cells (Hernández Losa et al., 
2003). Early and short p38 activation is principally described in cells 
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unresponsive to cisplatin, while long-term activation was found in sensitive 
clones. Moreover, in the light of the fact that this kinase has a role in modifying 
the chromatin environment of target genes, its involvement in cisplatin induced 
phosphorilation of histon 3 was determined (Wang and Lippard, 2004). 
TRAIL (tumor necrosis factor alpha(α)-related apoptosis inducing ligand) is a 
potent inducer of apoptosis through caspase-3 activation and PARP cleavage. The 
presence of cysteine rich domain in the structure of TRAIL specific death 
receptors, DR4 and DR5, indicated possibility that cisplatin directly interact with 
them (Gómez-Ruiz et al., 2012). Cisplatin may also induce apoptosis through the 
Fas/Fas ligand signaling complex (with activation of caspase 8, then caspase 3), 
although clearly cisplatin-induced apoptosis involves different pathways (Siddik, 
2003). Recent evidence about the biochemical mechanisms that mediate cisplatin 
cytotoxicity support the ability of cisplatin to induce oxidative damage, to 
interfere with cell metabolism and how this is the basis of its antineoplastic 
activity as well as of its main side effects. The increase of various reactive oxygen 
species (ROS) has been observed during cisplatin treatment. Several mechanisms 
have been proposed to account for the ROS generation under this condition. First, 
the depletion or inactivation of GSH and related antioxidants by cisplatin is 
expected to shift the cellular redox status, leading to the accumulation of 
endogenous ROS and oxidative stress within the cell. Second, cisplatin might 
induce mitochondrial dysfunction and increase ROS production by disrupting the 
mitochondrial respiratory chain. Moreover, cisplatin shifts cancer cell metabolism 
from glycolysis to oxidative phosphorylation (OXPHOS). OXPHOS is the source 
of ATP and ROS, which are essential for the p53-mediated apoptosis (Macciò and 
Madeddu, 2013). 
Evaluation of a 60 human tumor cell line panel conducted by the National Cancer 
Institute (NCI) revealed that functional p53 protein is very important for 
successful response to cisplatin treatment (Wang and Lippard, 2005). This tumor 
suppressor gene, a transcription factor that is considered a “guardian of the 
genome”, is crucial for many cellular processes and determines the balance 
between cell cycle arrest as a chance for repair and induction of apoptotic cell 
death. However, despite extensive NCI studies, there are controversial data about 
correlation between cisplatin sensitivity and p53. In addition, protein involved or 
influenced by p53 pathway, such as Aurora kinase A, cyclin G, BRCA1 as well as 
pro-apoptotic or anti-apoptotic mediators are also able to control cisplatin toxicity 
(Wang and Lippard, 2005) (Figure 3.5). 
Finally, the end result of cisplatin treatment is the activation of caspases leading to 
apoptosis, to cell cycle arrest, mitochondrial apoptotic pathway, to DNA damage-
induced apoptosis, as well as to upregulation in the expression levels of 
transcription factors that are tightly linked to apoptosis. Moreover, necrosis or 
accidental cell death due to general cell machinery failure was also reported as a 
cell-killing mechanism for cisplatin (Gonzalez et al., 2001; Lau, 1999). 
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Figure 3.5 Overview of pathways involved in mediating cisplatin-induced cellular effects. Cell 
death or cell survival will depend on the relative intensity of the signals generated and the 
crosstalk between the pathways involved. 
 
Even though cisplatin continues to be one of the most widely used drugs in 
modern chemotherapy its clinical applications is hundred by two major 
limitations: the development of cisplatin resistance by tumors and the related 
severe toxic side effects.  
 
 
3.2.4 Cisplatin resistance  
The use of cisplatin in cancer chemotherapy is limited by the insurgence of 
acquired or intrinsic resistance after drug exposure. 
Acquired resistance. This type of resistance develops both in patients undergoing 
chemotherapy and in cell lines exposed to increasing concentrations of cisplatin 
until they have reached a high tolerance for the drug.  
Intrinsic resistance. This type of resistance is a phenomenon encountered in 
patient tumors that are naturally unaffected by platinum treatment. Some cell lines 
cultured from these patients were more proficient at removing cisplatin-DNA 
adducts than cell lines with normal cisplatin sensitivity (Zwielly et al., 2011).  
In nature, intrinsic and acquired drug resistance occurs in all living organisms, 
from bacteria to human cancer cells. Resistance is a natural cellular self-defense 
 23 
 
mechanism developed by evolution to protect cells from toxic natural products 
and other environmental stressors. During the development of cisplatin resistance 
in human cancer cells in vivo and in vitro, numerous epigenetic and/or genetic 
changes can occur, probably reflecting activation of many different pathways that 
protect cells against environmental toxins (Shen et al., 2012).  
Because cisplatin has many different routes of cell entry and multiple cellular 
targets, resistance to this platinum compound is very complex, requiring multiple 
pathways, with profound changes at both the molecular and cellular levels (Shen 
et al., 2012). Therefore, although the large number of biochemical studies carried 
out on cisplatin activity have not clearly established yet the molecular bases of 
tumor resistance to this drug in any type of cell, at least they have identified 
several mechanisms that can contribute to this process (Figure 3.6).  
 
 
 
Figure 3.6 Representation of different mechanisms involved in cisplatin resistance. ↗: increase; ↘: 
decrease. 
 
Resistance to cisplatin is generally considered a multifactorial phenomenon, 
which can develop as a result of decreased intracellular drug concentration due to 
decreased uptake, increased efflux, or due to increased inactivation by sulfhydryl 
molecules, such as glutathione. Increased excision of the adducts from DNA by 
repair pathways or increased lesion bypass can result in resistance. Finally, altered 
expression of regulatory proteins involved in signal transduction pathways that 
control apoptosis can also affect sensitivity to the drug (Kartalou and Essigmann, 
2001). While it is possible that only one of these mechanisms may lead to 
resistance to cisplatin, it is more likely that a combination of these mechanisms 
results in a cisplatin-resistant tumor (Rabik and Dolan, 2007) (Figure 3.6). 
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3.2.4.1 Reduced drug accumulation 
A major mechanism of resistance to cisplatin is a decreased effective 
concentration of drug in the cell. Reduction in cisplatin concentration of 20–70% 
has been observed in cell lines resistant to cisplatin. This can be due either to 
decreased influx or increased efflux. It has long been presumed that cisplatin is 
taken up passively by the cell, as uptake is not saturable, nor is it inhibited by 
structural analogs. Accordingly, increased accumulation and therefore, increased 
toxicity can be attained in vivo by increasing the fluidity of the membrane by 
hyperthermia (Toffoli et al., 1989). However, as mentioned before, a role for 
transporters or gated channels has also been postulated in addition to passive 
diffusion. In this regard the copper transporter 1 (CTR1), has been shown to have 
a substantial role in cisplatin influx. Indeed, experiments with the yeast protein 
CTR1 and cisplatin, revealed that mutation or deletion of the CTR1 gene leads to 
stronger cisplatin resistance and to intracellular reduction of platinum levels in 
yeast and in mouse cells (Ishida et al., 2002). Interestingly, cisplatin accumulation 
in cells became increased when human CTR1 gene was overexpressed, although 
the ability of the drug to access its cytotoxic targets was unaltered (Holzer et al., 
2004). On the other hand, it has been found that copper-transporting P type 
adenosine triphosphate (ATP7B), which regulates copper homeostasis in the cell, 
has a role in cisplatin efflux and is associated with cisplatin resistance in vitro 
(Komatsu et al., 2000), and in various cancers (Nakayama et al., 2004). Hence, 
expression of ATP7B in human carcinoma cells modulates sensitivity to cisplatin 
and copper through a more efficient efflux of the two agents (Holzer et al., 2004). 
Altogether these data indicate that there is a connected transport for copper and 
cisplatin because both copper and cisplatin (i) can reduce the uptake of each other, 
(ii) trigger the degradation and delocalization of CTR1, and (iii) also show 
bidirectional cross-resistance  (Cepeda et al., 2007; Katano et al., 2002). 
The multidrug resistance-associated protein MRP1 (ABCC1) and other MRPs are 
now known to play important roles in detoxification and chemoprotection by 
transporting a wide range of compounds, especially secondary metabolite 
conjugates of lipophilic substances with glutathione, glucuronate, and sulfate. 
Although they modulate the pharmacokinetics of many drugs, no direct 
correlation with cisplatin resistance has been found in vitro or in patients.  
Whereas, another exporter protein implicated in cisplatin resistance through drug 
efflux is the ATP-binding cassette, sub-family C 2 (ABCC2 also known as MRP2 
or cMOAT) (Kool et al., 1997).  
One important consequence of selection of human cervical epidermal carcinoma 
cells KB in cisplatin is the reduced expression and internalization of Glut1 
(glucose transporter 1), normally located on the cell surface. This reduces glucose 
uptake, resulting in induction of Sirt1 in cisplatin-resistant cells, causing cisplatin 
resistance (Liang et al., 2008). The mitochondrial phenotype associated with up-
regulation of Sirt1 by glucose starvation, or Sirt1 transfection, decreases apoptosis 
and makes cells more resistant to cisplatin. Therefore, although Glut1 is not 
 25 
 
proposed to directly transport cisplatin, the mislocalization of the transporter 
exacerbates the cisplatin resistance phenotype. 
Reduced endocytosis is another way for cells to decrease uptake of cisplatin 
normally achieved via cellular fluid-phase endocytosis. Liang and coworkers 
(Liang et al., 2006) further tracked lipids in the endocytic recycling compartment 
(ERC) and found that the distribution of the ERC is altered in early-stage 
cisplatin-resistant human epidermoid carcinoma KB-CP.5 cells, compared with 
parental KB-3-1 cells. In addition, cells with a dispersed ERC under non 
permissive conditions were more resistant to cisplatin, indicating that this 
resistance might be due, in part, to reduced uptake of cisplatin resulting from an 
endocytic defect. Therefore, a defective endocytic pathway may constitute a 
cellular defense mechanism that protects the cell against toxic compounds from 
the exogenous environment by reducing influx of the compounds.  
 
 
3.2.4.2 Inactivation of cisplatin by sulfur-containing molecules 
Resistance to cisplatin because of enhanced inactivation by intracellular proteins, 
including the abundant nucleophilic glutathione (glutamylcysteinylglycine, GSH) 
and the cysteine-rich metallothionein, has also been reported (Godwin et al., 
1992).  
In particular, increased GSH may cause resistance by binding/inactivating 
cisplatin, enhancing DNA repair, or reducing cisplatin-induced oxidative stress 
(Siddik, 2003).  
The metabolic synthesis of glutathione involves peptide bond formation between 
cysteine and glutamic acid (rate limiting step catalyzed by γ-glutamylcysteine 
synthetase, γ-GCS), followed by peptide bond formation with glycine. Cisplatin 
can be covalently linked to GSH after nucleophilic attack of the glutathione 
thiolate anion, and this complex can be transported out of the cell by the ATP-
dependent glutathione S-conjugate export pump (Ishikawa and Ali-Osman, 1993). 
Conjugation with GSH inhibits the conversion of monoadducts to crosslinks, 
thereby reducing the cytotoxic potential of the adducts. In addition, GSH might 
protect cells by maintaining the dNTP pool size needed for DNA repair, by 
maintaining functional repair enzymes such as polymerase α, and by buffering 
endogenous drug-induced oxidative stress. This is consistent with reports that 
cells overproducing the Bcl-2 protein have correspondingly higher intracellular 
GSH levels, which may contribute to the anti-apoptotic functions of Bcl-2 
(Hockenbery et al., 1993). 
Increases in GSH have been demonstrated in a number of cisplatin-resistant tumor 
models, and confirmed in clinical studies (Wolf et al., 1987). Furthermore, in a 
panel of resistant ovarian tumor models, prominent elevations in GSH levels have 
been correlated directly with resistance. Such elevations may occur as a result of 
increased expression of the γ-GCS gene (Godwin et al., 1992; Lai et al., 1989). 
Overexpression of g-glutamyltransferase (γ-GT) in cisplatin resistance is also 
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observed, and this may further exacerbate inactivation of cisplatin (Daubeuf et al., 
2002).  
γ-GT is another key player in GSH homeostasis, and generates cysteinylglycine 
during GSH catabolism. Since cysteinylglycine is 10-fold more reactive toward 
cisplatin than is GSH, the overproduction of the more reactive thiol by γ-GT is 
potentially a major contributor to GSH-mediated resistance.  
Metallothioneins are a family of cysteine rich proteins involved in Zn2+ 
homeostasis and in the detoxification of heavy metals such as cadmium. 
Metallothioneins bind to cisplatin in a protein:drug ratio of 1:10 and may affect 
sensitivity to the drug (Pattanaik et al., 1992).  
The increase in metallothionein, up to five-fold over basal levels, have been 
observed in cisplatin-resistant murine and human tumor models (Kasahara et al., 
1991). It is noteworthy that in some studies, changes in metallothionein levels in 
resistant cell lines, or in human ovarian tumor biopsies taken before and after 
cisplatin based therapy, have not been observed (Murphy et al., 1991). These 
variations in the reported data again emphasize the multifactorial nature of 
resistance and also that the increase in metallothionein is not necessarily an 
absolute requirement for cells to attain the resistance phenotype (Siddik, 2003). 
 
 
3.2.4.3 Increased repair of platinum-DNA adducts 
Cell lines selected for resistance to cisplatin after prolonged culture in the 
presence of cisplatin have significantly higher levels of repair than the 
corresponding parental cell lines, indicating that DNA repair is an important 
determinant of cisplatin resistance. Moreover, differential capacity to repair 
cisplatin adducts is postulated to be responsible for part of the variability in 
clinical response to cisplatin-based chemotherapy (Jones et al., 1994). A cell line 
established from the tumor of an ovarian cancer patient that was not responding to 
chemotherapy had a three-fold higher repair synthesis activity than the cell line 
established from the tumor of the patient prior to the onset of resistance (Lai et al., 
1988). 
Nucleotide excision repair is believed to be the main process by which platinum 
adducts are removed from DNA. Mammalian cells deficient in nucleotide 
excision repair are more sensitive to cisplatin than the corresponding wild type 
cells. Excision repair assays using both human cell extracts or a reconstituted 
excinuclease confirmed that the 1,3-d(GpTpG) adduct is more efficiently repaired 
than the 1,2-d(GpG) or 1,2-d(ApG) adducts. No repair is detected for a cisplatin 
interstrand crosslink (Zamble et al., 1996). Interestingly, enhanced expression of 
XPA mRNA is observed in tumor tissues from ovarian cancer patients that are 
resistant to platinum-based chemotherapy compared to levels in tissues of patients 
that respond favorably to chemotherapy. Furthermore ERCC1 mRNA levels 
correlate with response to platinum-based chemotherapy with the higher mRNA 
levels observed in tumors refractory to chemotherapy (Dabholkar et al., 1994). Of 
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great importance is the recent observation that testicular tumor cells have low 
levels of the XPA protein and the ERCC1–XPF endonuclease complex. These 
proteins are necessary for nucleotide excision repair, indicating that the unique 
sensitivity of testicular cells to cisplatin may be attributed to the inability of these 
cells to repair cisplatin damage (Köberle et al., 1999).  
Cisplatin-resistant cell lines isolated after exposure to the drug in vitro frequently 
acquire the mutator phenotype associated with mismatch repair defects and are 
usually mutated in the hMLH1 genes (Aebi et al., 1996). Complementary studies 
with mismatch repair deficient cells have shown that inactivation of mismatch 
repair genes confers resistance to cisplatin. In particular, in colorectal and 
endometrial cancer cell lines. The importance of mismatch repair in clinical 
response was evaluated in a study that measured hMSH2 and hMLH1 expression 
in paired tumors of ovarian cancer patients obtained before and after platinum-
based chemotherapy. The hMSH2 and hMLH1 expression decreased significantly 
after treatment, consistent with the ability of cisplatin treatment to select for 
mismatch repair deficient cells in an animal model. However, no association 
between the expression of either protein and overall survival was apparent, 
suggesting that hMSH2 and hMLH1 levels are not predictive of clinical response 
(Samimi et al., 2000).  
HMG proteins are also implicated in cisplatin-mediated resistance. Several 
mechanisms have been proposed for how HMG domain proteins might modulate 
the sensitivity of cells to cisplatin but two of them seem to be the most feasible 
ones. The “repair shielding model” postulates that HMG proteins could protect 
cisplatin-DNA adducts from recognition by DNA repair enzymes (Ahmad, 2010). 
The second one, the so-called “hijacking model” establishes that HMG proteins 
could modulate cell cycle events subsequent to DNA damage and trigger cell 
death. Thus, this latter model postulates that the recognition by HMG cellular 
factors of cisplatin-DNA lesions would deviate them from their natural binding 
sites resulting in inhibition of vital cellular functions (Cepeda et al., 2007).  
 
 
3.2.4.4 Increase of cisplatin adducts tolerance and failure of cell death 
pathways 
A study of a panel of human ovarian cancer cell lines derived from patients who 
were or were not treated with cisplatin-based chemotherapy reveals that adduct 
level tolerance inversely correlates with sensitivity to cisplatin. Moreover, several 
reports have demonstrated that cisplatin-resistant cells have a higher capacity for 
adduct tolerance than the corresponding cisplatin sensitive parental cell lines 
(Johnson et al., 1997). The enhanced tolerance of cisplatin adducts has been 
correlated with the increased ability to replicate past cisplatin adducts. In order for 
platinated DNA to be replicated and tolerance to form, DNA polymerase must 
skip the platinum adduct, which is most commonly an intrastrand lesion. The 
classic DNA replication polymerases α, δ, and ε cannot bypass the lesion; 
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however, several polymerases have been shown to bypass intrastrand crosslinks 
by translesion synthesis namely, β, ε, δ, and ι (Havener et al., 2003). 
Overexpression of DNA polymerase β has been shown to lead to cisplatin 
resistance, while downregulation using anti-sense RNA leads to sensitivity 
(Albertella et al., 2005). The mutagenic consequence of replication bypass of a 
1,2-d(GpG) adduct by DNA polymerase β was determined in vitro and revealed a 
42% mutation frequency. The most frequent modifications are -1 deletions of the 
cytosine located immediately 5‟ of the adduct. In contrast, the overall mutation 
frequency in vivo is 21% and the most frequent modification are base 
substitutions, most of which occur at one of the platinated guanines (Hoffmann et 
al., 1996). 
In addition to replication bypass, adduct tolerance could also be attained by 
inhibition of apoptosis. Alterations in the expression of regulators of apoptosis can 
alter the sensitivity of the cells to apoptosis following cisplatin treatment. For 
example, cells that express high levels of an apoptosis inhibitor or low levels of an 
apoptosis promoter would require higher levels of damage before they initiate 
apoptosis. Accordingly, reduced expression of Bax, which promotes apoptosis, is 
seen in cisplatin-resistant ovarian cancer cells (Sakakura et al., 1997) and, 
conversely, human head and neck squamous cell carcinoma cells expressing Bax 
are more sensitive to cisplatin, both in culture and in animals (Sugimoto et al., 
1999). Furthermore, transfection of cells with Bcl-2 or Bcl-XL, which inhibit 
apoptosis, confers cisplatin resistance and downregulation of Bc-XL sensitizes 
cells to cisplatin (Taylor et al., 1999). 
Caspases 3, 8, and 9 are important in cisplatin-induced apoptosis (Siddik, 2003). 
Loss of caspase 8 pathway was associated with cisplatin resistance in a squamous 
cell carcinoma of the head and neck (SCCHN) cell line. Decreased Fas expression 
or pathway activation after cisplatin may lead to inhibition of activation of 
caspases 3 and 8 (Siddik, 2003), and was associated with cisplatin resistance in 
germ cell tumors and ovarian cancer cells. Decreased cisplatin caspase 9 
activation was noted in cells with normal mitochondrial cytochrome-c release and 
normal Bcl-2 and Bcl-XL expression (Stewart, 2007). Cisplatin-resistant cells 
have also been reported with abnormal mitochondrial membrane potential, 
intracellular distribution, or structure, and with up-regulation of cytochrome-c in 
the mitochondria, rather than release into the cytoplasm, in response to cisplatin 
(Isonishi et al., 2001). 
Overall, there is preclinical evidence of an association of platinum resistance with 
abnormalities of a variety of apoptotic factors. The effect of altered expression of 
regulatory proteins appears to be cell type specific and is not predictive of clinical 
response to cisplatin-based chemotherapy. It is noteworthy however, that genes 
that are induced in response to cisplatin damage, are upregulated in some cell 
lines selected for resistance to cisplatin. Furthermore, studies with cells in culture 
might not always mirror the situation in tumors and therefore, cannot identify 
mechanisms of resistance operative in vivo. Studies with cell lines can serve as an 
initial screen for agents that might modulate cisplatin resistance. Some 
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mechanisms of resistance might only operate at the organism level and not at the 
cellular level (Kartalou and Essigmann, 2001).  
 
 
3.2.5 Cisplatin toxicity 
Despite the positive effects of platinum compounds patients receiving these agents 
experience severe side effects that limit the dose which can be administered. The 
ability to manage this induced toxicity is crucial for the success of cancer 
chemotherapy (Florea et al., 2011). 
Toxicities associated with cisplatin range from mild to severe. The most common 
side effects are gastrointestinal toxicity, hearing loss (ototoxicity), decreased 
blood cell and platelet production in bone marrow (myelosuppression), damage of 
neurons (peripheral neuropathy), and damage to the kidney (nephrotoxicity), with 
the last two being the most serious (Rabik and Dolan, 2007) (Figure 3.7). 
 
 
 
Figure 3.7 Toxicities associated with cisplatin treatment.  
 
Gastrointestinal toxicity in the form of nausea and vomiting has been reported in 
most studies using fixed dosage regimen of cisplatin. The incidence of nausea 
ranges from 50 to 100%, and the incidence of vomiting ranges from 17 to 100%. 
Nausea and vomiting usually begins 1-6 hours after cisplatin administration. They 
usually do not last more than 24 hours, but anorexia and nausea may persist for up 
to a week (Wiltshaw and Kroner, 1976). Some investigators believe 
gastrointestinal toxicity is somewhat dose-dependent, whereas others believe 
severe nausea and vomiting can be seen at any dose level. Intravenous hydration 
before and after cisplatin seems to lessen the severity of drug-induced nausea and 
vomiting. A number of antiemetics have been used to prevent or treat nausea and 
vomiting. For the most part, none have been consistently helpful. Nabilone, has 
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been reported to have salutary effects against cisplatin induced gastrointestinal 
upset. Beneficial effects have also been reported with metoclopramide. Clearly, 
cisplatin-induced nausea and vomiting is a major problem, and more effective 
means to combat these bothersome side effects are needed (Von Hoff et al., 1979).  
Diarrhea has occasionally been encountered. No stomatitis has been reported with 
cisplatin administration (Von Hoff et al., 1979). 
Ototoxicity occurs in approximately 23-54% of patients receiving cisplatin 
treatment, and in greater than half of pediatric patients receiving cisplatin. 
Platinum-based chemotherapeutic agents damage the outer hair cells of the 
cochlea (inner ear), resulting in functional deficits. The mechanisms underlying 
these troublesome side effects most likely involve the production of reactive 
oxygen species (ROS) in the cochlea, which can trigger cell-death pathways. One 
strategy to protect the inner ear from ototoxicity is pre-treatment with thiol-
containing drugs that act as antioxidants, including sodium thiosulfate (STS), 
methionine, glutathione ester, and amifostine (Rybak and Whitworth, 2005).  
Due to the renal excretion of cisplatin, the kidney accumulates a higher effective 
concentration of cisplatin than any other organ. This accumulation preferentially 
affects the terminal proximal tubule and the distal nephron and can cause either 
apoptosis or necrosis, depending on exposure time and concentration. Low, 
prolonged doses of cisplatin typically induce apoptosis, whereas necrosis is 
caused by short exposures to higher concentrations of cisplatin (Ikari et al., 2005). 
Similar to cisplatin-induced ototoxicity, nephrotoxicity related to cisplatin 
treatment is due to the production of  ROS. ROS damage is thought to be 
mitigated by hypoxia-inducible factor 1a (HIF1a). Future studies hope to use 
activation of HIF-1 as a target for further protecting patients from nephrotoxicity, 
possibly with siRNA or gene therapy (Tanaka et al., 2005). The human organic 
cation transpoter (hOCT) has been proposed to be involved in potentiating 
cisplatin-induced nephrotoxicity in the proximal tubule. This transporter is 
expressed primarily in the kidney. After treatment with a concentration of 
cisplatin known to induce apoptosis, the hOCT2 substrate cimetidine was able to 
suppress cisplatin-induced apoptosis. Cotreatment of cisplatin with a hOCT2 
inhibitor could lead to reduction in nephrotoxicity (Ciarimboli et al., 2005). 
Nephrotoxicity has largely been controlled by diuretics and pre-hydration of 
patients. Many anti-oxidant treatments, including tiopronin, N-acetylcysteine pre-
treatment and sodium thiosulfate post-treatment, have been employed in 
protecting against nephrotoxicity (Dickey et al., 2005). 
The dorsal root ganglia of the spinal cord are the primary location of cisplatin 
damage in the central nervous system. This explains the primary sensory 
neuropathy commonly observed in patients treated with cisplatin (Meijer et al., 
1999). Cisplatin-induced neuropathy is characterized by decreased sensory nerve 
conduction velocity, possibly by acting as a calcium channel blocker. Co-
treatment of rats with acetyl- L-carnitine was able to protect animals from 
neurotoxicity while having no effect on the anti-neoplastic activity of cisplatin 
(Pisano et al., 2003). Vitamin E has been shown to be decreased in patients treated 
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with cisplatin, and vitamin E deficiency causes a sensory neuropathy very similar 
to that observed with cisplatin treatment. Therefore, vitamin E was tested as a 
means to protect against cisplatin-induced neuropathy in a controlled clinical trial. 
Neurotoxicity, as measured by a peripheral neuropathy score, was significantly 
decreased in patients treated with cisplatin plus vitamin E, as compared with those 
treated with cisplatin alone (Bove et al., 2001). Erythropoietin has also been 
associated with neuroprotection in vivo. Carbamylated erythropoietin is currently 
undergoing further experimentation for long-term side effects, with future clinical 
trials planned (Bianchi et al., 2006). 
Even though cisplatin has generally been regarded as nonmyelosuppressive, 
several investigators indicate hematologic toxicity may be dose-limiting. The drug 
affects all three blood elements. The incidence of leucopenia ranges from 0 to 
50%; white blood cells counts of < 1500/mm
3
 were seen in 3% of patients.. The 
degree of leucopenia seems to be dose-related and may be more common with the 
weekly schedule of drug administration. Leukopenia may be cumulative but is 
usually reversible. It is generally more severe in patients who have been 
extensively pretreated with many other cytotoxic drugs, particularly alkylating 
agents, and in patients who have had extensive prior radiotherapy (Talley et al., 
1973). Thrombocytopenia has also been reported as a dose-limiting toxic effect of 
cisplatin. The incidence of thrombocytopenia (platelet count < 100,000/mm
3
) 
ranges from 2 to 50%. Thrombocytopenia is dose-related and may be cumulative, 
but is usually reversibile; again, it is generally more severe in patients with a 
history of prior drug or radiation therapy. The incidence of cisplatin-induced 
anemia (hemoglobin drop of > 2.0 g/100 ml) ranges from 9 to 40%. There is no 
clear relationship between the dose or schedule of cisplatin administration and the 
severity of anemia. In summary, cisplatin can cause suppression of all three blood 
elements. Although it is still unclear which schedule or mode of administration 
causes the most myelotoxicity, it is clear that blood component support may be 
required when treating patients with cisplatin (Von Hoff et al., 1979).   
 
 
3.3 Liposomal formulations 
Despite being one of the most effective classes of chemotherapeutics, platinum 
drugs do have several significant shortcomings. Therefore, one of the key research 
areas in oncology has been to develop novel platinum analog drugs and engineer 
new platinum drug formulations to reduce  side effects, to enhance the therapeutic 
index and the effectiveness against cisplatin-resistant tumors with a potential 
application in patients who relapse after first-line platinum-based treatment. 
However, in spite of over 30 years of intensive research, no more than 30 new 
platinum compounds, over 3,000, have exhibited adequate pharmacological 
advantages relative to cisplatin, in order to be tested in clinical trials (Fuertes et 
al., 2002). Only four were registered for clinical use (Boulikas et al., 2007), 
proving that the search for novel platinum compounds remains a difficult task. 
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The vast majority of platinum compounds synthesized have been abandoned 
because of low efficacy, high toxicity, low water insolubility and other reasons. 
Another strategy to improve platinum drugs has been to improve the delivery of 
platinum therapeutics to tumors by use of nanoparticle drug delivery technology 
(Liu et al., 2013).  
A key challenge in cancer therapy is to deliver anticancer drugs and other 
chemotherapeutics selectively to tumors while minimizing accumulation in 
normal tissues. Such targeted delivery can improve therapeutic efficacy while 
reducing toxicity. Although such differential drug delivery is generally not 
possible with small molecular drugs, nanocarrier-based delivery can overcome 
this challenge via the enhanced permeability and retention effect (EPR) that 
allows the extravasation of nanoparticles in the tumor area (Jain and 
Stylianopoulos, 2010). Indeed, a distinct feature of tumor tissue compared with 
normal tissue is its rapid formation of vasculature triggered by vascular 
endothelial growth factor and other growth factors overexpressed in various 
cancerous cells. These newly formed vessels do not have a smooth muscle layer 
so are defective and have a wider lumen, leading to irregular and leaky 
boundaries. The other key feature of tumor tissue is dysfunctional lymphatic 
drainage, resulting in ineffective clearance of extravascular proteins, particles, and 
white blood cells (Mattheolabakis et al., 2012).  
Due to their large size, nanocarriers are not able to penetrate through the normal 
vasculature, but can penetrate through the leaky vasculature around tumor regions. 
Together with ineffective lymphatic drainage of tumor tissues, differential 
delivery/accumulation could be realized (Maeda and Matsumura, 2011). This 
effect, known as EPR effect, is considered to be passive targeting and is present in 
a wide variety of solid tumors. On the other hand, the passive accumulation of 
liposomes also occurs in tissues with discontinuous endothelium or fenestrated 
structure, such as the spleen, bone marrow and liver, while for tissues or organs 
with continuous non-fenestrated structure, where the tight endothelial junctions 
are ~5 nm, the extravasation of small liposomal carriers is prevented. The EPR 
effect is considered a heterogeneous process because it presents a high variability 
between different types of tumors, from patient to patient, and even within the 
tumor itself, where there are huge differences in vascular permeability. In 
addition, another important drawback associated with EPR effect is the 
penetration of nanoparticles in the tumor, which are able to cross not more than 
one or two cell layers (Zalba and Garrido, 2013). However, the pharmacokinetic 
profile of the encapsulated drug is basically modified in comparison with the free 
drug, with a view to obtain a pharmacodynamic advantage.  
Liposomes were engenireed in 1965, when Alec Bangham and colleagues 
published the first description of swollen phospholipid systems that established 
the basis for model membrane systems. Within a few years, a variety of enclosed 
phospholipid bilayer structures consisting of single bilayers, initially termed 
„bangosomes‟ and then „liposomes‟, were described, and the early pioneers such 
as Gregory Gregoriadis, established the concept that liposomes could entrap drugs 
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and be used as drug delivery systems (Allen and Cullis, 2013; Gregoriadis et al., 
1974). 
Liposomes, small artificial vesicles of spherical shape defined as drug carrier 
nanoparticles, consist of an aqueous core entrapped by one or more phospholipid 
bilayers, where the polar head groups are oriented in the pathway of the interior 
and exterior aqueous phase. Liposomes membrane is composed of natural and/or 
synthetic lipids which are relatively biocompatible, biodegradable and non-
immunogenic material (Akbarzadeh et al., 2013). 
Liposomes are formed when a thin lipid film is hydrated with aqueous buffer 
solution (Bangham method), and are typically sonicated or repeatedly extruded 
through a 100 nm polycarbonate membrane to reduce their size and narrow their 
size distribution to afford small or large unilamellar liposomes, respectively 
(Akbarzadeh et al., 2013). In addition to the Bangham method, several other 
techniques, such as detergent-depletion, ether/ethanol injection, reverse phase 
evaporation, and emulsion methods, have been reported for preparing liposomes 
with high-entrapment efficiency, narrow size distribution, and long term-stability. 
Recently, some alternative methods including dense gas and supercritical fluid 
techniques have been introduced. Due to the differences in preparation methods 
and lipid compositions, liposomes can be classified according to their lamellarity 
(uni- and multilamellar vesicles), size (small [≤100 nm], intermediate [100-250 
nm], or large [≥250 nm]), and surface charge (anionic, cationic, or neutral) 
(Chang and Yeh, 2012).  
Liposomes allow the encapsulation of amphiphilic drugs, incorporating the 
hydrophilic drugs in the aqueous compartment and entrapping the lipophilic drugs 
in the bilayers. Encapsulation of hydrophobic drugs inside liposomes significantly 
increases their solubility in aqueous solution. The size, charge, and surface 
properties of liposomes, that influence the pharmacokinetic profile of the 
encapsulated drug, can be easily manipulated (increased drug stability via 
encapsulation) (Torchilin, 2005). It is thus possible to prolong the half-life of a 
cytotoxic drug in the systemic circulation (increased drug exposure time) and alter 
its biodistribution pattern, leading to elevated accumulation in tumor tissue 
(selective passive targeting) and a decreased dose to normal tissues. Formulation 
of therapeutics with liposomes can significantly reduce their side effect profile by 
avoiding non-targeted systemic drug exposure in the body. Upon accumulation at 
tumor sites, liposomes can also provide a unique opportunity to facilitate drug 
uptake into targeted cells or even localize the drugs to specific cellular 
compartments (Liu et al., 2013). 
The use of liposomes as drug carriers presents some critical steps: the drug 
loading, the drug release, and the rapid cleareance of liposomes. However, due to 
extensive studies the efficacy of liposomal drug formulations has been enhanced 
by number of innovative strategies, such as remote drug loading (Haran et al., 
1993), extrusion for homogeneous size (Olson et al., 1979), long-circulating 
(PEGylated) liposomes (Klibanov et al., 1990), triggered-release liposomes (Bibi 
et al., 2012), and ligand-targeted liposomes (Sapra and Allen, 2002). 
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A very early observation was the difficulty in retaining some types of molecules 
entrapped in the liposome (Gregoriadis, 1973). Changing the content of the 
liposome bilayer, in particular by incorporating of of cholesterol (Allen and 
Cleland, 1980) was shown to „tighten‟ fluid bilayers and reduce the leakage of 
contents from liposomes. Switching from a fluid phase phospholipid bilayer to a 
solid phase bilayer also reduced leakage, as did incorporation of sphingomyelin 
into liposomes (Cullis and Hope, 1980).  
Similar to biological membranes, liposomes have low permeability to hydrophilic 
drugs and high permeability to hydrophobic drugs.  Indeed, to this day, retention 
of highly hydrophobic drugs such as paclitaxel in liposomes is problematic 
(Cabanes et al., 1998). A major advance in this area was the development of drug 
loading in response to transmembrane pH gradients. The term “remote loading” is 
often used to describe this procedure, because the drug is loaded after the vesicles 
are formed. The advantage of this is that the loading of the drug can be performed 
independent of the time and site of liposome manufacture. (Madden et al., 1990).  
The retention properties of drugs in liposomes are drug dependent; drugs such as 
doxorubicin precipitate readily inside liposomes following accumulation and have 
excellent retention properties, whereas other drugs, such as ciprofloxacin, which 
do not readily precipitate, are more difficult to retatin (Maurer et al., 1998). 
It is important to keep in mind that drug entrapped in liposomes is not 
bioavailable; it only becomes bioavailable when it is released. (Johnston et al., 
2006). The drug must be delivered to the disease site and become bioavailable at a 
level within its therapeutic window, and at a sufficient rate, for a sufficient period, 
to have optimal therapeutic activity. Therefore, being able to trigger the release of 
liposomal contents once they reached the target site would lead to improvements 
in therapeutic outcomes (Allen and Cullis, 2013).  
Two main types of triggers have been explored, remote triggers such as heat, 
ultrasound and light, and local triggers that are intrinsic to the disease site or 
cellular organelles such as enzymes and pH changes (Allen and Cullis, 2013). 
The first trigger for drug release was hyperthermia (remote trigger); delivery of 
liposomal methotrexate was demonstrated to be four-fold higher in heated tumors 
versus non-heated control tumors (Weinstein et al., 1979). Other recent advances 
in remote-triggered release systems include the use of ultrasound to trigger drug 
release from echogenic (“bubble”) liposomes; the use of light as a trigger in 
photosensitive liposomes; and magnetically responsive liposomes (Allen and 
Cullis, 2013). Liposomes can be designed to release their contents in the enzyme 
rich, low pH environment of endosome and lysosomes through the use of pH-
triggered approaches. Liposomes can also be designed to release their contents 
through the use of lipids of peptides that facilitate fusion with the target cell 
membrane (Guo and Szoka, 2001). Enzyme-triggered release of liposome 
contents has also been studied for a variety of different enzymes including: 
phospholipase C, phospholipase A2, alkaline phosphatase, and matrix 
metalloproteinases (Allen and Cullis, 2013). However, in general, triggered 
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release approaches, although promising in concept, have been disappointing in 
practice. 
Another problem was the rapid clearance of liposomes from circulation by uptake 
into the cells of the mononuclear phagocyte system (MPS), predominantly in the 
liver and spleen (Juliano and Stamp, 1975). The rapid uptake of liposomes into 
the MPS substantially reduced their distribution to other tissues of the body, and 
were also implicated in toxicities to the MPS organs (Ellens et al., 1982). Initially, 
attempts were made to increase the circulation half-life of liposomes by MPS 
blockade using large pre-doses of liposomes that contained no drug („empty‟ 
liposomes). Also the reduction in vescicle size modestly improved the half life 
circulation (Hwang et al., 1987). The opsonization of liposomes by serum proteins 
was suggested as a likely mechanism for the rapid clearance of liposomes into the 
liver and spleen (Hoekstra et al., 1981), and modifications of the membrane 
surface led to improvements in their circulation half-lives. Early research focused 
on identifying differences between plain or unmodified phospholipid membranes 
and biological membranes with a surface layer rich in carbohydrates. Addition of 
the monosialoglyprotein (GM1) to liposomes composed of egg 
phosphatidylcholine (egg PC), in combination with cholesterol for membrane 
rigidity, resulted in the first long-circulating liposomes that did not require MPS 
blockade to achieve the effect. Substitution of sphingomyelin for egg PC resulted 
in even longer circulation half-lives, and lower uptake of liposomes into the liver 
(Allen and Chonn, 1987). The mechanism was postulated to be due to increases in 
the surface hydrophilicity of the liposomes imparted by the gangliosides; these 
long-circulating liposomes were termed „Stealth‟ liposomes, a term subsequently 
adopted to apply to liposomes sterically stabilized with polymers such as 
polyethylene glycol (PEG). Indeed, research pointed the way towards a simpler 
way of increasing the circulation half-life of liposomes. The covering of 
liposomes surface with the synthetic neutral polymer PEG led to the formation of 
a protective hydrophilic layer and resulted in substantial reductions in the rapid 
clearance of liposomes into the MPS (Klibanov et al., 1990). 
Moreover, the use of liposomes conjugated with a specific ligand, which is able to 
recognize a specific expression pattern of membrane associated proteins such as 
receptors or membrane transport system, has been proposed to achieve an active-
targeting (Zalba and Garrido, 2013).  
Immunoliposomes combining the specificity of monoclonal antibodies (mAb) 
with the properties of liposomes in drug delivery have been described as the most 
specific targeted formulations (Pasquetto et al., 2011). Although the most 
common ligands reported in the literature coupled to nanoparticles are folate, 
transferrin and galactosamine, they are not considered tumor-specific, contrary to 
mAb used against tumor cells (Pasquetto et al., 2011). For this therapy, a high 
density of the antigen or receptor in the surface of the tumor cells is necessary. 
Few targeted liposomes for platinum derivatives have been reported in the 
literature. Indeed, the techniques for producing ligand-targeted liposomes are 
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tedious, difficult to control, expensive, and lead to poorly defined systems that are 
often rapidly cleared from the circulation (Allen and Cullis, 2013). 
These advanced techniques have indeed led to several liposomal formulations in 
clinical use, with AmBisome® (Astellas Pharma US Inc, Northbrook, IL, USA) 
and Doxil® (Johnson and Johnson, New Brunswick, NJ, USA) being the most 
successful examples. Doxil, a pegylated liposomal formulation of doxorubicin, is 
the first liposomal anticancer formulation approved by the US Food and Drug 
Administration (FDA); it received the approval in 1995 for the treatment of 
chemotherapy refractory acquired immune deficiency syndrome (AIDS)-related 
Kaposi‟s sarcoma (Immordino et al., 2006). In human studies, Doxil was found to 
have pharmacokinetics dramatically different to those of doxorubicin. Doxil has a 
half-life of approximately 90 hours, whereas doxorubicin has an initial 
distribution half-life of approximately 5 minutes followed by a terminal half-life 
of 20-48 hours. More importantly, as the very first proof of the enhanced 
permeability and retention effect observed in humans, Doxil was found to 
accumulate preferentially in tumor tissue through passive targeting (Gabizon et 
al., 1994). The differential pharmacokinetic profiles between Doxil and 
doxorubicin also led to differing toxicity profiles. Doxil has significantly reduced 
cardiotoxicity, allowing prolonged and repeated drug treatments that were 
previously not possible with doxorubicin. In addition to optimized biodistribution, 
tumor accumulation, and reduced cardiac toxicity, superior efficacy was observed 
in Kaposi‟s sarcoma and recurrent ovarian cancer, and equivalent efficacy was 
observed in metastatic breast cancer and multiple myeloma (Safra et al., 2000).  
Currently, there are more than twenty liposome-based drugs approved for clinical 
use (Table 3.1) and more are in various stages of clinical trials.  
 
Table 3.1 Liposomal formulation currently used in clinical application. 
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Liposomes have been extensively studied as drug carriers in the pharmaceutical 
and medical fields. 
For instance, Epaxal and Inflexal V are both vaccine products using the virosome-
based antigen delivery system for commercial use. Virosomes are reconstituted 
virus liposomes, constructed without the genetic information of the virus making 
them unable to replicate or cause infection. The incorporation of viral membrane 
proteins or peptide antigens into liposomes has been shown to potentiate cell-
mediated and humoral immune response, and generate solid and durable 
immunity against the pathogen (Zalba and Garrido, 2013). 
 
 
3.3.1 Liposomal formulations for cisplatin 
It is in the case of anticancer drugs that the liposome system represents an 
interesting challenge regarding the improvement of their therapeutic activity by 
reducing the side effects or/and increasing the antitumor efficacy (Gabizon, 2002). 
Within this type of drugs, platinum derivatives have been widely investigated in 
this field, especially cisplatin, due to its significant toxicity in patients. However, 
at the moment there are no formulations for this drug approved by the FDA, 
although some of them are being evaluated in Phase III clinical trials (Zalba and 
Garrido, 2013). 
SPI-007 (Alza Corp., California, CA, USA) is the first liposomal formulation of 
cisplatin. It is a sterically stabilized, PEGylated, long circulating liposome, 
encapsulating cisplatin. The bilayer consists of hydrogenated soy 
phosphatidylcholine (HSPC), cholesterol (CH) and DSPE-PEG2000 (Newman et 
al., 1999). The half-life was estimated to be 16 hours in mice, compared with 
cisplatin which has a half-life of 0.24 hours. In addition to a longer blood 
circulation time, SPI-77 exhibits a 60-fold larger plasma area under the curve 
(AUC, area under the plasma drug concentration-time curve reflects the actual 
body exposure to drug after administration of a dose of the drug; it is expressed in 
mg*h/L), three-fold higher peak plasma levels, a four-fold reduction in the 
amount of platinum delivered to the kidneys, and a 28-fold higher tumor AUC 
compared with cisplatin (Newman et al., 1999). Despite its superior 
pharmacokinetic properties, SPI-77 did not demonstrate enhanced therapeutic 
efficacy over cisplatin in preclinical experiments in a separate study of M-109 
lung carcinoma, J-6456 lymphoma, C-26 colon carcinoma, and A-375 melanoma 
(Bandak et al., 1999). 
To explain this lack of in vivo efficacy, Zamboni et al. developed a microdialysis 
study in mice (Zamboni et al., 2004). They found a high tumor accumulation of 
liposomes associated with a low antitumor effect, suggesting a very slow release 
of cisplatin from this formulation. Indeed, they also found low DNA-adduct 
concentration after liposome administration, in accordance with the poor 
antitumor efficacy. In vitro release experiments showed that less than 10% of 
cisplatin was released from the liposomes (Zalba and Garrido, 2013). 
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The lack of efficacy of SPI-007 has also been demonstrated in clinical trials. For 
example, in a Phase I study in pediatric patients, a range of doses between 40 and 
420 mg/m
2
 applied every 4 weeks, showed no significant therapeutic response. In 
this study total platinum clearance of SPI-077 displayed a value ≤ 20 ml/h, 
dramatically lower than the value reported for cisplatin, 10-20 l/h/m
2
. Regarding 
the urine excretion, only 4% of the applied dose of SPI-077 was found at 72 
hours, while for the free drug it was between 27 and 35% at 48 hours (Veal et al., 
2001).  
Similar results were found in adults (Harrington et al., 2001). Indeed, in several 
Phase II studies of patients with inoperable head and neck cancer, advanced non-
small-cell lung cancer (NSCLC), or platinum-sensitive recurrence of ovarian 
cancer SPI-77 did not produce significant clinical response rates, even though the 
formulation was shown to be well tolerated (Harrington et al., 2001). SPI-77 did 
not induce any of the toxicities commonly associated with platinum-based 
chemotherapy, such as nephrotoxicity and neutropenia. Side effects include mild 
gastrointestinal toxicity and mild anemia and muscle weakness. However, the lack 
of therapeutic efficacy was likely due to slow and inefficient release of platinum 
from SPI-77, as shown in preclinical studies. On this basis, Harrington et al. 
concluded in their Phase I/II study that a change or reformulation of SPI-077 
should be taken into consideration before continuing with its development 
(Harrington et al., 2001). 
Lipoplatin
TM
 (Regulon, Inc., Athens, Greece) is one of the most promising 
liposomal formulations for cisplatin. It is a PEGylated formulation that differs 
from SPI-77 in several ways. First, the loading method used in lipoplatin is based 
on formation of reverse micelles between cisplatin and dipalmitoyl phosphatidyl 
glycerol, while the mechanism of cisplatin encapsulation in SPI-77 is totally 
passive. Second, the lipoplatin formulation uses anionic dipalmitoyl phosphatidyl 
glycerol lipid and neutral soy phosphatidylcholine lipid, whereas SPI-77 uses only 
neutral lipids. Third, the cisplatin to total lipid ratio is around 1:10 in the case of 
lipoplatin, and much lower in SPI-77, 1:70 (Stathopoulos and Boulikas, 2012; 
Veal et al., 2001). Results in several Phase II and III trials seem to be encouraging 
(more details in section 3.3.2.). 
pH-Sensitive liposomal formulation (SpHL-CDDP) is a long circulating and pH-
sensitive liposome formulation for cisplatin. These liposomes have been prepared 
with dioleoylphosphatidylethanolamine (DOPE) and an unsaturated 
phosphatidylethanolamine (PE), which presents fusogenic properties to enhance 
the drug release into the cytosol. The formulation also includes cholesteryl 
hemisuccinate (CHEMS) and DSPE-PEG 2000. The incorporation of DOPE and 
CHEMS in the formulation leads to liposome destabilization and rapid release at 
acid pH (De Oliveira et al., 1998). Under this condition the release of the 
entrapped drug is very fast, representing an advantage in the case of the tumor 
site, where the environment reaches acid pH values. Although the results for 
SpHL-CDDP seem to be very promising, there are currently few articles in the 
literature regarding this formulation. One of the main objectives for these 
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liposomes was focused on the improvement in cisplatin release, because this was 
the major point responsible for SPI-077 failure (Zalba and Garrido, 2013). 
The release of encapsulated drugs from liposome carriers upon their deposition in 
tumor tissues is critical to confer antitumor activity. LiPlaCis®, a novel liposomal 
formulation of cisplatin, is designed to be degraded by secretory phospholipase 
A2. Given that secretory phospholipase A2 is relatively abundant in tumor sites, 
triggered drug release in tumor tissue is expected. Although LiPlaCis was 
designed to be decomposed by secretory phospholipase A2 specifically, other 
factors also contributed to the degradation of the particles because no correlation 
between the baseline levels of secretory phospholipase A2 and the initial half-life 
of LiPlaCis was observed in patients. In addition, renal toxicity was not prevented 
by treatment by LiPlaCis and acute infusion reactions were observed in many 
patients even with premedication. The poor safety profile of LiPlaCis led to early 
cessation of this particular formulation in the Phase I stage and LiPlaCis requires 
reformulation to enable further development (Liu et al., 2013). 
SPI-077 B103 (Alza Corp., USA) represents a modification of SPI-077. The 
difference between the two formulations is in the replacement of the HSPC by 
other unsaturated phospholipids to enhance the release of cisplatin from these new 
liposomes. However, preclinical studies did not suggest a great improvement with 
regard to SPI-077 (Zamboni et al., 2004).  
Thermosensitive liposomes (LTSL) of cisplatin were developed by Woo et al. 
(Woo et al., 2008). The composition of LTSL is dipalmitoylphosphatidylcholine 
(DPPC), monostearoylphosphatidylcholine (MSPC) and DSPE-PEG2000. MSPC 
is a lysolipid that confers a rapid release of the drug when liposomes are heated at 
40°-42°C. At this temperature the lysolipid is able to stabilize the pores formed at 
the melting temperature allowing a release of 95% of the entrapped drug within 
the first 5 minutes (Hossann et al., 2012). However, in the first approach in 
preclinical in vivo studies the formulation presented poor stability. This might be 
due to the presence of some components in blood, such as plasma proteins. They 
can interact with the lipids of the formulation increasing the drug leakage. Thus, 
albumin and IgG, the major protein components in blood, influence the stability of 
LTSL, representing an important issue for the efficacy of this formulation 
(Hossann et al., 2012). ThermoDox which is currently in Phase III is the most 
advanced clinical and commercial TSL formulation (Manzoor et al., 2012). 
New technologies and novel systems with improved encapsulation efficiency, 
drug loading capacity, and active targeting capability have been reported. 
Although many of these platforms are still in the early development stage (Liu et 
al., 2013). 
 
 
3.3.2 Lipoplatin 
Lipoplatin™ is a liposomal formulation of the FDA approved cisplatin, produced 
by the biopharmaceutical company Regulon. Regulon Inc. with headquarters in 
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Mountain View (California), and R&D in Alimos, Athens (Greece), is a 
biotechnology company focusing on the discovery, testing and commercialization 
of anticancer drugs and with demonstrated abilities in the liposomal encapsulation 
of toxic drugs (Stathopoulos et al., 2005).  
Liposomes of lipoplatin are composed of dipalmitoyl phosphatidyl glycerol 
(DPPG), soy phosphatidyl choline (SPC-3), cholesterol and methoxypolyethylene 
glycol-distearoyl phosphatidyl-ethanolamine (mPEG2000-DSPE). Lipoplatin is 
composed of 8.9% cisplatin and 91.1% lipids (w/w). It has an opaque appearance 
reflecting its liposomal nature and is being provided in 50-ml glass vials of 3 
mg/ml (concentration refers to cisplatin) (Figure 3.8). Lipoplatin is stored at 0-
4°C and has an expiration date of three years. The concentration of 3 mg/ml of 
cisplatin in lipoplatin exceeds the solubility of the free drug, cisplatin, usually 
provided as a 0.5 -1 mg/ml solution for intra venous infusion. Non-PEGylated 
liposomes are taken up by liver macrophages and destroyed with a half-life in 
body fluids of 20 minutes (Martin et al., 1998). On the contrary, PEGylated 
liposomes such as those of lipoplatin display a half-life of 120 hours in body 
fluids (Stathopoulos et al., 2005). 
 
Cisplatin
Liposome shell
PEG coating
A
 
 
       B  
B
 
 
Figure 3.8 Depiction of a lipoplatin nanoparticle (A). The model shows the lipid bilayer and the 
cisplatin molecules in its lumen (blue spheres) with the PEG molecules on its surface (white hair-
like structures) coating the particle with a hydrophilic inert polymer giving the ability to escape 
detection from macrophages and evade immune surveillance. (B) Lipoplatin 50/ml glass vial. 
 41 
 
Lipoplatin formulation is based on the formation of reverse micelles between 
cisplatin and DPPG under special conditions of pH, ethanol, temperature, ionic 
strength and other parameters. Cisplatin-DPPG reverse micelles are subsequently 
converted into liposomes by interaction with neutral lipids. This process, 
involving various steps sensitive to temperature, ethanol concentration, pH, ionic 
strength, type of salt, type of lipid and other sensitive parameters leads to very 
high encapsulation efficiencies (95-97%). About 15 repeated extrusions are 
performed using a Thermobarrel Extruder through membranes of 0.2, 0.1, 0.08 
and 0.05 mm pore sizes under pressure in ultra pure nitrogen to an average size of 
110 nm. Particles of larger sizes (100-150 nm) might display a better 
extravasation to tumors over normal tissue compared to smaller particles (60-100 
nm) (Boulikas, 2007). 
The lipoplatin formulation uses several advancements in its liposome 
encapsulation: i) the anionic lipid DPPG gives lipoplatin its fusogenic properties 
presumably acting at the level of entry of the drug through the cell membrane 
after reaching the target tissue; ii) the total lipid to cisplatin ratio is low (10:1 mg 
lipid/mg cisplatin) in lipoplatin, which means that less lipid is injected into the 
patient; and iii) the PEG polymer coating used on lipoplatin is meant to give the 
drug particles the ability to pass undetected by the macrophages and immune 
cells, to remain in the circulation of body fluids and tissues for long periods, to 
extravasate preferentially and to infiltrate solid tumors and metastatic tissue 
through the altered and often compromised tumor vasculature (Boulikas, 2007). 
Although the mechanism of entry of lipoplatin nanoparticles into cells has not 
been deciphered, tumor cells were proposed to uptake more avidly lipoplatin 
particles because of:  
 their tendency to uptake nutrients from the environment;  
 the proposed fusion of liposomes with the tumor cell membrane; 
 the higher concentration of the drug into tumors (Boulikas, 2009).  
Lipoplatin nanoparticles were proposed to diffuse to the extracellular space and to 
be taken up more avidly by the cell membrane of the tumor cell compared to 
normal cell (five times more). This is supposed to arise from the avidity of tumor 
cells for nutrients (the lipid shell of lipoplatin composed of lipids is mistaken as a 
nutrient).  
The fusion between liposomes and the cell membrane was suggested based on the 
fusogenic properties of DPPG and lipids integrated into the shell of lipoplatin 
(Figure 3.9).  
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Figure 3.9 Penetration of lipoplatin nanoparticles through the cell membrane of tumor cells. 
 
Subsequent cell culture studies, where the lipids of the lipoplatin nanoparticle 
were labelled with fluorescein isothiocyanate (FITC), established the rapid uptake 
and internalization of the nanoparticles. In these studies the fluorescent 
nanoparticles were incubated with MCF-7 breast cancer cells in culture for 
various times, ranging from 5 minutes to 24 hours. The study has provided proof 
that the lipids of lipoplatin are transferred initially (in less than 5 minutes) to the 
cell membrane of MCF-7 cells in culture and are then (from 5 minutes to 24 
hours) docked to the interior of the cell. The implications of this process are 
profound because lipoplatin demonstrated to deliver its toxic payload readily 
(within 5 min after reaching its cancer cell target), resulting in the destruction of 
the cancer cell; the membrane fusion is proposed to modulate signalling, an 
important process for cancer cell proliferation; moreover, lipoplatin could be used 
in patients previously treated with other platinum compounds (oxaliplatin, 
carboplatin, cisplatin) who have developed resistance to these drugs at the level of 
the cell membrane, bypassing this major type of resistance. Cells of patients in 
such tumors are impermeable to platinum drugs because of downregulation of the 
membrane cisplatin transporters (Ctr1). Provided that the platinum drugs in the 
market (cisplatin, oxaliplatin, carboplatin) are used in over 50% of human cancers 
and the fact that resistance is a major hurdle of chemotherapy, lipoplatin offers 
hopes to treat resistant tumors (Stathopoulos and Boulikas, 2012). 
Due to its particle size lipoplatin has the ability to target tumors and metastasis 
following intravenous administration, using the compromised endothelium of the 
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tumor vasculature sprouted during neoangiogenesis; this process, known as 
extravasation (Figure 3.10) has been demonstrated injecting in an 
immunodeficient mouse, implanted with MCF-7 human breast tumor cells, 
liposomes, with the same shell structure as lipoplatin, carrying the reporter β-
galactosidase gene to reveal the sites of transgene expression after relocalization 
of the gene vehicles. Preferential staining of the tumors, especially of the vascular 
system around the tumors, was shown. Even more important, the subcutaneous 
vasculature developed to supply the tumor with nutrients had a more pronounced 
staining indicating that cells (presumably endothelial cells) of tumor vasculature 
are the targets for entry of the liposome and expression of the foreign gene. This 
observation leads to the conclusion that lipoplatin not only kills tumor cells but 
also cells of the tumor vasculature. It could therefore be classified also as an anti-
angiogenesis agent. (Boulikas, 2007). Also in surgical specimens from patients, 
lipoplatin showed an enhanced concentration in tumors and metastases, at levels 
up to 200-fold higher compared to the adjacent normal tissue (Stathopoulos and 
Boulikas, 2012).  
 
 
 
Figure 3.10 Lipoplatin nanoparticles extravasation process. 
 
Furthermore, lipoplatin showed reduced adverse side effects compared with its 
parental compound, cisplatin. Preclinical study compared lipoplatin and cisplatin 
cytotoxicity in vitro in established cell lines derived from NSCLC, renal cell 
carcinoma, and in normal hematopoietic cell precursors. The results showed a 
superior cytotoxicity in all tumor cell models and a much lower toxicity in normal 
cells for lipoplatin compared with cisplatin, suggesting a higher therapeutic index 
for the liposomal compound (Arienti et al., 2008). Preclinical studies on nude 
mice, rats, and severe combined immunodeficiency mice have highlighted the 
milder adverse effects, especially to the kidney, of lipoplatin compared with 
cisplatin, confirming in vitro results (Boulikas, 2004; Devarajan et al., 2004). In 
subsequent studies, mice and rats injected with cisplatin developed renal 
insufficiency with clear evidence for tubular damage, but those injected with the 
same dose of lipoplatin were almost completely free of kidney injury. Treatment 
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of dogs with lipoplatin led to the conclusion that the drug can be safely 
administered to clinically normal dogs at dosages of up to 150 mg/m
2
 without the 
need for concurrent hydration protocols. The maximum tolerated dose (MTD) of 
unencapsulated cisplatin in dogs has been establishe as 70 mg/m
2
. Therefore, 
lipoplatin would allow the safe and repeated administration of doses higher than 
the MTD of unencapsulated cisplatin (Marr et al., 2004). 
Moreover, the intrapleural administration of lipoplatin in an animal model seems 
to offer a more effective therapeutic index while improving tolerability. Wistar 
rats were treated with doses of 10 mg/kg lipoplatin (intravenously) versus 10 or 
20 mg/kg lipoplatin (intrapleurally) corresponding to 60 and 120 mg/m
2
, 
respectively, in humans. The authors noted minor fibrotic changes in the pleura of 
rats injected intrapleurally, and mild kidney changes in rats injected intravenously, 
as expected (Froudarakis et al., 2011). 
 
 
3.3.2.1 Clinical trials Phase I studies 
There are more than 16 trials concerning lipoplatin.  
The human testing of this new agent primarily required pharmacokinetics studies 
and the definition of toxicity by investigating the MTD as well as the dose-limited 
toxicity (DLT) (Stathopoulos and Boulikas, 2012). 
A Phase I study of 27 patients with different malignancies was performed (19 
pancreatic carcinomas, 6 renal cell carcinomas, 1 gastric cancer and 1 squamous 
cell carcinoma of the head and neck (SCCHN)). Lipoplatin was administered as 
an 8 h infusion diluted in 1 L 5% dextrose, repeated every two weeks. The 
intravenous infusion was slow to reduce side effects (∼25 mg/(m2 hours)). There 
was no need for pre- or post-hydration of the patient with lipoplatin. This is in 
contrast to cisplatin chemotherapy that requires admittance of the patient the night 
before infusion for hydration, as well as extended stay in the hospital after 
infusion for post hydration, to reduce the nephrotoxicity of the drug. Interestingly, 
the maximum tolerated dose (MTD) was not reached even when the dose was 
increased up to 350 mg/m
2
 in one patient as a single infusion. The highlights of 
this study were that lipoplatin had mild hematological and gastrointestinal 
toxicity, did not show any nephro-, neuro- and oto-toxicity, did not cause hair loss 
and was void of most other side effects characteristic of cisplatin treatment. Grade 
1 and 2 myelotoxicity (neutropenia), and grade 1 and 2 gastrointestinal tract 
toxicity (vomiting) were observed only at the dose of 125 mg/m
2
. No other 
toxicity was observed even with repeated doses. A further finding was the long 
circulation of lipoplatin, a property necessary for its preferential extravasation 
through the leaky vasculature of tumors. Indeed, the half-life of total platinum in 
human plasma was determined to be 60-117 hours depending on the dose. At the 
dose of 100 mg/m
2
 the half-life was 117 hours (about 5 days) compared to ∼6 
hours for cisplatin (Stathopoulos et al., 2005). Although measurement of the 
response rate was not a primary goal of the study, 3 (11.1%) of 27 patients were 
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recorded to have achieved a partial response; of the remaining 24 patients, 14 
(51.9%) achieved stable disease and clinical benefit in a follow-up of 2-5 months 
(Stathopoulos et al., 2005). Provided that all patients had failed previous 
chemotherapy, that they all were at stage IV of their disease and had a rather poor 
performance status, this finding was very encouraging. 
In a different Phase I study, lipoplatin dose-escalated at 100 mg/m
2
 by increments 
of 10%, was combined with gemcitabine 1000 mg/m
2
 in 13 patients with 
refractory or resistant NSCLC. The dose of 120 mg/m
2
 of lipoplatin was defined 
as the MTD in its combination with gemcitabine (Froudarakis et al., 2008). The 
drug was also successfully used for mesothelioma by the same group (Karpathiou 
et al., 2007). The small number of 13 patients was not efficacious enough to 
determine ample data concerning toxicity. In both these aforementioned studies, 
there was also a defect in that all of the patients had undergone chemotherapy 
pretreatment when they were recruited and the efficacy of lipoplatin was tested.  
A proper third Phase I trial was eventually performed. The main objective of this 
study was to determine the DLT and MTD of lipoplatin tested as a single agent 
and in combination with a second cytotoxic agent. The selected second agent was 
paclitaxel. Sixty-six patients with NSCLC were recruited. Thirty-nine patients 
comprised the group that received lipoplatin monotherapy, and 27 patients were 
given lipoplatin in combination with paclitaxel. It was determined that 350 mg/m
2
 
was the DLT and 300 mg/m
2
 the MDT. The results of the combined treatment 
evaluation determined the DLT as 250 mg/m
2
 and the MTD, 200 mg/m
2
. Nausea, 
vomiting, fatigue, and neutropenia were not higher than grade 1-2, and other 
adverse reactions in a small percentage of patients reached grade 3. In the 
combined modality, other side effects, such as neurotoxicity, were observed, and 
this was attributed to paclitaxel. Grade 1 nephrotoxicity was observed in a small 
percentage of patients, but this was only temporary (Stathopoulos et al., 2010). 
Intravenous infusion of lipoplatin results in tumor targeting in four independent 
patient cases (one with hepatocellular adenocarcinoma, two with gastric cancer 
and one with colon cancer) who underwent lipoplatin infusion followed by a 
prescheduled surgery ~20 hours later. Direct measurement of the platinum levels 
in specimens from the excised tumors and normal tissues showed that the total 
platinum levels were on average 10-171 times higher in malignant tissue 
compared to the adjacent normal tissue specimens; most effective targeting was 
observed in colon cancer, with an accumulation up to 200-fold higher in colon 
tumors compared to normal colon tissue (Boulikas et al., 2005).  
 
 
3.3.2.2 Clinical trials Phase II studies 
A pilot Phase II study using lipoplatin at dose levels of 75, 100, 125 mg/m
2
 every 
14 days in combination with gemcitabine 1000 mg/m
2
 was tested on 26 patients 
(19 patients with pancreatic cancer and 7 with NSCLC). All patients were 
resistant to previous first- or second-line chemotherapy and lipoplatin plus 
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gemcitabine was given as a third-line treatment. No renal toxicity, neuropathy, 
ototoxicity, hepatotoxicity, cardiotoxicity or allergic reactions were observed. 
Lipoplatin at 125 mg/m
2
 induced grade III and IV neutropenia and grade III 
nausea and vomiting. Six (23%) patients showed partial response. Stable disease 
was seen in 65.3% of the patients and clinical benefit in 42.3% (Stathopoulos et 
al., 2002). 
A Phase I-II cohort, dose escalation trial of lipoplatin and gemcitabine was 
conducted on 24 advanced-stage pretreated pancreatic cancer patients who were 
refractory to previous chemotherapy. Preliminary objective response rate data 
showed a partial response in 2 (8.3%) patients, disease stability in 14 (58.3%) 
patients for a median duration of 3 months (range 2-7 months), and clinical 
benefit in 8 (33.3%) patients. At the end of the study, 7 (29.2%) patients were still 
alive. Taking into account that all of the patients were refractory or in disease 
progression while on a previous treatment including gemcitabine, the response 
rate produced were attributed to the addition of lipoplatin (Stathopoulos et al., 
2006). 
Recently a Phase II study of lipoplatin 120 mg/m
2
 and gemicitabine 1000 mg/m
2 
versus cisplatin 100 mg/m
2
 and gemcitabine 1000 mg/m
2
 has been completed on 
88 patients with NSCLC. The lipoplatin/gemcitabine treatment was better 
tolerated, with myelotoxicity as the main side effect. The overall response rate 
across all histological subtypes of NSCLC was 31.7% in the 
lipoplatin/gemcitabine arm versus 25.6% in the cisplatin/gemcitabine arm, but not 
statistically significant (p value = 0.411). However, a preliminary efficacy of 
lipoplatin/gemcitabine versus cisplatin/gemcitabine in the adenocarcinoma 
histological subtype of NSCLC showed 83.3 versus 54.2% response/stabilization 
rates (Mylonakis et al., 2010). This was an exciting finding proposed to be 
investigated further in a Phase III on non-squamous NSCLC. 
The cisplatin/vinorelbine combination has been studied recently in patients with 
breast cancer and an overall response rate of 64% was obtained. Nevertheless, the 
use of cisplatin was limited by the frequently induced nausea, vomiting and 
nephrotoxicity. The aim of the Phase II study was to evaluate the efficacy and 
safety of the lipoplatin/vinorelbine combination as first-line treatment in advanced 
breast cancer patients. Twenty patients with HER2/neu negative advanced or 
metastatic breast cancer, with no previous treatment, were treated with 30 mg/m
2
 
vinorelbine and 120 mg/m
2
 lipoplatin. Sixteen patients were evaluable for 
response. An objective tumor response was achieved in 8 (50%) patients, with 
complete response in 2 (13%) patients. Six (38%) patients had stable disease. All 
patients (20) were evaluable for toxicity. Most adverse events were mild to 
moderate. The new combination of lipoplatin and vinorelbine showed promising 
activity and good tolerance as first-line treatment for HER2/neu negative 
advanced or metastatic breast cancer  (Farhat et al., 2011). 
A Phase II trial is evaluating response and toxicity in advanced NSCLC patients 
who underwent previously cisplatin-based chemotherapy; thus, this trial is 
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addressing the efficacy of lipoplatin plus gemcitabine in patients whose disease is 
refractory to classical cisplatin chemotherapy. 
Patients were treated with lipoplatin 120 mg/m
2
 plus gemcitabine 1000 mg/m
2
. 
Twenty-seven (77.8%) patients were assessable for response and toxicity 
according to the World Health Organization (WHO) criteria. Partial response was 
observed in 6 (22.2%), stable disease in 5 (18.5%) and progressive disease in 16 
(59.2%) patients. Grade 3-4 neutropenia was observed in six (22.2%) patients, 
grade 3 thrombocytopenia in one (3.7%) patient and grade 3 anemia in one (3.7%) 
patient. Other toxicities included grade 3-4 nausea/emesis in nine (33.3%) 
patients, grade 3 fever in nine (33.3%) patients, and grade 3 nephrotoxicity in one 
(3.7%) patient. Further toxicities such as rush, constipation and peripheral 
neuropathy were rare and/or mild. Median overall time to tumor progression was 
14  weeks (3-50). 
The preliminary results of this continuing Phase II trial were encouraging in terms 
of response rate and toxicity  (Anevlavis et a., 2008). Especially important is the 
fact that lipoplatin seems to have activity in cisplatin-resistant tumors, something 
predicted previously from the liposomal nature of the drug; lipoplatin was 
proposed to be able to treat cisplatin-resistant tumors with resistance arising at the 
cell membrane level and not at the level of DNA repair  (Boulikas, 1998). 
Patients with locally advanced gastric cancer or gastric cancer inoperable for 
medical reasons or recurrent carcinomas were recruited. The objective of this 
Phase II study was to investigate the toxicity, response rates, and overall survival 
of lipoplatin radio-chemotherapy in locally advanced gastric adeno-carcinomas, in 
those unable to undergo surgery and to test the radiosensitizing ability of 
lipoplatin because of the concentration of its nanoparticles in tumors. Lipoplatin 
was given at a dose of 120 mg/m
2
, 5-fluorouracil (5-FU) at 400 mg/m
2
, while 
radiotherapy was given through 3.5 Gy fractions. The response rates assessed with 
CT-scan, endoscopy and biopsies confirmed 33% (2/6) complete remission and 3 
(50%) of 6 partial response in patients treated with four cycles and 4 (80%) of 5 
complete remission in patients treated with five cycles  (Koukourakis et al., 2010). 
Pancreatic cancers (>230,000 cases worldwide) are very hard to diagnose because 
they grow in the absence of alarming symptoms; about 85% of the patients are 
usually diagnosed at an advanced stage and have bad prognosis. Lipoplatin 
received the orphan drug status by the European Medicines Agency (EMEA). A 
multi-center Phase II/III registrational clinical study is in progress using lipoplatin 
plus gemcitabine as first-line treatment in inoperable, locally advanced or 
metastatic pancreatic cancer with the involvement of 20 oncology centers of 
excellence in various EU countries. During Phase II, 61 patients will receive i.v. 
lipoplatin 120 mg/m
2
 plus gemcitabine 1000 mg/m
2
. During Phase III, 328 
patients will be randomized (164 in each arm) to compare the same schedule of 
lipoplatin plus gemcitabine as in Phase II with i.v. gemcitabine 1000 mg/m
2
 
(Boulikas, 2009). 
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3.3.2.3 Clinical trials Phase III studies 
A randomized multi-center Phase III non-inferiority clinical study compared 
lipoplatin 120 mg/m
2
, plus gemcitabine 1000 mg/m
2
 with cisplatin 100 mg/m
2
 
plus gemcitabine 1000 mg/m
2
 as first-line treatment in patients with NSCLC. The 
primary end points were overall survival; secondary end points were toxicity, 
overall response rates, progression-free survival, and quality of life. Fiftynine  
patients were included, of whom 33 received the lipoplatin/gemcitabine regimen 
and 26 the cisplatin/gemcitabine one. Particularly important might be the 
significantly lower neuro- and nephro-toxicity of the lipoplatin arm and its 
administration on an outpatient basis with clear pharmacoeconomic benefits; 
lipoplatin was administered without pre- and post-hydration as a 6-hours infusion 
(Boulikas, 2009). An interim analysis of this trial on 101 patients of whom 60 
received the lipoplatin/gemcitabine and 41 the cisplatin/gemcitabine regimen, 
with a stratification for histological subtypes of NSCLC, showed there was a 
significant reduction in nephrotoxicity, nausea/vomiting, neurotoxicity and 
asthenia in the lipoplatin/gemcitabine compared to cisplatin/gemcitabine 
treatment arms  (Kosmas et al., 2009). In this study, that recruited more than 280 
patients, lipoplatin, under the name Nanoplatin, received in 2009 the consent of 
EMEA to be tested as first line against non-squamous NSCLC mainly composed 
of adenocarcinomas.  
The use of a taxane in combination with a platinum compound has become an 
acceptable standard as first-line treatment for patients with advanced or metastatic 
NSCLC (Kim et al., 2003). This randomized Phase III used 200 mg/m
2
 lipoplatin 
plus 135 mg/m
2
 paclitaxel (Arm A) and 75 mg/m
2
 cisplatin plus 135 mg/m
2
 
paclitaxel (Arm B). The main objective of the study was to show that lipoplatin 
was not inferior to cisplatin when combined with paclitaxel as first-line treatment, 
as assessed by overall survival in a randomized group of patients with NSCLC at 
stage IIIB/IV (with locally advanced or metastatic disease), but that patients in the 
lipoplatin/paclitaxel arm had a better toxicity profile and showed a better quality 
of life. Secondary objectives of the study were to compare the time to tumor 
progression, 1-year survival, and response rate between the two arms. 
It was concluded that the response rate was similar but toxicity, and in particular 
nephrotoxicity, neurotoxicity, and myelotoxicity were significantly lower in the 
lipoplatin arm (Stathopoulos et al., 2011). This Phase III was terminated 
successfully after treating 229 patients; the data showed the non-inferiority of the 
lipoplatin/paclitaxel combination compared to cisplatin/paclitaxel in the schedule 
described above but with statistically significant lower toxicities in the 
lipoplatin/paclitaxel arm for nephrotoxicity, grade 3 and 4 leukopenia, grade 2 and 
3 neuropathy, asthenia (fatigue) and gastrointestinal toxicity (nausea/vomiting). 
There was no significant difference in median and overall survival (Boulikas, 
2009). 
A randomized, multi-center Phase III trial against SCCHN was designed, in which 
conventional cisplatin or lipoplatin were used in combination with 5-FU, to 
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compare efficacy and safety profiles of both treatment arms. This study is used 
treatment with 100 mg/m
2
 lipoplatin plus 1000 mg/m
2
 day 5-FU (Arm A). The 
comparative arm (Arm B) used 100 mg/m
2
 cisplatin with pre- and post-hydration. 
An interim analysis was reported (Jehn et al., 2008) on 46 evaluable patients, 25 
in the lipoplatin/5-FU and 21 in the cisplatin/5-FU arm, respectively, after at least 
two cycles in both arms. The main end points for this interim analysis were 
hemato- and nephro-toxicity. Seven patients had to stop cisplatin therapy due to 
severe toxicity as compared to one patient in the lipoplatin treatment arm. Severe 
hematotoxicity was more frequent in the cisplatin arm, with grade III and IV 
toxicity occurring in 31.7% of the patients treated with the cisplatin-based 
regimen versus 12% in the lipoplatin-based regimen. Grade IV leucopenia 
occurred in 22.2% of the patients treated with cisplatin/5-FU, whereas in the 
lipoplatin/5-FU arm 0% grade IV leukopenia occurred. One of the most 
debilitating toxic side effects and a great impingement on the quality of life of 
cisplatin-based chemotherapies is neuropathy. Lipoplatin seems to reduce neuro-
toxicity profoundly. A total of 67% of the patients treated with the cisplatin 
regimen experienced grade I and II neuropathy compared to 27% in the lipoplatin 
arm. The renal toxicity profile of both drugs also showed marked differences: 
23.8% of the treated patients suffered a significant reduction in kidney function. A 
high rate of stable disease was observed in the lipoplatin versus cisplatin arms (64 
versus 50%); also the clinical benefit rate (stable disease plus partial remission) 
was similar for the cisplatin (88.5%) and lipoplatin combinations (83%), although 
there were more objective responses seen in the cisplatin arm (Jehn et al., 2008). 
One of the serious adverse reactions with the administration of 
chemotherapeutical agents is renal failure. In general, when the level of 
creatinine/glomerular filtration data is high, chemotherapy involving almost all 
cytotoxic agents is avoided or the dosage is reduced. In the present trial, lipoplatin 
was tested as monotherapy and in combination with gemcitabine or paclitaxel or 
5-FU-leucovorin, mainly in lung and bladder cancer patients with renal 
insufficiency. The primary objective of the present study was to investigate the 
administration of lipoplatin in patients with renal insufficiency and secondly, to 
determine the response of patients with bladder cancer, the majority of whom 
received the present treatment as first-line therapy. Forty-two patients (14 with 
NSCLC, 2 with squamous cell carcinoma non-small-cell lung cancer, 16 with 
bladder cancer, and 10 gastrointestinal tract cancer) were included. Lipoplatin and 
gemcitabine were administered to patients with bladder cancer, paclitaxel plus 
lipoplatin were administered to lung cancer patients, and patients with 
gastrointestinal tract cancer received 5-FU and leucovorin plus lipoplatin. Serum 
creatinine was 1.6 mg/dl to 4.0 mg/dl (median 2.4 mg/dl). No serum creatinine 
increase was observed in any of the patients. Grade 1-2 myelotoxicity and anemia 
were observed in 28.57% and 50% of the patients, respectively. Results showed 
that lipoplatin may favorably be considered as the treatment solution for cancer 
patients with renal insufficiency (Stathopoulos et al., 2012). 
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3.3.2.4 Pharmacoeconomics 
Lipoplatin is being administered on an outpatient basis without pre- or post-
hydration and with clear pharmacoeconomic benefits over cisplatin that requires 
admittance of the patient to the hospital a day before and a day after treatment for 
pre- and post-hydration. Hospitalization costs are usually $1000/day in most 
Western countries. In addition, there is less healthcare requirements for the 
recovery of patients from adverse reactions, especially nephro- and neuro-toxicity 
as well as less use of the expensive hematopoietic factors GM-CSF after 
administration of lipoplatin compared to cisplatin. The expected increase in 
overall survival and improvement in the quality of life suggested from preliminary 
results are also considered important benefits. Although lipoplatin has not 
received marketing authorization yet, its pricing takes into consideration its 
affordability for establishing it as a drug able to replace cisplatin in all world 
markets (Boulikas, 2009). 
 
 
3.4 Tumor models 
3.4.1 Cervical cancer 
Cancer of the cervix uteri is the second most frequent cancer in women in the 
world (529,409 new cases in 2008) and the third greatest cause of death from 
cancer in women. Many more women die of cervical cancer in the developing 
world than in wealthier countries. Of the estimated 274,883 deaths from cervical 
cancer every year, more than 85% occur in developing countries (Sanjosé et al., 
2012). Before the introduction of screening and vaccination programs the 
incidence of cervical cancer in many of the more developed countries was similar 
to that in less developed countries today. Between 1955 and 1992, cervical cancer 
death rate declined by almost 70%. The main reason for this change was the 
increased use of the Pap test. The Pap smear test (Papanicolaou test) is a screening 
test for cervical cancer in which cells are scraped from the cervix and looked at 
under a microscope. Screening should start at age 21. Most of the time, cervical 
cancer develops very slowly and follow-up Pap smears should identify worrisome 
changes in time for treatment (Bradford and Goodman, 2013). The high mortality 
rate from cervical cancer globally could be reduced by effective screening and 
treatment programs also in developing countries. 
Cervical cancers start in the cells on the surface of the cervix. There are two types 
of cells on the surface of the cervix, squamous and columnar. The majority of 
cases are squamous cell carcinoma and adenocarcinomas are less common. From 
2006 to 2010, the median age at diagnosis for cancer of the cervix uteri was 49 
years of age. 
Cervical cancer is almost always caused by human papillomavirus (HPV) 
infection. 
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HPV is a very common virus that can affect the cells of the cervix. It is mainly 
passed on during sex. Having sex at an early age and having several sexual 
partners can increase the risk of catching HPV and developing cervical cancer.  
There are more than 100 different types of HPV, many of which are harmless. 
However, some types of HPV can disrupt the normal functioning of the cells of 
the cervix and can eventually trigger the onset of cancer. At present, there are two 
HPV vaccines, a bivalent (Cervarixc ) and a quadrivalent (Gardasilc ) HPV 
vaccine (Cutts et al., 2007). Both vaccines are composed of HPV L1 proteins that 
spontaneously self assemble into Virus-like particles (VLPs). Cervarixc was 
designed to prevent infection by HPV16 and 18, the two types that cause 70% of 
cervical cancer. Gardasilc targets the same two cancer causing types and, in 
addition, is intended to prevent infection by HPV6 and 11, which cause 75-90% 
of external genital warts. The vaccine is given as a series of three shots. It is 
recommended for girls and women ages 9 - 26. Both vaccines are prophylactic but 
not therapeutic, so cervical screening programs are still needed for women already 
infected or unimmunized with the potential for future infection (Kahn, 2009). 
HPV is a necessary cause of cervical cancer, but it is not a sufficient cause. Other 
cofactors are necessary for progression from cervical HPV infection to cancer: 
• Giving birth to many children. 
• Having many sexual partners. 
• Having first sexual intercourse at a young age. 
• Smoking cigarettes. 
• Using oral contraceptives ("the Pill"). 
• Having a weakened immune system. 
Cancer of the cervix is not infectious and can‟t be passed on to other people 
(Deacon et al., 2000). 
If cervical cancer is diagnosed at an early stage it is usually possible to treat it 
using surgery. In some cases it is possible to leave the womb in place, but it may 
need to be removed. The surgical procedure used to remove the womb is called a 
hysterectomy.  
Radiotherapy is an alternative to surgery for some women with early stage 
cervical cancer. In some cases it is used alongside surgery. More advanced cases 
of cervical cancer are usually treated using a combination of chemotherapy and 
radiotherapy. Drugs most often used to treat cervical cancer include: cisplatin, 
carboplatin, paclitaxel (Taxol®), topotecan, and gemcitabine (Gemzar®). Some 
other drugs can be used as well, such as docetaxel (Taxotere®), ifosfamide 
(Ifex®), 5-fluorouracil (5-FU), irinotecan (Camptosar®), and mitomycin. Often 
combinations of these are used (Yee et al., 2013). 
Based on phase III results, the combination of cisplatin and paclitaxel remains the 
standard of care for treatment of recurrent cervical cancer, although clinical 
benefit is limited. Indeed, although cisplatin is the most effective agent for 
metastatic cervical cancer, prolonged treatment induces multiple mechanisms of 
tumor resistance and is associated with significant toxicity (Leath and Straughn, 
2013). Therefore, the development of new cisplatin formulations to overcome 
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both resistance and toxicity remains a high priority and is crucial for a better 
treatment and a more prolonged survival. 
 
 
3.4.2 Ovarian cancer 
The term "ovarian cancer" includes several different types of cancer. Epithelial 
ovarian cancer (EOC) accounts for about 70% of all ovarian cancers. It is 
generally thought of as one of three types of cancer that include ovarian (epithelial 
ovarian cancer), fallopian tube, and primary peritoneal cancer that all behave, and 
are treated the same way, depending on the type of cell that causes the cancer. 
There are also less common forms of ovarian cancer that come from within the 
ovary itself, including germ cell tumors and sex cord-stromal tumors (N et al., 
1998). The four most common cell types of epithelial ovarian cancer are serous, 
mucinous, clear cell, and endometrioid. These cancers arise due to DNA changes 
in cells that lead to the development of cancer. Serous cell type is the most 
common variety. It is now thought that many of these cancers actually come from 
the lining in the fallopian tube, and fewer of them from the lining on the surface 
of the ovary, or the peritoneum. However, it is often hard to identify the sources 
of these cancers when they present at advanced stages, which is very common 
(Bell, 2005). 
The median age at presentation of ovarian cancer is 63 years (Cannistra, 2004). 
Worldwide, the estimated annual incidence of ovarian cancer is 204,000, with 
125,000 deaths, identifying ovarian carcinoma as the fifth leading cause of cancer-
related death among women (Jemal et al., 2008). The high mortality of this tumor 
is largely explained by the fact that the majority (75%) of patients are diagnosed 
with advanced stage, with widely metastatic disease within the peritoneal cavity. 
This is mostly due to the lack of definite symptoms at the early stages of 
development of the disease process. 
There is a close correlation between stage at presentation and survival; therefore, 
early detection of ovarian cancer represents the best hope for mortality reduction 
and long-term disease control. However, so far there are no effective ovarian 
cancer screening tests. The cancer antigen 125 (CA-125) has become well 
established as tumor marker for epithelial ovarian cancer, but its sensitivity and 
specificity is known to be poor. It is only raised in approximately 50% of stage I 
epithelial ovarian cancers and in 75% to 90% of patients with advanced disease 
(Jacobs and Bast, 1989). 
Most women diagnosed with ovarian cancer have the sporadic variety; however, a 
subset of ovarian cancer cases occur in a familiar fashion. For this subset, a strong 
family history of ovarian or breast cancer is the most important risk factor. 
Overall, hereditary predisposition accounts for at least 10% of all epithelial 
ovarian cancers. Mutations in the BRCA genes account for approximately 90% of 
these cases, with most of the remaining 10% attributable to Lynch syndrome 
(hereditary nonpolyposis colorectal cancer (HNPCC)) (Chen et al., 2006). The 
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cumulative lifetime risk of ovarian cancer is 40% to 50% for BRCA1 mutation 
carriers and 20% to 30% for BRCA2 mutation carriers. The cumulative risk of 
ovarian cancer in HNPCC families is more than 12%. Nulliparity, early menarche, 
late menopause, and increasing age are also associated with increased risk, 
whereas oral contraceptive use, pregnancy, lactation, and tubal ligation are 
associated with reduced risk (Hankinson et al., 1993).  
The standard initial management of epithelial ovarian cancer consists of 
aggressive surgical cytoreduction, to remove all visible disease in the abdomen, 
including total abdominal hysterectomy (surgery to remove the uterus and the 
cervix) and bilateral salpingo-oophorectomy (a surgical procedure to remove both 
ovaries and both fallopian tubes), and platinum/taxane combination chemotherapy 
(Cannistra, 2004).  
There are two ways to give chemotherapy in ovarian cancer. Traditionally, it is 
given into the vein intravenously (IV). Another way of giving the chemotherapy is 
to place it directly into the abdomen (intraperitoneal or IP). In many studies, 
intraperitoneal administration has been shown to significantly increase survival. 
This is most often used after optimal surgical debulking. When initially 
diagnosed, the two most common drugs are carboplatin and paclitaxel. Currently, 
the drugs used are cisplatin and paclitaxel. There are studies that are looking at 
substituting carboplatin for cisplatin, because the side effects are less. 
Unfortunatly, recurrence is very frequent. When epithelial ovarian cancer recurs 
the type of drugs used for second line chemotherapy are determined by how long 
it has been since the last time a patient has taken a drug containing platinum. If it 
has been less than 6 months, then the patient is termed platinum-resistant. If it has 
been more than 6 months since the last day of platinum-based chemotherapy, then 
often a platinum-containing drug will be used again. If the patient is platinum-
resistant it will receive a non-platinum drug that can be pegylated liposomal 
doxorubicin, docetaxel, paclitaxel, topotecan, gemcitabine, etoposide, and 
bevacizumab (Wp and Rf, 1998). 
Unlike most other cancers, ovarian carcinoma rarely disseminates through the 
vasculature. However, pelvic and/or para-aortic lymph nodes can be involved 
(Eisenkop and Spirtos, 2001). Ovarian carcinoma metastasizes either by direct 
extension from the ovarian/fallopian tumor to neighboring organs (bladder/colon) 
or when cancer cells detach from the primary tumor (Figure 3.11).  
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Figure 3.11 Model of ovarian cancer progression. 
 
Invasion of the mesothelium is an early step of ovarian carcinoma metastasis. 
Indeed, exfoliated tumor cells from the primary tumor can subsequently attach to 
the mesothelial cell lining and invade, forming metastatic outgrowths. Late stage 
cancers are frequently associated with ascites, and tumor cells can be shed into the 
ascites fluid either as single cells or multicellular aggregates called spheroids (A 
Farghaly, 2013). It is not clear whether single cells detach and then aggregate to 
form spheroids, or if the cells detach as cell clumps that stay together while 
floating in ascites (Figure 3.11). However, several in vitro studies have explored 
the possibility that spheroids are less susceptible to chemotherapy than single 
cells. This raises the possibility that spheroids are implicated as factor in disease 
persistence or recurrence (Lengyel, 2010). 
Despite advances in the treatment of ovarian cancer, effective screening, early 
detection, and cure remain elusive for most women. 
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4. MATERIALS AND METHODS 
4.1 Drugs 
Lipoplatin™, the liposomal formulation of cisplatin, was generously provided by 
Regulon (Regulon, Athens, Greece); cisplatin was purchased from Mayne Pharma 
(Napoli, Italy); abraxane (Celgene Corporation, Milano, Italy); doxorubicin 
(Pfizer, Latina, Italy); docetaxel (Hospira, Napoli, Italy); and paclitaxel (Actavis, 
Milano, Italy). Drugs were dissolved in medium at the indicated concentrations 
immediately before use. 
 
 
4.2 Cell lines and culture conditions 
Human ovarian epithelial adenocarcinoma derived cancer cell lines A2780 
(Sigma-Aldrich), the parent cisplatin-resistant A2780cis (Sigma-Aldrich), MDAH 
2774 (ATCC CRL-10303), OVACR-3 (ATCC HTB-161), OVACR5 (NIH), 
SKOV-3 (ATCC HTB-77), TOV21G (ATCC CRL-11730), and the highly 
invasive cervical cancer-derived HeLa (ATCC CCL-2), ME-180 (ATCC HTB-33) 
(HPV+) cell lines were purchased from the American Type Culture Collection 
(ATCC, Rockville, MD, USA). The cisplatin-resistant variant R-ME-180 was 
generated by weekly selection and maintained in 1 µM cisplatin. Cell lines used in 
the study were further authenticated for their origin by BMR Genomics (Padova, 
Italy). Ovarian cancer cell lines were cultured in RPMI medium (Sigma-Aldrich-
Italy), cervical cancer cell lines in DMEM medium (Sigma-Aldrich-Italy) 
supplemented with 10% heat-inactivated Fetal Bovine Serum (FBS; Gibco), 0.2 
mg/ml penicillin/streptomycin (Cambrex) and 0.1% (w/v) L-glutamine (Cambrex) 
at 37°C in a 5% CO2 fully humidified atmosphere.  
 
 
4.3 Cytotoxicity assay 
4.0x10
3
 cells were plated in 96-well flat-bottomed plates and allowed to adhere 
for 24 hours, then exposed to increasing concentrations of lipoplatin (2.5-100 µM) 
or cisplatin (2.5-100 µM) at 37ºC for 72 hours. Triplicate cultures were 
established for each treatment. Cytotoxicity was measured by using MTT assay. 
Following drug treatment, the 3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) solution was added to the culture medium 
and the culture further incubated for 4 hours at 37 °C. The degree of cell survival 
was determined by checking conversion of MTT to formazan. The absorbance 
was measured at 570/630 nm using a plate reader (Sunrise, TECAN) and the 
cytotoxicity percentage was calculated. IC50 values (representing the 
concentration of a substance required for 50% growth inhibition in vitro) were 
calculated using the CalcuSyn software (Biosoft,
 
Ferguson, MO, USA)(Chou and 
Talalay, 1984).  
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4.4 Experimental Design for Drug Combinations and Chou–
Talalay analysis for synergy 
Methods for assessing synergy were used as described earlier (Chou, 2006). In 
particular, we used the diagonal constant ratio combination design proposed by 
Chou and Talalay (1984), in which a small number of data points were combined 
so that the contributions of effects of each drug to the combination were almost 
equal (Table 4.1). We first determined the IC50 for abraxane, docetaxel, 
doxorubicin, and paclitaxel for OVCAR5 and SKOV3. Then 4.0×10
3 
cells/well, 
plated in 96-well, were incubated with each drug alone or in combination with 
lipoplatin for 72 hours, and cell viability was evaluated by MTT assay. 
Calcusyn (version 2.0), a Windows
®
-based computer program automating the 
multiple-drug-effect analysis of Chou and Talalay, based on the median-effect 
principle (Chou and Talalay, 1984), was used to calculate combined drug effects. 
The combination index (CI) was then used to determine synergy, additivity or 
antagonism. Combination indices of <1, =1 and >1 represent synergy, additivity 
and antagonism, respectively.  
 
Table 4.1 A proposed experimental design showing the outlay of dose range and dose density of 
two drugs for drug combination analysis. 
 
 
 
 
4.5 Evaluation of cell cycle progression and apoptosis 
Effects on the cell cycle were evaluated by propidium iodide (PI) staining. 5x10
5
 
cells cultured in a 10 ml petri dish were treated 72 hours with 30 µM lipoplatin. 
Cells were fixed and permeabilized 15 minutes in ice with 70% ethanol. 
Afterwards they were incubated 1 hour at room temperature with PI solution (PI 
1mg/ml, NP40 1%, RNAsi 10mg/ml in sodium citrate 0.1%) Data analysis was 
performed by ModFit LT™ software (Variety Software House, Topsham, ME, 
USA). 
To assess Annexin-V binding, DNA fragmentation, features of mitochondrial 
apoptotic pathway, mitochondrial reactive oxygen species (ROS) formation, 
1.0x10
5
 cervical and 5.0x10
4
 ovarian tumor cells were incubated for 72 hours on 
6-well plates in complete medium in the presence of lipoplatin or cisplatin. All the 
cells were harvested.  
Annexin-V was assessed incubating fluoresceine isothiocyanate (FITC) Annexin-
V (Becton-Dickinson [BD]-Pharmingen, San Jose, CA, USA) for 15 minutes in 
 57 
 
Annexin-V Binding Buffer. 0.7 µg/ml of propidium iodide was added and sample 
were analyzed by flow cytometry.  
DNA fragmentation within cells was detected using the Apo-Direct kit (BD 
Pharmingen) following the manufacturer's instructions.  
To evaluate the dissipation of the mitochondrial membrane potential, 200 nM 
Chloromethyl-X-rosamine (CMXRos) (Molecular Probes, Eugene, OR, USA) 
(Pendergrass et al., 2004) was added to the cell culture for 30 minutes, then the 
cells were washed twice and analyzed by flow cytometry.  
For B-cell lymphoma/leukemia-2 (Bcl-2), B-cell lymphoma-extra large (Bcl-xL) 
and Bcl-2 associated x protein (Bax) analysis, fixed and permeabilized cells (FIX 
& PERM cell fixation and permeabilization kit, Invitrogen) were incubated with 
10 mg/l FITC-conjugated mouse anti-human Bcl-2 (clone 124) (DAKO 
Citomation, Milan, Italy), with rabbit anti-human Bcl-xL (54H6) (Cell Signalling, 
Danvers, MA, USA) (1:400) followed by goat anti-rabbit immunoglobulin (IgG) 
FITC-coniugated (BD), and with 1 µg/ml of mouse anti-Bax generated from Bax-
alpha (BD), followed by 10 µg/ml phycoerythrin (PE)-conjugated goat anti-mouse 
IgG (BD).  
Cytochrome-c (Cyt-c) release was assessed, as explained elsewhere (Campos et 
al., 2006), with minor modifications. Briefly, tumor cells were permeabilized with 
100 µg/ml digitonin (Sigma) and fixed with 4% paraformaldehyde in PBS for 20 
minutes at room temperature. After washing twice with PBS, the cells were 
incubated in labeling medium (2% FBS, 0.2% sodium azide, 0.5% Triton X-100 
in PBS) for 10 minutes, then with 1 µg/ml of mouse anti-Cytochrome-c antibody 
(BD), and finally with PE-conjugated goat anti-mouse IgG (BD). 
For mitochondrial ROS evaluation, cells were incubated with 5 µM of MitoSox 
reagent working solution (Molecular Probes, Invitrogen, Milan, Italy) for 30 
minutes at 37º C. Red fluorescence was immediately analyzed by flow cytometry. 
Caspase activity was ascertained with the fluorochrome-labeled inhibitors of 
caspases (FLICA), CaspaTagTM caspase-3/7 (FAM-DEVD-FMK) and caspase-9 
(FAM-LETD) (FITC-IETD-FMK) (Chemicon International, Milan, Italy). Cells 
were treated with 30 µM of lipoplatin or cisplatin for 0, 24 and 48 hours, then 
harvested, washed, resuspended in warmed complete medium supplemented with 
FLICA for 1 hours at 37°C under 5% CO2, and immediately analyzed by flow 
cytometry.  
Viable antibody-labeled cells were identified according to their forward and right-
angle scattering, electronically gated. Data were collected and analyzed on a 
FACScan flow cytometer (BD) using CellQuest software (BD). 
 
 
4.6 Thioredoxin Reductase (TrxR) enzyme activity assay 
TrxR activity was assessed using the Thioredoxin Reductase Assay Kit (Sigma-
Aldrich), according to the manufacturer‟s instructions: 1.0x105 cells were treated 
with 20 and 30 µM lipoplatin or cisplatin and, after 72 hours, cells were lysed 
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with lysis buffer (50 mM Tris-HCl, 0.1% Triton X-100, 0.9% NaCl, pH 7.6) and 
incubated for 30 minutes on ice. Total protein content was analyzed with the 
protein assay dye reagent (Bio-Rad Laboratories, Hercules, CA, USA). The cell 
lysates were then incubated in 100 mM of potassium phosphate with 10 mM 
ethylenediaminetetraacetic acid (EDTA) and 0.24 mM nicotinamide adenine 
dinucleotide phosphate (NADPH) with and without a TrxR inhibitor. The reaction 
was started by adding dinitrothiocyanobenzene (DNTB) and was monitored 
spectrophotometrically at 412 nm. 
 
 
4.7 Cell migration assay 
Cell migration was assessed using the scratch wound healing assay, as described 
elsewhere (Liang et al., 2007). Briefly, cells were grown to confluence in tissue 
culture dishes, then 10 µM of lipoplatin, cisplatin or medium alone were added. 
After 72 hours treatment, the cells were washed twice with PBS and scraped up 
using a sterile pipette tip, then washed again and cultured in DMEM with 0.5% 
FCS. The percentage of cell migration was evaluated by the Image Tool Software 
measuring the area of the scratch covered by the migrated cells after 24 and 48 
hours (http://ddsdx.uthscsa.edu/dig/itdesc.html; San Antonio, TX, USA). 
 
 
4.8 Cell invasion assay 
Cervical cancer cell lines were treated 12 hours with 30 µM lipoplatin, ovarian 
cancer cells were treated 72 hours with 10 µM lipoplatin . Invasion was assessed 
by FATIMA assay as previously described (Spessotto et al., 2009). Briefly, after 
drug treatment viable cells (1.0x10
5
 cells/insert), tagged with the lipophylic dye 
Fast DiI (Molecular Probes), were seeded in 150 µl SF medium in the upper side 
of collagen type I-coated Boyden chamber inserts. Migration was then monitored 
at different time intervals for 24 hours, using a computer-interfaced GeniusPlus 
microplate reader. FATIMA software determined the percentage of transmigrated 
cells out of the total amount introduced into the system. Complete medium 20% 
FCS was used as chemoattractants. Each experiment was performed at least three 
times, in duplicate. 
 
 
4.9 Expression of Epithelial Growth Factor Receptor (EGFR)  
1.0x10
5
 cervical and 5.0x10
4
 ovarian tumor cells were incubated for 72 hours on 
6-well plates in complete medium in the presence of lipoplatin or cisplatin (20 and 
30 µM). After fixing cells (FIX & PERM cell fixation and permeabilization kit, 
Invitrogen), the surface expression of the EGFR was analyzed by flow cytometry 
using the PE mouse anti-human EGFR antibody, as indicated in the 
manufacturer‟s instructions (20 µl per test).  
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4.10 Identification of cancer stem cells (CSCs) 
CSCs were identified by alcohol dehydrogenase (ALDH) and CD133 stem cell 
markers. 
To detect ALDH enzymatic activity I used the Aldeflour reagent based (Stem Cell 
Technologies, Vancouver, Canada) flow cytometry method according to the 
manufacturer‟s instructions. This method relies on the increased ALDH activity of 
CSCs. Briefly, adherent cells were trypsinized and washed with phosphate 
buffered saline (PBS). Cells (2x10
5
 cell/ml) were then suspended in cell 
suspension buffer provided in the kit. Aldeflour reagent was then added to the cell 
suspension followed by the incubation for 40 minutes at 37°C. For each cell type 
tested, a negative control comprising cells treated with ALDH-inhibitor 
diethylamino-benzaldehyde (DEAB) was also included. Cells were recovered by 
centrifugation finally resuspended in ice cold cell suspension buffer. Cell analysis 
were carried out using a FACSCalibur flow cytometer (BD). ALDH+ cells were 
quantified by calculating the percentage of total cells that displayed greater 
fluorescence compared with the negative control.  
5.0x10
4
 ovarian tumor cells were incubated for 72 hours on 6-well plates in 
complete medium in the presence of lipoplatin. All the cells were harvested and 
fixed (FIX & PERM cell fixation and permeabilization kit, Invitrogen). The 
surface expression of CD133 was assessed using the antibody anti-human 
CD133/1(AC133)-PE (Miltenyi Biotec), as indicated in the manufacturer's 
instructions, (diluition 1:11) and analyzed by flow cytometry. 
 
 
4.11 Multicellular tumor spheroid formation assays 
To obtain multicellular tumor spheroids in vitro, 24-well plates were coated twice 
with poly(2-hydroxyethyl methacrylate) 20 mg/ml (poly-HEMA; Sigma, Inc., St. 
Louis, MO, USA) (Ivascu and Kubbies, 2006) in 95% ethanol and washed once 
with PBS before cell seeding. Spheroids were obtained plating 5x10
4
 R-ME-180 
or SKOV3 cells in complete medium in the presence of 10, 25 or 50 µM of 
lipoplatin or cisplatin. To evaluate apoptosis or ALDH activity, spheroids treated 
for 72 hours were trypsinized in a single cell suspension. To obtain a second 
generation, formed spheroids (72 hours) were dissociated and then replated on 
poly-HEMA coated wells for other 72 hours. 
 
 
4.12 Spheroid volume growth kinetic and spheroid cell viability 
Tumor spheroid growth kinetics and treatment with test compounds was 
performed as reported. For single spheroid generation 100 µl/well of SKOV-3 cell 
suspension at optimized density (1.0x10
4
) were dispensed into poly-HEMA 
coated round-bottom 96-well. Plates were incubated for 4 days at 37°C, then 
spheroids were treated with increasing concentrations of lipoplatin (10-100 µM). 
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Spheroid size was measured up to 15 days after initiation. A 50% medium 
replacement was performed on days 3, 7, 10 and 15. Responses were evaluated by 
spheroid volume measurements at regular intervals  (Bandekar et al., 2012) using 
inverted microscope (Eclipse TS/100, Nikon) magnification 4x with the 
photomicrographic systems DS Camera Control Unit DS-L2. Spheroid volume  
was calculated according to the formula: (width
2 
x length x 3.14)/6 (Liu et al., 
2005), and the percentage of volume change was calculated as Vt/V0x100 where 
Vt is the calculated volume at time t of at least three single spheroids and Vo the 
mean spheroid volume right before the start of incubation with drug treatment.  
To assess spheroid cell viability, single spheroids were incubated for 30 minutes 
with 2 µg/ml propidium iodide before being observed under the fluorescence 
microscope (DMI 600013, Leica) (original magnification 4×). 
 
 
4.13 Tumor spheroid-based migration assay on matrix protein 
 
To assess cell dissemination I used a spheroid adhesion and migration assay. 
Spheroids were grown in poly-HEMA coated round-bottom 96-well as described 
above. The disaggregation assay was performed in 96-well plates coated with 
collagene (10 μg/ml) I and blocked with BSA (1 mg/ml) for 2 hours. Plates were 
washed with PBS and 3-5 spheroids suspended in complete medium were layered 
on the wells in absence or presence of 25 and 50 µM lipoplatin. Spheroids were 
sized and photographed at 0, 24 and 48 hours. The pixel area of the cells was 
determined using Adobe Photoshop by outlining the entire area of the dispersed 
cells with the lasso tool. The fold change in area was then calculated by dividing 
the pixel area of the spheroid at 24 and 48 hours by the pixel area at time 0. 
 
 
4.14 Tumor xenograft experiments 
Six-week-old female athymic nu/nu (nude) mice were purchased from Charles 
River (Lecco, Italy) and 2.5x10
6
 R-ME-180 and 2.7x10
6 
OVCAR5 cells 
suspended in 0.1 ml of matrigel (1:3 in PBS) were inoculated in the right flank of 
each mouse. When cervical tumors reached ~32 mm
3
 and ovarian tumors ~44 
mm
3
 in volume, mice were divided randomly into two groups of 5 and 8 mice 
each, for cervical and ovarian tumors, respectively. Mice were treated every other 
day. Tumor size was measured over time using a caliper, and volumes were 
calculated according to a standard formula: (width
2 
x length x 3.14)/6. Mice 
carrying cervical cancer cells were treated with intraperitoneal injection of 10 
mg/kg lipoplatin or drug-free vehicle, and were sacrificed after 28 days of 
treatment, when control tumors had reached a volume of ~600 mm
3
. 
Mice carrying ovarian cancer cells were treated with intraperitoneal injection of 
20 mg/kg lipoplatin or drug-free vehicle. At day 39 the treatment was suspended. 
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After 14 days, when control tumors had reached a volume of ~1000 mm
3
, mice 
were sacrificed.  
The mouse organs were excised and fixed in formalin for tissue toxicity analyses. 
Sections were cut and counterstained with haematoxilin and eosin according to 
standard procedures.  
To estimate the equal sample size for the mouse study groups, the experiment was 
designed to be able to detect a 0.60 difference with 0.90 power and an α error of 
0.05. 
 
 
4.15 Software and statistical analysis of  data  
Graphs were generated using Microsoft Office Excel (Microsoft Italia, Segrate, 
Italy) and SigmaPlot software (Systat Software Inc., San Jose, CA, USA). Values 
are presented as the mean with the standard error of not less than three 
measurements (unless otherwise stated) (mean ± SEM). Statistical analysis was 
performed using GraphPad Prism 6 Software (GraphPad, San Diego, CA, USA). 
The statistical significance of differences was determined by Student‟s t-test for 
comparison between two groups. Analysis of variances (ANOVA) was used to 
evaluate the correlation of data among three or more groups; consecutive multiple 
comparison analysis was performed using Dunnett‟s or Tukey‟s tests. Differences 
were considered statistically significant at P<0.05.  
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5. RESULTS 
5.1 Lipoplatin activity on cervical cancer cells 
5.1.1 Lipoplatin inhibited cervical cancer cell proliferation and induced 
apoptosis  
I compared the in vitro cytotoxic effects of lipoplatin (Fig. 5.1A) on cervical 
cancer derived tumor cells HeLa, ME-180, and its cisplatin-resistant clone R-ME-
180. Treatment with increasing concentrations of lipoplatin or cisplatin (2.5-100 
µM) induced a dose-dependent inhibition of cell proliferation, as evaluated by 
MTT cell viability assay (Fig. 5.1). IC50, the concentration of drug that inhibits 
50% of cell proliferation, was calculated using the CalcuSyn software (Table 5.1).  
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Figure 5.1 Lipoplatin inhibits cell growth. Cells were exposed to lipoplatin or cisplatin (2.5-100 
µM). After 72 h the viable cell number was evaluated by MTT staining. IC50 values (i.e. the 
concentration of drug that reduces cell growth by 50%) were calculated using the Calcusyn 
software. Results represent the mean ± SEM of three replicate wells from three independent 
experiments. 
 
Table 5.1 Growth inhibition of ME-180, R-ME-180 and HeLa cells by lipoplatin and cisplatin. 
 
 
 
 IC50 ( M)  
ME-180 R-ME-180 HeLa 
Lipoplatin 
Cisplatin 
24.8±2.3 
 
6.5±0.7 
 
18.1±1.7 
 
55.5±5.1 
 
 
19.6±1.8 
8.6±0.8 
 
 
IC50 values are mean ± SEM from 3 independent experiments. 
 
The IC50 of cisplatin in the cisplatin-resistant cell line R-ME-180 was about 9-fold 
higher than in ME-180 cisplatin-sensitive cells (Table 5.1). 
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 Interestingly, the IC50 of lipoplatin was similar in both cell lines, and even 3-fold 
lower than the IC50 of cisplatin in R-ME-180 cells. A similar IC50 for lipoplatin 
was also obtained in HeLa cells. 
Cisplatin affects tumor cell proliferation by activating the process of programmed 
cell death (Brozovic et al., 2010).  
One of the early events of apoptosis is the loss of plasma membrane asymmetry: 
in apoptotic cells, the membrane phospholipid phosphatidylserine (PS) is 
translocated from the inner to the outer leaflet of the plasma membrane. Annexin-
V protein has a high affinity for PS, and binds to cells with exposed PS. Viable 
cells with intact membranes exclude the fluorescent dye propide iodide (PI), 
whereas the membranes of dead and damaged cells are permeable to PI. Cells that 
are Annexin-V positive and PI negative are considered in early apoptosis, cells 
that are both Annexin-V and PI positive are considered in late apoptosis or 
necrotic cells. 
I evaluated apoptosis induction by lipoplatin in ME-180 and its cisplatin-resistant 
clone R-ME-180, including cisplatin as reference drug.   
Increasing lipoplatin concentrations (10, 20, 30 µM) correlated with an increase of 
apoptotic cells. At the highest concentration (30 µM) lipoplatin demonstrated a 
significant apoptosis induction in both cell lines. Lipoplatin treated R-ME-180 
cells showed a higher amount of Annexin-V/PI positive cells (late apoptosis) than 
ME-180 cells. On the contrary, cisplatin used at the same concentrations, did not 
induce apoptosis in R-ME-180 cells (Figure 5.2). 
Moreover, I evaluated DNA fragmentation, one of the later steps in apoptosis, a 
process which results from the activation of endonucleases during the apoptotic 
program.  
APO-DIRECT™ is a single-step staining method for labeling DNA breaks to 
detect apoptotic cells by flow cytometry. An increase of fluorescence signal is 
associated with the presence of DNA breaks.  
Apoptosis induction by lipoplatin (30 µM for 72 hours) was further confirmed in 
both cell lines by the presence of DNA damage (Figure 5.3A). Cisplatin induced a 
remarkable DNA fragmentation only in cisplatin-sensitive ME-180 cells, as 
showed in the representative flow cytometry histograms (Figure 5.3A). 
 
 
 
 
 65 
 
A
0 20 40 60 80 100
0
25
50
75
100
125
lipoplatin (µM)
IC50=18.1
IC50=24.8
v
ia
b
le
 c
e
ll
 (
%
)
cisplatin (µM)
IC50=55.5
IC50=6.5
****
0 20 40 60 80 100
0
25
50
75
100
125
ME-180
R-ME-180
Hela
IC50=8.6
IC50=19.6
B
annexin V/ PI
annexin V
10 20 30 10 20 30 10 20 30 10 20 30
ME-180 R-ME-180
cisplatin (µM) cisplatin (µM)lipoplatin (µM)lipoplatin (µM)
A
n
n
e
x
in
-V
-F
IT
C
 (
%
)
****
****
****
****
****
****
****
****
****
0
20
40
60
80
100
120
 
 
Figure 5.2 Lipoplatin induces apoptosis. FACS analysis of cells after 72 h incubation at 37 °C 
with different concentrations of either lipoplatin or cisplatin (10, 20, and 30 µM) and double 
stained with Annexin-V-FITC and PI. Values in the bar graph represent the mean ± SEM of three 
different experiments. ****P < 0.0001 drug vs medium. 
 
 
5.1.2 Lipoplatin activated mitochondrial apoptotic pathway 
Apoptosis induction by cisplatin is mediated by various signals including the 
activation of mitochondrial pathways (Brozovic et al., 2010).  
The mitochondrial or intrinsic apoptotic pathway is characterized by 
mitochondrial outer membrane permeabilization (MOMP), cytochrome-c release, 
apoptosome assembly, and activation of the caspase cascade through caspase 9, 
which subsequently activates effector caspase 3. Permeability of the outer 
mitochondrial membrane is regulated via the opposing activities of the pro- and 
anti-apoptotic members of the Bcl-2 family. The balance between these 
competing activities determines cell fate (Adams and Cory, 1998; Mayer and 
Oberbauer, 2003). 
ME-180 and R-ME-180 were treated with lipoplatin (30 µM) for 72 hours. Then I 
assessed the activation of the mitochondrial apoptotic pathway by flow cytometry. 
Chloromethyl-X-rosamine (CMXros) is a fluorescent dye that stains mitochondria 
in live cells and its accumulation is dependent upon membrane potential 
(Pendergrass et al., 2004).   
The treatment with lipoplatin led to a decline in the mitochondrial membrane 
potential, revealed by the decreased fluorescent signal of CMXros, and to the  
release of cytochrome-c, evaluated by antibody staining, in both ME-180 and R-
ME-180 cell lines (Figure 5.3A).  
Moreover, lipoplatin treatment increased the expression of the pro-apoptotic 
molecule Bax, while it decreased the expression of the anti-apoptotic molecules 
Bcl-2 and Bcl-xL (Figures 5.3B). 
Consistently, I found the activation of caspases 9 and 3 in both cell lines after 48 
hours of lipoplatin treatment (Figure 5.3C).  
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Taken together these results suggested that lipoplatin activated the mitochondrial 
apoptotic pathway in both cell lines. On the contrary, cisplatin, at the same 
experimental conditions, induced apoptosis only in ME-180 cisplatin-sensitive 
cells (Figures 5.3A, B and C). 
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Figure 5.3 Lipoplatin induces mitochondria-mediated apoptosis and modulates Bax, Bcl-2 and 
Bcl-xL expression. (A) DNA fragmentation, mitochondrial membrane permeabilization 
(CMXRos), and cytochrome-c release were assessed by flow cytometry after treatment for 72 h 
with either lipoplatin or cisplatin (30 μM). (B) Analysis of Bax, Bcl-2 and Bcl-xL expression. 
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Cells were incubated with either lipoplatin or cisplatin (30 μM). After 72 h, Bax, Bcl-2, and Bcl-
xL expression was assessed by flow cytometry. (C) Analysis of caspases activation after 
incubating cells with either lipoplatin or cisplatin (30 μM) for 24 and 48 h. Cells were harvested, 
washed and resuspended in complete medium supplemented with FLICA for 1 h at 37 °C, then 
washed again and analyzed by flow cytometry. Dotted lines indicate background fluorescence of 
cells. X- and Y-axes indicate the logarithms of the relative fluorescence intensity and relative cell 
number, respectively. FACS histograms are representative of one of three different experiments. 
 
 
5.1.3 Lipoplatin induced ROS formation and affected TrxR activity 
Several mechanisms are believed to mediate cisplatin-induced apoptosis including 
the generation of reactive oxygen species (ROS) (Brozovic et al., 2010).  
Consistently, induced ROS formation after lipoplatin treatment was observed in 
both cell lines (ME-180 = 21% and R-ME-180 = 39% ROS positive cells), while 
cisplatin induced ROS formation only in the cisplatin-sensitive ME-180 cells 
(Figure 5.4A). Representative flow cytometry dot plots are shown in Figure 5.4B.  
Thioredoxin reductase (TrxR) is a selenoenzyme essential to maintain the balance 
of the cellular redox status and to protect the cells against oxidative damage due to 
ROS accumulation (Mahmood et al., 2013). R-ME-180 cells expressed higher 
enzymatic activity of TrxR than ME-180 cells (about 3-fold) (Figure 5.4C). Both 
lipoplatin and cisplatin reduced TrxR activity in a dose-dependent manner (20 and 
30 μM) in both cell lines, but only lipoplatin (30 μM) was able to reduce TrxR 
activity in R-ME-180 cells to levels lower than those of sensitive ME-180 cells.  
These results suggested that reduced enzymatic activity of TrxR by lipoplatin 
could be involved in ROS accumulation and consequent apoptosis induction.  
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Figure 5.4 Lipoplatin induces ROS accumulation and inhibition of TrxR activity. Cells were 
treated with either lipoplatin or cisplatin (30 μM) for 72 h. (A) ROS production was analyzed with 
MitoSox reagent; the bar graphs represent the percentage of ROS (MFI = mean fluorescence 
intensity) as the mean ± SEM of three different experiments. (B) Representative FACS dot plots of 
one of three independent experiments showing ROS formation. (C) TrxR enzymatic activity 
evaluated with the Thioredoxin Reductase Assay Kit after 72 h treatment with lipoplatin (20 and 
30 µM). Values in the bar graph represent the mean ± SEM of three different experiments. ***P < 
0.001, ****P < 0.0001 drug vs medium, ^^^^P < 0.0001 R-ME-180 vs ME-180. 
 
 
5.1.4 Lipoplatin inhibited cancer cell migration, invasion and down-
modulated EGFR expression 
Metastasis is a multistep process where tumor cells disseminate from the primary 
tumor and colonize distant organs. To achieve this, cell motility and cell invasion 
of basement membranes and of surrounding tissues are crucial (Bravo-Cordero et 
al., 2012).  
I evaluated the effect of lipoplatin on cancer cell migration using the scratch 
wound healing assay and the FATIMA assay for cell invasion.  
Cells were treated  72 hours with low drug concentration (10 µM) to avoid cell 
death. To exclude that in untreated cells a higher migration rate could be 
attributable to an increased cell proliferation, cells were cultured in the presence 
of low serum concentration.  
After 48 hours untreated control cells almost closed the wound, while the 
migration rate (the percentage of the surface area covered by tumor cells after the 
scratch) of lipoplatin treated cells was 57% in ME-180 and 60% in R-ME-180. At 
the same experimental conditions cisplatin reduced cell migration only in ME-180 
cells (Figures 5.5A and B).  
In subsequent experiments, I assessed invasion of tumor cells, treated for a short 
time (12 hours) with 30 μM lipoplatin, through a type I collagen-coated Boyden 
chamber. Invasion was evaluated after 5 and 24 hours. R-ME-180 cells exhibited 
enhanced invasive properties compared to ME-180 cells (Figure 5.5C). At 24 
hours lipoplatin decreased the invasion rate of about 35% in ME-180 and 50% in 
R-ME-180 cells (Figure 5.5C).  
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Epithelial growth factor receptor (EGFR), also known as Her or ErbB, is over-
expressed in approximately 85% of invasive cervical tumors, it is associated with 
higher stages and poor prognosis, and its inhibition significantly decreases tumor 
cell metastases (Soonthornthum et al., 2011).  
I evaluated the surface expression of EGFR in ME-180 and R-ME-180 cells by 
flow cytometry. R-ME-180 (mean fluorescence intensity (MFI) = 387.26 ± 42) 
expressed higher amounts of EGFR than ME-180 cells (MFI = 201.68 ± 30). 
Lipoplatin (30 μM) decreased EGFR expression in both cell lines, while cisplatin, 
used at the same concentration, remarkably down-modulated EGFR in ME-180 
cells and only minimally affected R-ME-180 cells (Figure 5.5D). A representative 
experiment is shown in Figure 5.5E. 
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Figure 5.5 Lipoplatin inhibits cell migration and decreases EGFR expression. Cells were treated 
with lipoplatin or cisplatin at 10 μM for 72 h. Then cell confluent monolayers were scraped up 
three times and cultured in low serum medium for additional 48 h: (A) representative scratch test 
analysis of cell migration (phase contrast microphotographs, original magnification 10×); (B) 
migration rate represented as the distance between the edges of the wound (defined by the lines), 
indicating the surface area occupied by the migrating cells after 24 and 48 h. Values in the bar 
graph represent the mean ± SEM of three different experiments. (C) Migration of cervical cancer 
cells through a collagen type I-coated Boyden chamber (invasion) after treatment for 12 h with 30 
μM lipoplatin. *P < 0.05, **P < 0.01, ***P < 0.001 drug vs medium. (D) Cells were treated for 72 
h with either lipoplatin or cisplatin (30 μM). Then EGFR surface expression was analyzed by flow 
cytometry using the anti-EGFR mAb 528. Mean fluorescence intensity (MFI) values in the bar 
graph represent the mean ± SEM of three different experiments. *P < 0.05, ****P < 0.0001 drug 
vs medium. ^^^^P < 0.0001 R-ME-180 vs ME-180. (E) Representative FACS histograms of one of 
three independent experiments showing EGFR expression after drug treatment. 
 
 
5.1.5 Spheroids-forming efficiency and ALDH are increased in R-ME-
180 cells: lipoplatin inhibited spheroid formation and reduced 
ALDH(+) cells 
Spheroids represent a three-dimensional in vitro system that more closely 
resembles the in vivo tumor microenvironment. A greater ability to form spheroids 
(Sugihara and Saya, 2013) and the expression of Aldehyde Dehydrogenase 
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(ALDH) enzyme (López et al., 2012) usually indicate an increase in the Cancer 
Stem Cell (CSC) population.  
Cisplatin-resistant R-ME-180 cells, but not ME-180, spontaneously formed 
spheroids when cultured in non-adherent conditions (poly-HEMA coated wells). 
Consistently, R-ME-180 expressed a higher amount of ALDH(+) cells than ME-
180 when cultured as monolayer. The percentage of ALDH(+) cells increased in 
R-ME-180 cultured as spheroids (I gen). Then, to further select ALDH(+) cells I 
dissociated the first generation of spheroids to single cells and replated them 
under non-adherent conditions (II gen). In this second generation of spheroids I 
found an enriched ALDH(+) cell population compared to the first generation 
spheroids. 
ALDH activity was about 0.2% in ME-180 and 0.51% in R-ME-180 cells grown 
as monolayer. The percentage of ALDH(+) cells in R-ME-180 cultured as 
spheroids was 4.45-fold (I gen) and 6.82-fold (II gen) higher than R-ME-180 
cultured as monolayer (Figure 5.6A). A representative FACS dot plot showing 
ALDH expression is shown in Figure 5.6B.  
Then, I investigated whether lipoplatin could affect spheroid formation and the 
amount of ALDH(+) cells.  
Lipoplatin (10, 25, 50 μM) inhibited spheroid formation in poly-HEMA coated 
wells. After 72 hours R-ME-180 cells formed several large and dense spheroids, 
whereas lipoplatin treated cells formed small spheroids with dead cells 
interspersed among cell aggregates (Figure 5.7A). At the highest lipoplatin 
concentration (50 μM) I detected only dead cells (Figure 5.7A).  
Then, I dissociated R-ME-180 spheroids and evaluated apoptosis and ALDH(+) 
enzymatic activity by flow cytometry. 
Lipoplatin induced apoptosis (Figure 5.7B), evaluated by Annexin-V/PI staining, 
and decreased the percentage of ALDH(+) cells in a dose-dependent manner 
(Figure 5.7C). Representative flow cytometry dot plots of ALDH activity are 
shown in Figure 5.7D.   
Under the same experimental conditions cisplatin did not affect spheroid 
formation and only slightly induced apoptosis (Figures 5.7A and B). 
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Figure 5.6 Spheroid-forming efficiency and ALDH are increased in R-ME-180 cells. (A) ALDH 
expression was evaluated by flow cytometry in ME-180 and R-ME-180 monolayers and in first (I 
gen.) and second generation (II gen.) spheroids. Values in the bar graph, reported as the percentage 
of ALDH positive cells, represent the mean ± SEM of three different experiments. ^^^P < 
0.001ME-180 vs R-ME-180 monolayer; ****P < 0.0001 R-ME-180 monolayer vs I and II gen. 
spheroids, °°°°P < 0.0001 I gen. vs II gen. spheroids. (B) Representative FACS dot plots of one of 
three independent experiments showing ALDH expression. 
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Figure 5.7 Lipoplatin inhibits spheroid formation and reduces ALDH(+) cells. (A) R-ME-180 
cells, cultured on plates covered with poly- HEMA (2-hydroxyethyl methacrylate), were treated 
with lipoplatin or cisplatin (10, 25, 50 μM). After 72 h spheroids were photographed (phase 
contrast microphotographs, original magnification 4×) and then disrupted to evaluate apoptosis (B) 
or ALDH expression (C-D). (B) The graph indicates the mean ± SEM values of the percentages of 
apoptotic cells evaluated by Annexin-V/PI staining from three independent experiments, each 
performed in duplicate. (C) The graph represents ALDH quantification, as MFI percentage, after 
spheroid treatment with lipoplatin. Data are expressed as mean ± SEM of three separate 
experiments. (D) Representative FACS dot plots of one of three independent experiments showing 
ALDH expression (% of positive cells). 
 
 
5.1.6 Lipoplatin inhibited the growth of cervical cancer xenografts 
Finally, I evaluated lipoplatin anticancer activity in vivo. 
Cisplatin-resistant R-ME-180 cells (2.5×10
6
) were injected into the right flank of 
6-week-old female athymic nude mice. After 4 days (tumor size of about 32 mm
3
) 
mice were randomly divided in two groups (5 mice per group) and treated 
intraperitoneally either with 10 mg/kg lipoplatin or with vehicle. Treatment for 28 
days resulted in a significant (P<0.01) tumor growth inhibition, approximately 
70%. The tumors of the untreated control group grew to a mean tumor size of 
615.4 ± 50 mm
3
, while in lipoplatin treated mice tumors reached a mean size of 
192 ± 15 mm
3
 (Figure 5.8). There was no histological detectable cytotoxicity 
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involving the animals‟ heart, spleen, liver, and kidney, whereas treatment with the 
same concentration of cisplatin was lethally toxic for mice (data not shown). 
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Figure 5.8 In vivo anticancer activity of lipoplatin (xenograft). Tumor volume was measured in 
female athymic nude mice after intraperitoneal (i.p.) injection of either drug-free medium or 
containing 10 mg/kg lipoplatin, three times a week using a caliper. Points represent the mean ± 
SEM of five animals per group. **P < 0.01 lipoplatin vs control. 
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5.2 Lipoplatin activity on ovarian cancer cells 
5.2.1 Lipoplatin inhibited ovarian cancer cell proliferation and induced 
apoptosis and cell cycle modifications 
I evaluated the antiproliferative activity of lipoplatin in a panel of ovarian cancer 
cell lines of different histotypes and with various degrees of cisplatin sensitivity: 
A2780, A2780cis, MDAH, OVCAR-5, OVCAR-3, SKOV-3, and TOV-21G.  
Seventy-two hours treatment with increasing concentrations of lipoplatin or 
cisplatin (2.5-100 µM) induced a dose-dependent inhibition of cell proliferation, 
as evaluated by MTT cell viability assay. Using the CalcuSyn software I 
calculated the IC50. 
All the ovarian cancer cell lines expressed similar sensitivity to lipoplatin. The 
IC50 of lipoplatin was about 17 µM for all cell lines, excluding OVCAR3 cells (32 
µM), while the IC50 for cisplatin was very different, ranging from 1.5 µM to 11.9 
µM, with OVCAR5 being the less sensitive cell line (Table 5.2). 
Also A2780 cells and its parental cisplatin-resistant cell line, A2780cis, showed a 
comparable sensitivity to lipoplatin (Table 5.2). On the contrary, the IC50 of 
cisplatin was about 7-fold higher in the cisA2780 (IC50 = 10.4 µM) compared to 
the parental cisplatin-sensitive cell line A2780 (IC50 = 1.5 µM). 
 
Table 5.2 Growth inhibition by lipoplatin and cisplatin in a panel of ovarian cancer cell lines. 
 
 
  
                                              IC50 ( M) 
 
A2780 A2780cis MDAH OVCAR3 OVCAR5 SKOV3 TOV21G  
Lipoplatin 
Cisplatin 
17.8±1.6 
1.5±0.1 
17.2±1.5 
10.4±0.9 
14.6±1.4 
 
4.3±0.3 
32.1±3.3 
 
5.9±0.6 
16.9±1.5 
 
11.9±1.2 
 
17.1±1.5 
5.4±0.6 
17.8±1.7 
 
3.2±0.2 
 
 
IC50 values are mean ± SEM from 3 independent experiments. 
 
Then, I evaluated apoptosis induction after lipoplatin treatment. For this purpose I 
used the most cisplatin-resistant cell line OVCAR5, and SKOV3 cells, capable to 
generate tumor spheres (Ma et al., 2010).  
Lipoplatin induced apoptosis in a dose-depent manner in both OVCAR5 and 
SKOV3 cells, as evaluated by Annexin-V and PI staining (Figure 5.9A).  
Apoptosis induction after lipoplatin treatment (30 µM for 72 hours) was also 
confirmed by the presence of DNA fragmentation, a late event in apoptosis 
(Figure 5.10A).  
It is known that cisplatin affects cell cycle progression (Liu et al., 2000).  
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Lipoplatin treatment (30 µM for 24 hours) determined an arrest of the cell cycle in 
the G2/M phase in SKOV3 cells, and an increase in S and G2/M phase in 
OVCAR5 cells (Figure 5.9B). 
 
annexin V + PI
annexin V
F
IT
C
-A
n
n
e
x
in
-V
 (
%
)
10 20 30 10 20 30
OVCAR5 SKOV3
lipoplatin (µM)
****
****
*
****
****
0
10
20
30
40
50
60
70
80
90
100
00
A
 
 
                 
OVCAR5 
DNA content T = 24 hs
c
e
ll
 n
u
m
b
e
r
lipoplatin
SKOV3 
200 400 600 800 1000 400200 1000600 800
0%
G0G1
S
G2M
44
37
19
0%
G0G1
S
G2M
0
25
75
medium
G0G1
S
G2M
0%
48
35
17
G0G1
S
G2M
11
51
38
0%
B
 
OVCAR5 
DNA content T = 24 hs
c
e
ll
 n
u
m
b
e
r
lipoplatin
SKOV3 
200 400 600 800 1000 400200 1000600 800
0%
G0G1
S
G2M
44
37
19
0%
G0G1
S
G2M
0
25
75
medium
G0G1
S
G2M
0%
48
35
17
G0G1
S
G2M
11
51
38
0%
B
 
 
Figure 5.9 Lipoplatin induces apoptosis and cell cycle modifications. (A) FACS analysis of cells, 
double stained with Annexin-V-FITC and PI, after 72 h incubation at 37 °C with different 
concentrations of lipoplatin. Values in the bar graph represent the mean ± SEM of three different 
experiments. ****P < 0.0001 drug vs medium. (B) FACS histograms showing cell cycle 
progression. Cells were treated 24 h with 30µM lipoplatin and stained with PI. The percentages of 
cells in the G0/G1 phase, S phase, and G2M phase are reported, as well as the percentage of sub-
G1 cells. FACS histograms are representative of one of three different experiments. 
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5.2.2 Lipoplatin affected mitochondrial functions, ROS formation and 
TrxR activity 
Similarly to the results obtained with cervical cancer cells, lipoplatin treatment 
(30 µM for 72 hours) led to a decline in the mitochondrial membrane potential, 
revealed by the decreased fluorescent signal of CMXRos, and to the  release of 
cytochrome-c, as evaluated by flow cytometry, in both OVACR5 and SKOV3 
cells (Figure 5.10A). Moreover, after lipoplatin treatment the expression of the 
pro-apoptotic molecule Bax remarkably increased, whereas the anti-apoptotic 
molecule Bcl-2 decreased. The expression of Bcl-xL did not change (Figure 
5.10A and B). Consistently, lipoplatin determined the activation of caspases 9 and 
3, in both cell lines (Figure 5.10C and D).  
Lipoplatin (20 and 30 µM for 72 hours) let to a dose-dependent induction of  ROS 
in both cell lines (Figures 5.11A). At concentration 30 µM ROS accumulation 
remarkably increased. Representative FACS dot plots of ROS formation are 
shown in Figure 5.11B. 
Subsequently, I evaluated the enzymatic activity of the ROS scavenger TrxR. 
OVCAR5 cells expressed higher amounts of TrxR than SKOV3 cells (OVCAR5 
U/mg = 276 and SKOV3 U/mg = 217) (Figure 5.11C). Lipoplatin treatment 
reduced TrxR activity in a dose-dependent manner (20 and 30 μM for 72 hours) in 
both cell lines. At the highest concentration, lipoplatin reduced TrxR activity to 
less than 20% of control (Figure 5.11C). 
 
OVCAR5 SKOV3 OVCAR5 SKOV3 OVCAR5 SKOV3
drug
medium
IgG
medium
drugIgG
medium
drugIgG
medium
drugIgG
drug
medium
drug
medium
IgGIgG
fluorescence intensity 
BclxLBcl-2Bax
lipoplatin 
c
e
ll
 c
o
u
n
t
c
e
ll
 c
o
u
n
t
lipoplatin 
mediumdrug
IgG
medium
drugIgG
drug
medium
drug
medium drug
medium medium
drug
OVCAR5 SKOV3 OVCAR5 SKOV3 OVCAR5 SKOV3
Cyt-CCMXrosDNA FRAGMENTATION
fluorescence intensity 
A
B
 
 
 78 
 
c
e
ll
 c
o
u
n
t
T= 48h
c
a
s
p
a
s
e
 9
 
T= 24h
T= 0h
fluorescence intensity 
T= 48h
c
a
s
p
a
s
e
 3
 
T= 24h
T= 0h
medium
drug
medium
drug
fluorescence intensity
OVCAR5 SKOV3 
lipoplatin 
OVCAR5 SKOV3 
lipoplatin 
c
e
ll
 c
o
u
n
t
C D
 
 
Figure 5.10 Lipoplatin induces mitochondria-mediated apoptosis and modulates Bax and Bcl-2. 
(A) DNA fragmentation, mitochondrial membrane permeabilization (CMXRos), and cytochrome-c 
release were assessed by flow cytometry after treatment for 72 h with lipoplatin (30 μM). (B) 
Analysis of Bax, Bcl-2 and Bcl-xL expression. Cells were incubated with lipoplatin (30 μM). After 
72 h, Bax, Bcl-2, and Bcl-xL expression was assessed by flow cytometry. (C) Analysis of caspases 
activation after incubating cells with lipoplatin (30 M) for 24 and 48 h. Cells were harvested, 
washed and resuspended in complete medium supplemented with FLICA for 1 h at 37 °C, then 
washed again and analyzed by flow cytometry. Dotted lines indicate background fluorescence of 
cells. X- and Y-axes indicate the logarithms of the relative fluorescence intensity and relative cell 
number, respectively. FACS histograms are representative of one of three different experiments. 
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Figure 5.11 Lipoplatin induces ROS accumulation and inhibition of TrxR activity. Cells were 
treated with lipoplatin (20 and 30 μM) for 72 h. (A) ROS production was analyzed with MitoSox 
reagent; the bar graphs represent the percentage of ROS as the mean ± SEM of three different 
experiments. (B) Representative FACS dot plots of one of three independent experiments showing 
ROS formation. Percentage of ROS positive cells are shown. (C) TrxR enzymatic activity 
evaluated with the Thioredoxin Reductase Assay Kit. Values in the bar graph represent the mean ± 
SEM of three different experiments. ****P < 0.0001 drug vs medium, ^^P < 0.0001 OVCAR5 vs 
SKOV3. 
 
 
5.2.3 Lipoplatin inhibited cancer cell invasion and down-modulated 
EGFR expression 
I evaluated the effect of lipoplatin on cancer cell invasion through a type I 
collagen-coated Boyden chamber using the FATIMA assay. Cells were treated 72 
hours with low drug concentration (10 μM) to avoid apoptosis.  
Lipoplatin decreased cell invasion of both cell lines of more than 40% (Figure 
5.12A). 
EGFR is involved in ovarian cancer cell invasion, representing an attractive target 
in the treatment of epithelial ovarian cancer (Gui and Shen, 2012; Jeong et al., 
2013). 
Cells were treated with lipoplatin (20 and 30 μM) for 72 hours. OVCAR5 cells 
expressed a higher level of EGFR (MFI = 818 ± 73) than SKOV3 cells (MFI = 
639 ± 57) (Figure 5.12B). At the concentration of 20 µM lipoplatin decreased 
EGFR surface expression to less than 20% of control in both cell lines (Figure 
5.12B). Representative flow cytometry histogram plots are shown in Figure 
5.12C. 
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Figure 5.12 Lipoplatin inhibits cell invasion and decreases EGFR expression. (A) Invasion of 
ovarian cancer cells through a collagen type I-coated Boyden chamber after treatment for 72 h 
with 10 μM lipoplatin. **P < 0.01drug vs medium. (B) Cells were treated for 72 h with lipoplatin 
(20 and 30 μM), then EGFR surface expression was analyzed by flow cytometry using the anti-
 81 
 
EGFR mAb 528. Values in the bar graph represent the mean ± SEM of three different 
experiments. ****P < 0.0001 drug vs medium. ^^P < 0.0001 OVCAR5 vs SKOV3. (C) 
Representative FACS histograms of one of three independent experiments showing EGFR 
expression after drug treatment. 
 
 
5.2.4 Lipoplatin drug combination  
Synergy occurs when drugs can interact in ways that their combined effect is 
greater than the sum of their individual effects. Drug combination is widely used 
in treating cancer. The main aims are to achieve synergistic therapeutic effect, 
dose and toxicity reduction, and to minimize or overcome the induction of drug 
resistance (Chou, 2010).  
I combined lipoplatin with the most commonly drugs used to treat ovarian cancer: 
abraxane, docetaxel, doxorubicin, and paclitaxel.  
OVCAR5 and SKOV3 cells were cultured in the presence of a single 
chemotherapeutic agent or in combination with lipoplatin. After 72 hours 
treatment, I assessed cell viability using the MTT assay and determined the 
possible synergistic activity calculating the combination index (CI) using the 
Calcusyn software. Values of CI less than 1 indicate synergy, CI over 1 indicate 
antagonism, and CI about 1 indicate additive effect (Table 5.3) (Bijnsdorp et al., 
2011).  
 
Table 5.3 Table showing the combination index values and their indication. 
 
 
 
The combination of lipoplatin and abraxane showed synergistic activity against 
OVCAR5 and SKOV3 cells with CI minor than 0.7 at low drug concentrations. At 
high concentrations an additive or even antagonistic effect was observed (Figure 
5.13B and C). A representative synergy effect of lipoplatin and abraxane on cell 
viability is shown in Figure 5.13A. 
OVCAR5 cells were less sensitive to doxorubicin compared to SKOV3 cells (IC50 
= 0.87 ng/ml and IC50 = 0.13 ng/ml, respectively). The combination of lipoplatin 
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and doxorubicin showed synergism at IC50 concentrations in both OVCAR5 and 
SKOV3 cell lines (Figure 5.13D and E). An additive or even antagonistic effect 
was observed at the extremes of the dose-response curves in SKOV3 cells and at 
the highest concentration in OVCAR5 (Figure 5.13F).  
In OVCAR5 cells the combination of lipoplatin with docetaxel was moderate or 
additive (Figure 5.14B and C). Similar results were obtained also in SKOV3 cells, 
even if docetaxel did not reach an IC50 (Figure 5.14B and C). A representative 
growth-inhibitory effect of lipoplatin and docetaxel on cell viability is shown in 
Figure 5.13A. 
Interestingly, IC50 of paclitaxel was 25.27 ng/ml in OVCAR5 and 136.45 ng/ml in 
SKOV3 cells, whereas the calculated IC50 of abraxane, the albumin-bound 
paclitaxel formulation, was almost similar in both cell lines. The combination of 
lipoplatin and paclitaxel showed a moderate synergism or an additive effect in 
both cell lines, with CI of about 0.7 (Figure 5.14D, E and F).  
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Figure 5.13 Combination of lipoplatin with abraxane and doxorubicin. OVCAR5 and SKOV3 
cells were incubated with each drug alone or in combination for 72 h and cell viability was 
determined by the MTT assay. Synergy was determined by calculating the combination index (CI) 
analyzed by Calcusyn software. Each value represents a mean of 3 independent experiments 
performed in triplicate (± SEM). ***P < 0.001, ****P < 0.0001 single drug vs combination 
treatment. Representative experiments demonstrating synergistic effects on cell viability of 
lipoplatin with abraxane (A) and doxorubicin (D).  
Synergy between lipoplatin and abraxane (ABX) (B), doxorubicin (DOXO) (E) using a range of 
drug concentrations. CI<1 denotes synergism, CI=1 additivity and CI>1 antagonism. * indicates 
drug IC50.  
CI for lipoplatin combined with abraxane (C) and doxorubicin (F). The horizontal dashed line 
highlights CI=1. 
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Figure 5.14 Combination of lipoplatin with docetaxel and paclitaxel. OVCAR5 and SKOV3 cells 
were incubated with each drug alone or in combination for 72 h and cell viability was determined 
by the MTT assay. Synergy was determined by calculating the combination index (CI) analyzed by 
Calcusyn software. Each value represents a mean of 3 independent experiments performed in 
triplicate (± SEM). *P < 0.05, **P < 0.01, ***P < 0.001 single drug vs combination treatment. 
Representative experiments demonstrating synergistic effects of lipoplatin with docetaxel (A) and 
paclitaxel (D).  
Synergy between lipoplatin and docetaxel (DTX) (B), paclitaxel (PTX) (E) using a range of drug 
concentrations. CI<1 denotes synergism, CI=1 additivity and CI>1 antagonism. * indicates drug 
IC50.  
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CI for lipoplatin combined with docetaxel (C) and paclitaxel (F). The horizontal dashed line 
highlights CI=1. 
 
 
5.2.5 Lipoplatin decreased cancer stem cell markers and prevented 
tumor spheroid formation  
Cancer seems to be driven by tumor-initiating cells, popularly known as cancer 
stem cells (CSC). CSC are characterized by their ability to form tumor spheres 
and are involved in drug resistance and disease recurrence (Shank et al., 2012). 
Markers identifying CSC in ovarian cancer include CD133 and the aldehyde 
dehydrogenase (ALDH) enzyme activity. Drugs that are able to target CSC may 
offer a great promise to improve the therapeutic outcome (Silva et al., 2011). 
I evaluated by flow cytometry ALDH enzymatic activity and CD133 surface 
expression in both, OVCAR5 and SKOV3 cells, after lipoplatin treatment. 
OVCAR5 cells showed a 2-fold higher level of ALDH positive cells compared to 
SKOV3 cells (ALDH+ = 7.96% and 4.08%, respectively) (Figure 5.15A), 
whereas CD133 expression was almost similar in both cell lines (CD133+ = 5.4% 
and 5.6%, respectively) (Figure 5.15C). The treatment of OVCAR5 and SKOV3 
cells with increasing concentrations (10, 20, and 30 µM) of lipoplatin for 72 hours 
reduced ALDH (Figure 5.15A) and CD133 (Figure 5.15C) positive cells in a 
dose-dependent manner. 
Representative flow cytometry dot plots of ALDH(+) cells (Figure 15B) and  
histogram plots of CD133 surface expression (Figure 5.15D) are shown.  
It is known that in the ascites of a patient with advanced ovarian cancer there is 
the presence of multicellular tumor aggregates or spheroids that are believed to 
make a significant contribution to chemoresistance and intraperitoneal spread 
(Lengyel, 2010).  
SKOV3 cells spontaneously produced compact spheroids when cultured under 
non-adherent conditions. The spheroids obtained with the poly-HEMA technique 
were similar to those I observed in the ascites of patients with ovarian cancer 
(Figure 5.16A). Lipoplatin (10, 25, and 50 µM) reduced in a dose-dependent 
manner spheroid formation. At the highest lipoplatin concentration (50 μM) I only 
detected dead cells, as confirmed by the Annexin-V/PI staining (Figure 5.16B and 
C) performed on dissociated spheroids. 
Taken together, these results demonstrated that lipoplatin decreased two markers 
of ovarian cancer stem cells and spheroids formation. 
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Figure 5.15 Lipoplatin decreases cancer stem cell markers. ALDH enzymatic activity and the 
surface expression of CD133 was evaluated by flow cytometry in OVCAR5 and SKOV3 after 72h 
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treatment with  lipoplatin (10, 20, and 30 μM). (A) Values in the bar graph, reported as the 
percentage of ALDH positive cells, represent the mean ± SEM of three different experiments. *P < 
0.05, ****P < 0.0001 drug vs medium. (B) Representative FACS dot plots of one of three 
independent experiments showing ALDH expression. (C) Graph representing CD133 
quantification as percentage of positive cells. Data are expressed as mean ± SEM of three separate 
experiments. ****P < 0.0001 drug vs medium. (D) Representative FACS histogram plots of one of 
three independent experiments showing CD133 expression.  
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Figure 5.16 Lipoplatin inhibits spheroid formation. (A) Phase contrast microphotographs (original 
magnification 4×, 10×, 20×) SKOV3 generated tumor spheroids on poly-HEMA (left) and patient 
ascites derived multicellular aggregates (right). (B) SKOV3 cells, cultured on plates covered with 
poly- HEMA were treated with (10, 25, 50 μM) lipoplatin. After 72 h spheroids were 
photographed (phase contrast microphotographs, original magnification 4×) and then disrupted to 
evaluate apoptosis (C). (C) The graph indicates the mean ± SEM values of the percentages of 
apoptotic cells evaluated by Annexin-V/PI staining from three independent experiments, each 
performed in duplicate. *P < 0.05, ****P < 0.0001 drug vs medium. 
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5.2.6 Lipoplatin affected SKOV3 spheroid volume growth, cell viability 
and dissemination 
Spheroids have been used as models for evaluation of drug activity in ovarian 
cancer and are typically more resistant to chemo-and radiotherapies compared to 
cells cultured as 2-D monolayers (Soriţău et al.,2010; Mehta et al., 2012).  
I evaluated lipoplatin activity using single spheroids of defined size. SKOV3 
spheroids of four days, with a volume of ~100 µm
3
*10
5
, were treated with 
increasing concentrations of lipoplatin (10-100 µM). I determined spheroid 
growth by calculating the volume at time 0, 3, 7, 10 and 15 days (Figure 5.17A).  
Lipoplatin inhibited in a dose-dependent manner spheroid growth, evaluated as 
spheroid volume. The volume of spheroids treated with 25 µM lipoplatin did not 
change compared to the initial volume (time 0). At higher lipoplatin 
concentrations (50 and 100 µM) spheroids volume even significantly decreased 
(Figure 5.17A and B). Figure 5.17C shows representative tumor spheroid growth 
in the presence of 25 or 50 µM lipoplatin.  
To detect dead cells interspersed into lipoplatin treated spheroids (25 and 50 µM), 
I used the PI staining. After 3, 7, 10, and 15 days PI positive cells were recorded 
using a fluorescent microscope. Consinstently with the observed growth 
inhibition, treatment with lipoplatin increased in a time- and dose-dependent 
manner PI positive cells. Moreover, cells surrounding spheroids also were positive 
for PI staining (Figure 5.17D). 
Taken together these results demonstrated that lipoplatin affects spheroid volume 
growth exerting a cytotoxic effect. 
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Figure 5.17 Lipoplatin activity on tumor spheroid volume growth and viability. SKOV3 single 
spheroids (four days old) of defined size, ~100 µm3*105,  were treated with increasing 
concentrations of lipoplatin (0, 10, 25, 50, 100 µM) and after 0, 3, 7, 10, and 15 days their size was 
recorded and the volume calculated. (A) Graph represents the curve of spheroids volume growth of 
at least three spheroids per condition. (B) Values in the bar graph were reported as the percentage 
of increased volume compared to T0 volume. They represent the mean ± SEM of three 
independent spheroids. ****P < 0.0001 drug vs medium. (C) Representative microphotographs 
(original magnification 4×) showing the volume growth of one of three independent lipoplatin (25, 
50 µM) treated spheroids. (D) Representative microphotographs (original magnification 4×) 
showing cell viability using PI staining of at least three independent lipoplatin (25, 50 µM) treated 
spheroids. 
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Then, I evaluated lipoplatin activity on spheroids with larger volume (~300 
µm
3
*10
5
). SKOV3 spheroids of four days were treated with increasing 
concentrations of lipoplatin (10-100 µM). I determined spheroid growth by 
calculating the volume at time 0, 3, 7, 14 and 17 days (Figure 5.18A). 
In these spheroids lipoplatin used at 10 and 25 µM did not significantly affect the 
volume growth. A growth inhibition was obtained at higher concentrations. The 
concentration of lipoplatin to achieve a volume growth arrest was 50 µM. A 
volume growth reduction was observed at 75 or 100 µM (Figures 5.18B and C). 
Representative microphotographs of tumor spheroids treated with 50 or 100 µM 
lipoplatin are shown in figure 5.17G.  
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Figure 5.18 Lipoplatin activity on tumor spheroid. SKOV3 single spheroids (four days old) of 
defined size, ~300 µm3*105, were treated with increasing concentrations of lipoplatin (0, 10, 25, 
50, 75, 100 µM) and after 0, 3, 7, 10, 14 and 17 days their size was recorded and the volume 
calculated. (A) Graph represents the curve of spheroids volume growth of at least three spheroids 
per condition. (B) Values in the bar graph were reported as the percentage of increased volume 
compared to T0 volume. They represent the mean ± SEM of three independent spheroids. *P < 
0.05, ****P < 0.0001 drug vs medium. (C) Representative microphotographs (original 
magnification 4×) showing the volume growth of one of three independent lipoplatin (50, 100 µM) 
treated spheroids.  
 
I used a tumor spheroid-based assay migration in vitro to mimic tumor cell 
dissemination from a solid microtumor or micrometastasis. Cell spreading was 
evaluated onto an extracellular matrix coated surface (Vinci et al., 2012).  
I transferred single formed SKOV3 spheroids onto collagene-I coated wells. Then 
spheroids were cultured in the presence or absence of lipoplatin (25 and 50 µM). 
Within a few hours tumor cells disseminated from the spheroid over the coated 
surface, as shown in the representative microphotographs in Figure 5.19B. After 
24 and 48 hours, I recorded the leading edge of the migrating cells and calculated 
the covered area in fold increase compared to time 0 area of each sample.  
The migration rate of SKOV3 cells, evaluated after 24 and 48 hours, decreased of 
about 50% in lipoplatin treated spheroids (25 and 50 µM) (Figure 5.19A). 
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Figure 5.19 Lipoplatin inhibits tumor cell dissemination. Day 4 SKOV3 spheroids were placed on 
collagene-I coated plates and treated with lipoplatin (25 and 50 μM). Images were captured at time 
24 h and 48 h using an inverted microscope (phase contrast microphotographs, original 
magnification 4×). (A)Values shown represent the average fold change in pixel area compared to 
T0 area. **P < 0.01, ***P < 0.001, ****P < 0.0001 drug vs medium. (B) Representative images of 
one of three separate experiments are shown. 
 
 
5.2.7  Lipoplatin inhibited the growth of ovarian cancer xenografts 
OVCAR5 (2.7×10
6
) were injected into the right flank of 6-week-old female 
athymic nude mice. After 3 days (tumor size of about 44 mm
3
) mice were 
randomly divided in two groups, including 7 mice/group, and were treated 
intraperitoneally with either 20 mg/kg lipoplatin or vehicle. Treatment for 41 days 
resulted in a significant (P<0.01) tumor growth inhibition, approximately 82% of 
control. The tumors of the untreated control group grew to a mean tumor size of 
about 417.2 mm
3
, while the lipoplatin treated tumors reached a mean size of about 
73.1 mm
3
 (Figure 5.20A).  
Then, I investigated whether suspending the treatment allowed the restart of tumor 
growth. After 12 days of treatment suspension I measured the tumor volumes. The 
mean volume size of the untreated control group reached a tumor volume of about 
969.6 ± 204.8 mm
3
, whereas the volumes of the lipoplatin treated group were 
about 107.4 ± 30.3 mm
3
 (Figure 5.20A, dotted line), with a tumor growth 
inhibition of about 89% (Figure 5.20B). 
There was no histological detectable cytotoxicity involving the animals‟ heart, 
spleen, liver, and kidney, whereas treatment with the same concentration of 
cisplatin was lethally toxic for mice (data not shown). 
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Figure 5.20 In vivo anticancer activity of lipoplatin (xenograft). (A) Tumor volume was measured 
in female athymic nude mice after intraperitoneal (i.p.) injection of either drug-free medium or 
containing 20 mg/kg lipoplatin, three times a week using a caliper. Points represent the mean ± 
SEM of seven animals per group. Dotted lines represent treatment suspension. **P < 0.01 
lipoplatin vs control. (B) Image showing untreated mouse (right) and lipoplatin treated mouse 
(left). 
 94 
 
 
 95 
 
6. DISCUSSION 
Cisplatin is highly effective in the treatment of testicular and ovarian cancers and 
it is also widely employed for treating bladder, cervical, head and neck, 
oesophageal, and small cell lung cancer. Despite its success, cisplatin has several 
disadvantages, which comprise severe side effects that reduce the dose that can be 
applied to patients (Giaccone, 2000). Moreover, the use of cisplatin in cancer 
chemotherapy is limited by acquired or intrinsic resistance (Fuertes et al., 2003). 
Patients usually have a good initial response to cisplatin-based chemotherapy but 
later relapse, because the development of cisplatin resistance markedly reduces its 
clinical effectiveness. The molecular mechanisms that underlie cisplatin resistance 
are poorly understood because cisplatin has many different routes of cell entry and 
multiple cellular targets (Shen et al., 2012). Considering these drawbacks, one of 
the key research areas in oncology has been to engineer new platinum drug 
formulations to reduce the severe toxicities and to enhance the therapeutic 
effectiveness against cisplatin-resistant tumors (Boulikas et al., 2007). Such 
efforts have led to the reformulation of platinum drugs using liposomes. 
Liposomes possess several attractive biological activities, including 
biocompatibility, high drug loading, and improved pharmacokinetics, that are well 
suited for platinum drug delivery (Liu et al., 2013). However, few liposomal 
formulations have demonstrated a significant advantage in therapeutic terms. At 
the moment, lipoplatin (Biopharmaceutical Company Regulon, Athens, Greece) 
represents the most promising cisplatin liposomal formulation (Zalba and Garrido, 
2013). 
The advantage of lipoplatin over cisplatin is the reduced toxicity that results from 
the ability of lipoplatin to target primary tumors and metastases. The enhanced 
permeability and retention effect (EPR) allows the extravasation of lipoplatin 
nanoparticles preferentially in the tumor area through the leaky vasculature of 
newly formed tumor vessels. Indeed, as demonstrated in human studies, lipoplatin 
showed an enhanced concentration in tumors and metastases, at levels up to 200-
fold higher compared to the adjacent normal tissue (Stathopoulos and Boulikas, 
2012).  
Moreover, lipoplatin nanoparticles displayed enhanced circulation in body fluids 
and evaded immune surveillance by their coating with PEG. The long circulation 
of lipoplatin is a property necessary for its preferential extravasation through the 
leaky vasculature of tumors. The half-life of total platinum in human plasma was 
determined to be 60-117 hours for lipoplatin, compared to ∼6 hours for cisplatin 
(Stathopoulos et al., 2005). Interestingly, in clinical trials lipoplatin was 
administered as intravenous infusion without the need for pre- or post-hydration 
of the patient. This is in contrast to cisplatin chemotherapy that requires 
admittance of the patient the night before infusion for hydration, as well as 
extended stay in the hospital after infusion for post hydration, to reduce the 
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nephrotoxicity of the drug, with improvement in the quality of life and clear 
pharmacoeconomic benefits (Boulikas, 2009). 
There are preclinical data of lipoplatin in cancer cell cultures and in animals as 
well as clinical data which involve Phase I studies, pharmacokinetics and Phase II 
and Phase III studies. Clinical studies were performed in patients with pancreatic 
cancer, non-small-cell lung cancer (NSCLC), head and neck, breast, gastric, and 
bladder cancer.  
The most effective chemotherapeutic agent for the treatment of cervical and 
ovarian cancer is cisplatin. However, severe renal, neurologic, and gastrointestinal 
side effects and acquired chemoresistance are the major reasons of cisplatin 
treatment failure in cancer of the cervix and of the ovary (Leath and Straughn, 
2013; Siegel et al., 2012). 
In this study I evaluated the activity of lipoplatin in cervical and ovarian cancer 
models. For this purpose I used the cervical cancer-derived tumor cell line ME-
180 and its cisplatin-resistant clone R-ME-180, and a panel of ovarian cancer cell 
lines with different histotypes and with various degrees of cisplatin sensitivity. 
The IC50 of cisplatin in R-ME-180 cervical cancer cells was almost 9-fold higher 
than in ME-180 cells.  
OVCAR3 (Godwin et al., 1992), OVCAR5 (Chock et al., 2010), and SKOV3 
ovarian cancer cell lines were reported to be cisplatin-resistant (Mistry et al., 
1992). The panel also included the cisplatin-sensitive cell line A2780 and its 
parental cisplatin-resistant cell line A2780cis, which presented a 7-fold higher 
IC50 for cisplatin. 
In all cell lines, lipoplatin significantly reduced cell proliferation with comparable 
IC50. Lipoplatin also potently inhibited the proliferation of the cisplatin-resistant 
R-ME-180 cell line with an IC50 comparable to that of the parent cisplatin-
sensitive ME-180 and of HeLa cell lines. Interestingly, lipoplatin displayed an 
antiprolifeartive activity in cell lines of different ovarian cancer histology origins: 
ovarian carcinoma (A2780 and A27080cis), clear cell carcinoma (TOV21G), 
endometriod carcinoma (MDAH), and malignant cells derived from the ascites 
(OVCAR3, OVCAR5, and SKOV3). 
These results demonstrated that lipoplatin affected cell proliferation exhibiting a 
similar cytotoxic effect in cell lines with a wide range in sensitivity to cisplatin, 
including cisplatin-resistant cell lines. Lipoplatin bypassed cisplatin resistance 
mechanisms likely because it has a different mechanism of cell influx. Cisplatin 
enters the cell by passive diffusion or active uptake, while it has been 
demonstrated that lipoplatin directly fuses with the cell membrane, thanks to the 
fusogenic dipalmitoyl phosphatidyl glycerol (DPPG) lipids that compose its shell, 
delivering cisplatin across the membrane barrier (Boulikas, 2007).  
Subsequent studies in ovarian cancer cells were performed using the cisplatin-
resistant cell line OVCAR5, and SKOV3 cells capable to generate compact tumor 
spheres (Ma et al., 2010). 
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Many anticancer drugs affect the cell cycle progression and then induce cell death 
by apoptosis (Pietenpol and Stewart, 2002). G2 arrest seems to be essential to 
trigger cisplatin-induced cell death (Cepeda et al., 2007). Accordingly, lipoplatin 
treatment determined an arrest of the cell cycle in the G2/M phase in SKOV3 
cells, and an increase in S and G2/M phase in OVCAR5 cells. 
Cisplatin is believed to kill cancer cells by inducing apoptosis (Brozovic et al., 
2010), as demonstrated in HeLa cervical cancer cell line (Liu et al., 2008). Upon 
entrance to the cytoplasm, also lipoplatin leads to the induction of tumor cell 
apoptosis (Arienti et al., 2008). In agreement with Arieti et al., I demonstrated that 
lipoplatin induced its potent cytotoxic effect, on both cervical (ME-180, R-ME-
180) and ovarian cancer cells (OVCAR5, SKOV3), by activating apoptosis, 
inducing mitochondrial membrane depolarization, cytochrome-c release, and 
caspases 9 and 3 activation, indicating that its activity was exerted through the 
mitochondrial intrinsic apoptotic pathway. Consistently, the pro-survival protein 
Bcl-2 was reduced, and the pro-apoptotic Bax protein increased (Youle and 
Strasser, 2008).  
The intrinsic apoptotic pathway is activated by cytotoxic drugs that perturb the 
redox balance within a cell (Tonissen and Di Trapani, 2009). Many studies have 
indicated that platinum compounds might also target the Thioredoxin (Trx) 
system, which is related to different cellular processes including antioxidant 
defense, redox and cell growth regulation, as well as selenium metabolism (Cai et 
al., 2012; Liu et al., 2012; Mahmood et al., 2013). One of the main functions of 
the Trx system is to counteract oxidative stress by scavenging reactive oxygen 
species (ROS) and by regulating other enzymes that help to reduce oxidative 
stress. The Trx reductase (TrxR) enzyme shows elevated levels in several human 
cancer cell lines and appears increased in tumors as compared with normal tissue 
(Berggren et al., 1996). The cisplatin-resistant variants of HeLa cells, established 
by continuous exposure to cisplatin exhibited an increased expression and activity 
of TrxR, as well as Trx, compared with the parental cells (Sasada et al., 1999). 
Thus, TrxR-targeting may contribute to prevent or reverse resistance mechanisms 
(Urig and Becker, 2006). Moreover, inhibiting the function of Trx system can lead 
to an imbalance in the redox state that can ultimately cause apoptosis (Tonissen 
and Di Trapani, 2009). Consistently, we found that R-ME-180 cells expressed 3-
fold more TrxR than ME-180 cells. Lipoplatin remarkably reduced TrxR 
enzymatic activity with enhanced ROS accumulation, possibly overcoming the 
resistance mediated by TrxR over-expression. Cisplatin decreased TrxR levels in 
R-ME-180 cells to a lesser extent than lipoplatin, and to levels comparable to 
those of untreated cisplatin-sensitive cells, suggesting that cisplatin resistance 
depends on a reduced capability to increase ROS levels because of the higher 
TrxR enzymatic activity in R-ME-180 cells. Also in ovarian cancer cell lines, 
OVCAR5 and SKOV3, lipoplatin induced a dose-dependent induction of ROS 
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and inhibition of TrxR enzymatic activity, possibly overcoming a cisplatin-
resistance mediated by TrxR over-expression. 
Proteins over-expressed on the surface of tumor cells can be selectively targeted 
in cancer therapy. Epidermal growth factor receptor (EGFR) is among the most 
often targeted proteins. There are two different ways to pharmacologically target 
EGFR: anti-EGFR monoclonal antibodies (cetuximab, panitumumab) and specific 
inhibitors of the EGFR tyrosine kinase domain (gefitinib, erlotinib and lapatinib). 
Currently, EGFR-target therapy for the treatment of cervical and ovarian cancer is 
not defined for clinical use (Soonthornthum et al., 2011), even though the 
presence of EGFR has been associated with accelerated tumor progression, poor 
prognosis and therapeutic resistance (Siwak et al., 2009; Iida et al., 2011; Shen et 
al., 2008) .  
EGFR activation is related with cell proliferation, resistance to cell apoptosis and 
cancer progression. HB-EGF, a ligand of EGFR produced by stromal fibroblasts 
in uterine cervical cancer, contributes to ME-180 cell proliferation (Murata et al., 
2011). In addition, treatment with cisplatin led to EGFR degradation in sensitive 
head and neck cancer cell lines, and this degradation strongly correlates with 
cytotoxicity (Ahsan et al., 2010).  
I demonstrated that the R-ME-180 cells expressed higher amounts of EGFR than 
ME-180 cells and lipoplatin, but not cisplatin, down-modulated EGFR expression 
in cisplatin-resistant cells. As a consequence, lipoplatin, by reducing EGFR, could 
exert not only direct cytotoxic effects on cervical cancer cells, but also affect the 
proliferation induced by HB-EGF secreting stromal cells of the tumor 
microenvironment. Lipoplatin, and also cisplatin, decreased EGFR expression in 
cisplatin-sensitive cells: this implies that an appropriate treatment schedule should 
be considered when cisplatin and gefitinib, or other similar drugs, are used 
together since cisplatin treatment might hinder targeted therapy against molecules 
susceptible to down-regulation. 
EGFR is directly involved in ovarian cancer cell invasion, and angiogenesis 
(Jeong et al., 2013). OVCAR5 and SKOV3 showed comparable EGFR expression 
and invasive properties. SKOV3 cell line was reported as a strong EGFR-
expressing (Gottschalk et al., 2012) and as a highly invasive cell line (Dolo, 
2009). Lipoplatin potently decreased EGFR expression in OVCAR5 and SKOV3 
cells. Moreover, I found that lipoplatin significantly reduced the invasiveness of 
both cell lines. Therefore, the reduction of EGFR expression by lipoplatin could 
enhance chemotherapy effect by decreasing tumor progression, invasion, and 
metastasis. 
EGF has also been reported as a potent stimulator of cervical cancer cell 
invasiveness, and EGFR signaling is involved in the regulatory mechanisms of 
epithelial-mesenchymal transition (EMT) of cervical cancer cells. Acquisition of 
EMT by primary carcinoma cells is associated with disrupted epithelial integrity, 
local invasion, and ultimately metastasis. Cervical cancer usually spreads to the 
 99 
 
adjacent organs through the angiolymphatic system. Although uncommon at 
initial diagnosis, metastatic disease will develop in a high percentage of patients, 
usually within the first two years of completing treatment and in the majority of 
cases metastatic cervical cancer is not curable (Scatchard et al., 2012).  
Interestingly, R-ME-180 cells exhibited enhanced invasive properties compared to 
ME-180 cells. My study showed that lipoplatin inhibited cell migration and 
invasion of cisplatin-resistant cells, opening the possibility that this drug 
formulation could be effective also to reduce/inhibit cancer cell local invasion and 
metastases. 
Chemotherapy regimens or treatment plans may use a single drug or a 
combination of drugs. A drug combination is synergistic, additive or antagonistic 
if the effect is greater than, equal to, or less than the summed effects of the partner 
drugs (Chou, 2006). The term synergy is derived from the Greek syn-ergos, 
"working together". Synergistic drug combinations have been explored to achieve 
one or more favorable outcomes: enhanced efficacy; decreased dosage at equal or 
increased level of efficacy; reduced or delayed development of drug resistance; 
and simultaneous enhancement of therapeutic actions and reduction of unwanted 
actions (efficacy synergism plus toxicity antagonism) (Jia et al., 2009). 
The standard approach for the treatment of ovarian cancer is the combination of a 
platinum compound, such as cisplatin or carboplatin, with a taxane, such as 
paclitaxel (Taxol
®
) or docetaxel (Taxotere
®
) (Jelovac and Armstrong, 2011). One 
of the alternatives for recurrent is doxorubicin, an anthracycline antiobiotic 
(Ushijima, 2009). I combined lipoplatin with doxorubicin and three different 
taxanes: abraxane, docetaxel and paclitaxel. Paclitaxel and docetaxel share a 
similar mechanism of action: the promotion of microtubule assembly and 
inhibition of microtubule disassembly. Abraxane is the albumin-bound 
formulation of paclitaxel. The simultaneous combination of lipoplatin with 
paclitaxel or docetaxel showed a moderate synergy or even an additive effect, 
whereas the combination of lipoplatin with abraxane or doxorubicin demonstrated 
a synergistic effect. Interestingly, both cell lines showed a comparable sensitivity 
to abraxane, but not to paclitaxel, that resulted less active in SKOV3 cells (IC50 5-
fold higher than OVCAR5 cells), which were reported to be paclitaxel-resistant 
(Chen et al., 2005; Wang et al., 2013). These results indicated that an appropriate 
drug combination should be adopted to obtain an enhanced therapeutic effect and 
among the tested taxanes the best to use in combination with lipoplatin could be 
abraxane. 
One of the current emerging concepts concerning tumorigenesis is that tumors are 
composed of heterogeneous populations of cells with different biological 
properties and tumorigenic potentials. Cancer stem cells or tumor-initiating cells 
(CSC/TIC) are a subpopulation able to form new tumors and metastases by their 
capacity to self-renew and originate all of the heterogeneous lineages of cells that 
comprise a tumor (Lopez et al., 2012). CSC/TICs are thought to play a crucial role 
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in tumor development, chemoresistance, and relapse after initial treatment in 
cervical cancer (Feng et al., 2009) and ovarian cancer (Skubitz et al., 2013). 
The ability to form spheroids (Djordjevic et al., 2012; Feng et al., 2009) and 
several cell surface markers, including CD133 and aldehyde dehydrogenase 
(ALDH), define CSC/TIC populations in cervical (Liu and Zheng, 2013) and 
ovarian tumors (Silva et al., 2011). Importantly, in ovarian cancer these markers, 
not only identify CSC/TICs, but are also associated with poor clinical outcome of 
patients, being therefore promising targets for treatment (Silva et al., 2011). 
Preclinical studies demonstrate that knockdown of ALDH can restore 
chemosensitivity in ovarian cancer cell lines (Burgos-Ojeda et al., 2012; Wintzell 
et al., 2012).  
R-ME-180 cells were able to generate spheroids and expressed ALDH positive 
cells, displaying a putative stem-like signature. Lipoplatin inhibited spheroid 
formation and reduced the percentage of ALDH+ cells. OVCAR5 and SKOV3 
cell lines showed a significant percentage of ALDH and CD133 positive cells that 
decreased in a dose-dependent manner in the presence of lipoplatin.  
These results suggested that the treatment with lipoplatin could decrease CSC/TIC 
population and as a consequence reduce tumor relapse due to this chemo-resistant 
subpopulation. Furthermore, lipoplatin could avoid CSC/TICs induction by 
cisplatin-based chemotherapy (Latifi et al., 2011; Wintzell et al., 2012). 
Epithelial ovarian cancer has an unusual mechanism of dissemination that rarely 
requires blood or lymph vessels (Naora and Montell, 2005). Malignant cells are 
shed from the primary tumor into the peritoneal cavity where they are 
disseminated throughout the abdominal cavity by peritoneal fluid or ascites. These 
malignant cells often aggregate and form spheroid-like structures (Allen et al., 
1987) and are proposed to attach to and invade the peritoneum and potentially 
seed metastatic tumor growth (Burleson et al., 2006). Additionally, it has become 
apparent that aggregates of malignant cells, contained within malignant ascites, 
represent a significant impediment to efficacious treatment of late stage ovarian 
cancer (Shield et al., 2009).  
SKOV3 cells spontaneously produced compact spheroids when cultured under 
non-adherent conditions. Lipoplatin was able to inhibit spheroid formation and 
induce apoptosis. Moreover, using a new spheroid migration assay as a model for 
tumor cell dissemination from a solid micrometastasis or a spheroid, I found that 
lipoplatin decreased cell migration. Taken together these data indicated that the 
formation of spheroids and their ability to contribute to metastasis formation by 
tumor cell migration/dissemination could be strongly reduced by lipoplatin 
treatment.  
Spheroids are extensively used in preclinical studies to investigate the effect of 
various therapies. In the clinical setting, the efficacy of any treatment is proven by 
reduced tumor growth and, eventually, reduced tumor mass. Analogously, 
spheroid volume can be used as a measure of efficacy in preclinical therapy 
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studies (Rodday et al., 2011). The treatment with lipoplatin of SKOV3 spheroids 
showed a dose-dependent inhibition of the spheroid growth. Accordingly to the 
inhibitory effect of lipoplatin, I detected a cell viability decline in treated 
spheroids. To obtain a volume growth inhibition of spheroid with larger size I had 
to increase lipoplatin concentrations.  
Finally, lipoplatin strongly decreased tumor xenograft of cisplatin-resistant 
cervical R-ME-180 and ovarian cancer OVCAR5 cells without apparent toxicities. 
Interestingly, ovarian cancer tumor xenografts, after treatment suspension, did not 
start to grow showing an irreversible effect of lipoplatin. Cisplatin, used at the 
same concentration, caused severe toxicities in nude mice (Chahinian et al., 
1984). The lower toxicity of lipoplatin compared to cisplatin may be due to 
alterations in its pharmacokinetics, preferential localization to tumors containing 
compromised vasculature and differences in cellular uptake (Devarajan et al., 
2004).  
A better radiosensitizing activity of lipoplatin compared to cisplatin has been 
shown in preclinical studies (Charest et al., 2010). Because cisplatin is the 
standard care for the treatment of cervical cancer in combination with radiation 
therapy (RT), replacement of cisplatin by lipoplatin against cervical cancer would 
add the advantage of lower toxicities to patients as shown in randomized Phase II 
and Phase III studies against NSCLC (Stathopoulos et al., 2011; Mylonakis et al., 
2010).  
 
 
In conclusion, lipoplatin was able to exhert a cytotoxic effect on conventional 
monolayer cultures, on three-dimensional spheroids, and also in vivo. Hence, 
these promising results suggest  that lipoplatin could be used for the treatment of 
cervical and ovarian cancer patients, single or in combination therapy, as an 
alternative or a substitute of cisplatin to reduce cisplatin‟s systemic toxicity while 
improving the targeting of the drug to the tumor. 
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